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ABSTRACT
Mucins are high molecular weight glycoproteins that are the principal protein 
components o f mucus and are found on epithelial surfaces throughout the body, 
where they play a protective role. Changes in mucin expression have been 
demonstrated in various diseases, such as asthma and COPD; and in the respiratory 
system, overproduction o f mucus can cause blockage o f the airways. Experimental 
studies show co-ordinated upregulation o f both mRNA and mucin protein in 
response to inflammation.
Recent work suggests that allelic differences in gene expression are a 
common occurrence in the genome. The major research question addressed in this 
thesis is whether the MUC genes exhibit this phenomenon and if such allelic 
differences in expression might contribute to an individual’s susceptibility to disease. 
Two mucins, MUC4 (membrane-bound) and MUC5B (secreted) were examined, and 
their relative allelic transcript levels studied by a single-base extension (SBE) 
method and related to haplotypes o f the two genes.
The first aim for MUC4 was to explore the possible influence of tandem 
repeat length on mRNA expression. However it was discovered that MUC4 
alternative splicing is much more extensive than previously reported, with hints that 
this might be genetically determined, but making the original question unanswerable.
The remainder o f the thesis foccussed on MUC5B. For the expression studies, 
a total o f 42 heterozygous samples were tested by SBE, o f which 10 showed strong 
evidence o f an allelic difference in MUC5B expression. These constitutive 
differences were small (greatest difference about two-fold). However, a highly 
significant association between MUC5B promoter haplotype heterozygosity and the 
magnitude o f the detected allelic differences in MUC5B expression was 
demonstrated. A high expressing haplotype was identified (HI) and carriers of 
marker alleles for this haplotype were tested in a longitudinal birth cohort (n=2807) 
to examine this variation in relation to respiratory outcomes (eg. asthma), as well as 
to measures o f lung function.
Significant correlations were detected between MUC5B and allergy and 
wheeze history, although the significance o f these correlations is unclear and could 
reflect differences in MUC5B properties rather than expression, or might have arisen 
from multiple testing.
2
ACKNOWLEDGEMENTS
I wish to begin by thanking my primary supervisor Prof Dallas Swallow for 
her support and guidance these past few years. Her great enthusiasm for research, 
vast experience in the field of mucins and astute scientific judgement have been 
influential throughout my doctoral work. I am particularly grateful that whilst Dallas 
was always interested in my research, she also allowed me the freedom I needed to 
explore things on my own. It has truly been an honour and joy to work with her.
I also wish to express my gratitude to my second supervisor Prof Sue Povey 
for her advice and concern at many points during my time here at the Galton 
Laboratory. I have benefited greatly from Sue’s wisdom and I am grateful for the 
times she put my mind at ease when things seemingly were not going so well.
I am greatly indebted to several past members o f the Galton Lab: Mrs Lynne 
Vinall, Dr Ana Teixeira and in particular, Dr Karine Rousseau. They served as my 
informal mentors and between them taught me almost everything I know about 
experimental work in the lab. My thanks also go to Dr Wendy Ng who helped with 
the various RNA extractions and with the Southern blot experiments, thereby saving 
me valuable time.
Mr Imran Shah, Ms Lauren Johnson, Ms Ranji Arasaretnam, Mr Christopher 
Plaster and Mr Krishna Veeramah assisted me in various technical aspects of my 
PhD work. Imran performed the various logistic regression and statistical analyses 
on the 1946 birth cohort data; Lauren assisted with the genotyping of the 1946 
cohort; Ranji helped with the gDNA extractions; Chris assisted with running the ABI 
3100 sequencer and Krishna wrote several programs, which greatly reduced the time 
required to format my data before it could be used by the various computer programs 
in my research. To each of you, many thanks. I am also grateful to Mr Jed Digby 
who provided the fetal samples for this project.
I have had the privilege of sharing an office with Ms Catherine Ingram over 
the past year or so. Kate was a wonderful friend to talk to, to confide in and I have 
very much enjoyed sharing an office with her.
3
I also wish to thank the Overseas Research Students Award Scheme 
(ORSAS) for giving me a research grant to do my doctoral work.
Lastly, I wish to thank my Father, Dr James Loh, who has been both my 
strongest critic and strongest supporter. Dad, thank you for looking after me all these 
years, for listening patiently whenever I complained about problems with my 
research and encouraging me to soldier on, and for spending extended periods of 
time with me in London during the past two years, cooking and cleaning when you 
could have stayed back home and let someone cook and clean for you instead.
I wish to dedicate this thesis to the memory of my Mother, Mei Loh, who 
passed away after a long and difficult struggle with cancer during the course of my 
PhD. Words are insufficient to describe my gratitude for all that she has done for me. 
Mom, I miss you and love you very much - this one is for you.
Andrew X W Loh
Oct 2007, London
4
TABLE OF CONTENTS
ABSTRACT............................................................................................................................................................2
ACKNOWLEDGEMENTS................................................................................................................................ 3
LIST OF TABLES................................................................................................................................................9
LIST OF FIGURES........................................................................................................................................... 11
LIST OF EQUATIONS.....................................................................................................................................13
1 INTRODUCTION....................................................................................................................................15
1.1.............................MUCINS......................................................................................................................... 15
1.1.1 Mucus and its Functions........................................................................................................... 15
1.1.2 Mucus and Disease................................................................................................................ 16
1.1.3 Mucins and the MUC Genes...................................................................................16
1.1.4 MUC4............................................................................................................................18
1.1.5.....................................MUC5B..................................................................................................... 21
1.1.6 Evidence of Changes in MUC Gene Expression in relation to Disease............................ 24
1.2 CONTROL OF GENE EXPRESSION...........................................................................30
1.2.1 Restriction of Gene Expression...............................................................................................30
1.2.1.1 Spatial Restriction................................................................................................................ 30
1.2.1.2 Temporal Restriction............................................................................................................ 31
1.2.2 Levels of Gene Regulation.......................................................................................................... 31
1.2.3 An Overview of the Control of Transcription Regulation -  Cis vs. Trans-acting 32
1.2.4 Classes of Cis-acting Regulatory Elements involved in Transcriptional Regulation....33
1.2.4.1 Core Promoter Elements......................................................................................................33
1.2.4.2 Proximal Promoter Elements...............................................................................................35
1.2.4.3 Enhancers............................................................................................................................. 35
1.2.4.4 Silencers............................................................................................................................... 35
1.2.4.5 Response Elements.............................................................................................................. 36
1.2.5 Transcriptional Regulation of MUC4 and MUC5B Expression........................................ 36
1.2.5.1 MUC4 Promoter................................................................................................................... 36
1.2.5.2 MUC5B Promoter................................................................................................................ 38
1.2.5.3 Evidence of changes in MUC4 and MUC5B expression in response to inflammatory
mediators 40
1.3 ALLELIC VARIATION IN GENE EXPRESSION...............................................................45
1.3.1 Causes of Allelic Variation in mRNA Expression................................................................ 45
1.3.1.1 Genomic Imprinting and X-chromosome Inactivation........................................................ 45
1.3.1.2 Regulatory Polymorphisms..................................................................................................45
1.3.2 Methods for Detecting Allelic Variation in mRNA Expression due to Cis-acting
Regulatory Polymorphisms.......................................................................................................................47
1.3.2.1 In Vitro Methods.................................................................................................................. 47
1.3.2.2 In Vivo Methods................................................................................................................... 47
1.3.2.2.1 Early methods................................................................................................................49
1.3.2.2.1.1 Restriction Fragment Length Polymorphisms (RFLP) and Single-strand
Conformation Polymorphism (SSCP)........................................................................................... 49
1.3.2.2.1.2 33P-based Sequencing............................................................................................. 50
1.3.2.2.2 More Recent methods....................................................................................................51
1.3.2.2.2.1 Single-base Extension (SBE)...................................................................................51
1.3.2.2.2.2 Pyrosequencing....................................................................................................... 53
1.3.2.2.2.3 SBE with MALDI-TOF MS.................................................................................... 54
1.3.2.2.2.4 HaploChIP............................................................................................................... 55
1.3.2.3 In Silico Methods................................................................................................................. 57
1.3.3 Evidence Suggesting that MUC Gene Expression may be Influenced by Regulatory
Polymorphisms...........................................................................................................................................58
1.3.3.1 Heritable Differences in Gene Expression Levels are Common in the Human Genome.. 58
1.3.3.2 Allelic Variation in Non-imprinted Autosomal Genes - A Heritable and Common
Occurrence in the Human Genome..........................................................................................................59
1.4 HYPOTHESIS AND AIMS OF THE PROJECT...................................................................... 61
5
1.4.1 Hypothesis.................................................................................................................................... 61
1.4.2 A ims of Project............................................................................................................................ 62
2 MATERIALS AND M ETHODS..........................................................................................................64
2.1 SAMPLES.........................................................................................................................................64
2.1.1 Human Fetal Samples................................................................................................................ 64
2.1.2 MRC National Survey of Health and Development (NHSD) - 1946 Longitudinal Birth
Cohort) 64
2.2 LIST OF BUFFERS AND SOLUTIONS..................................................................................... 65
2.3 RNA/DNA EXTRACTION FROM FETAL TISSUE............................................................... 66
2.3.1 Tissue Homogenisation.............................................................................................................. 66
2.3.2 RNA Extraction........................................................................................................................... 67
2.3.3 gDNA Extraction following RNA Extraction..........................................................................69
2.3.4 gDNA Extraction for Southern Blots....................................................................................... 69
2.3.5 Reverse Transcription (Single-stranded cDNA Synthesis)...................................................71
2.4 DETERMINATION OF TANDEM REPEAT LENGTHS USING SOUTHERN
BLOTTING...................................................................................................................................................... 72
2.4.1 Digestion of DNA Samples.........................................................................................................72
2.4.2 Gel Electrophoresis..................................................................................................................... 72
2.4.3 Southern Blotting.....................................................................................................................73
2.4.4 Radioactive Detection of DNA Fragments............................................................................ 73
2.4.4.1 Membrane Pre-hybridisation................................................................................................73
2.4.4.2 Labelling of Probe................................................................................................................74
2.4.4.3 Probing of Membrane.......................................................................................................... 75
2.4.4.4 Washing of Membranes....................................................................................................... 75
2.4.4.5 Probe Detection.................................................................................................................... 75
2.4.4.6 Tandem Repeat Size Determination...................................................................................76
2.5 POLYMERASE CHAIN REACTION (PCR)............................................................................76
2.5.1 Taq polymerase PCR...................................................................................................................76
2.5.2 Thermo-Start Taq Polymerase................................................................................................80
2.5.3 Standard Procedure for Agarose Gel Electrophoresis.........................................................82
2.6 GENOTYPING................................................................................................................................83
2.6.1 Restriction Enzyme Digestion................................................................................................. 83
2.6.2 Tetra-ARMS allele specific PCR (Ye, Humphries, and Green 1992).................................84
2.6.3 Sequencing..................................................................................................................................85
2.6.3.1 Purifying PCR Products....................................................................................................... 85
2.6.3.2 Sequencing Reaction............................................................................................................ 85
2.6.3.3 Sequencing Reaction Clean-up............................................................................................86
2.6.3.4 Electrophoresis and Detection of Sequencing Products...................................................... 86
2.6.4 Multiplex Single Base Extension (SBE)................................................................................... 86
2.6.4.1 Multiplex PCR......................................................................................................................87
2.6.4.2 PCR Product Purification..................................................................................................... 87
2.6.4.3 SBE.......................................................................................................................................88
2.6.4.4 Post-extension Treatment..................................................................................................... 88
2.6.4.5 Electrophoresis and Detection of SBE Products..................................................................89
2.7 TESTING FOR ALLELIC VARIATION IN MRNA EXPRESSION USING SB E ............90
2.7.1 PCR and PCR Product Cleanup.............................................................................................. 90
2.7.2 SBE and Post-extension Treatment..........................................................................................90
2.7.3 Electrophoresis, Detection of SBE Products.......................................................................... 90
2.8 STATISTICAL ANALYSIS.........................................................................................................92
2.8.1 (Chi-Square) Test................................................................................................................. 92
2.8.2 Fisher’s Exact Test....................................................................................................................92
2.8.3 Student’s t Test.............................................................................................................................93
2.8.4 Bayesian Algorithm.....................................................................................................................93
2.8.5 Exact Test of Population Differentiation Based on Haplotype Frequencies (Goudet et
al. 1996)....................................................................................................................................................... 94
2.8.6 Cross Tabulations........................................................................................................................94
2.8.7 Analysis of Variance (ANOVA).................................................................................................94
2.8.8 Likelihood Ratio Test................................................................................................................95
2.8.9 Logistic Regression................................................................................................................... 95
2.9 COMPUTER SOFTWARE.............................................................................................................96
6
3 STUDY OF ALLELIC VARIATION IN MUC4 EXPRESSION............................................... 99
3.1 INTRODUCTION........................................................................................................................... 99
3.1.1 Tandem Repeat Length Variation in MUC4............................................................................99
3.1.2 Alternative Splicing in MUC4.................................................................................................100
3.2 INITIAL SELECTION OF SAMPLES.......................................................................................103
3.3 GENOTYPE ANALYSIS.............................................................................................................103
3.4 DETERMINATION OF MUC4 TANDEM REPEAT LENGTH........................................... 107
3.5 ANALYSIS OF LINKAGE DISEQUILIBRIUM BETWEEN MUC4 POLYMORPHISMS 
111
3.6 HAPLOTYPE ANALYSIS...........................................................................................................113
3.7 RT PCR MUC4 EXON EXPRESSION ANALYSIS............................................................... 114
3.8 TESTING FOR ALLELIC VARIATION IN MUC4 MRNA EXPRESSION BY SBE
METHOD........................................................................................................................................................119
3.9 DISCUSSION................................................................................................................................. 121
4 DEVELOPMENT OF SINGLE-BASE EXTENSION METHOD FOR DETECTING
ALLELIC DIFFERENCES IN MRNA EXPRESSION........................................................................125
4.1 INTRODUCTION......................................................................................................................... 125
4.2 DETECTION OF FLUORESCENT DYES...............................................................................127
4.3 NUCLEOTIDE INCORPORATION..........................................................................................128
4.3.1 Template Concentration........................................................................................................... 128
4.3.2 Primer Concentration Titration............................................................................................. 130
4.4 UNEQUAL PCR AMPLIFICATION.........................................................................................130
4.5 THE POSSIBILITY OF SEGMENTAL GENE DUPLICATIONS OF THE SBE PRIMER
ANNEALING SITE..................................................................................................................................... 130
4.6 CALCULATING ALLELIC RATIOS IN CDNA.................................................................... 133
4.7 ADDRESSING THE ISSUE OF DIFFERENT ALLELIC RATIOS FROM THE SAME
INDIVIDUAL WHEN DIFFERENT MARKER SNPS ARE USED.................................................. 135
4.8 DISCUSSION................................................................................................................................. 137
5 STUDY OF ALLELIC VARIATION IN MUCSB EXPRESSION ................................ 140
5.1 INTRODUCTION......................................................................................................................... 140
5.1.1 MUCSB and Diffuse Panbronchiolitis (DPB) -  Initial Research Suggesting the
Presence of Allelic Variation in MUC5B Expression........................................................................140
5.2 INITIAL SELECTION OF SAMPLES.......................................................................................143
5.3 GENOTYPE ANALYSIS............................................................................................................. 143
5.4 ANALYSIS OF LINKAGE DISEQUILIBRIUM BETWEEN MUC5B SN PS.................. 146
5.5 HAPLOTYPE ANALYSIS........................................................................................................... 147
5.5.1 Haplotype Reconstruction using MUCSB Exonic SNPs..................................................... 147
5. S. 2 Haplotype Reconstruction using MUC5B Exonic SNPs and Promoter Polymorphisms
from Kamio Study.................................................................................................................................... 148
5.6 TESTING FOR ALLELIC VARIATION IN MUCSB MRNA EXPRESSION BY SBE
METHOD....................................................................................................................................................... 151
5.6.1 Final Selection of Samples for Study......................................................................................151
5.6.2 SBE Results................................................................................................................................ 152
5.6.2.1 gDNA Allelic Ratio Results...............................................................................................154
5.6.2.2 Corrected cDNA Allelic Ratio Results............................................................................. 156
5.7 RELATING SBE RESULTS TO HAPLOTYPES................................................................... 160
5.7.1 Inferring Relative Transcriptional Activities of Promoter Haplotypes........................... 164
5.8 DISCUSSION................................................................................................................................. 165
6 STUDY OF MUCSB EXPRESSION IN RELATION TO RESPIRATOY OUTCOMES IN 
A LONGITUDINAL BIRTH COHORT....................................................................................................171
6.1 INTRODUCTION..........................................................................................................................171
6.1.1 The 1946 Birth Cohort..............................................................................................................171
6.2 GENOTYPE & HAPLOTYPE ANALYSIS..............................................................................173
6.3 VARIOUS VARIABLES TESTED AND RATIONALE FOR TESTING THEM.............175
6.3.1 Respiratory Outcomes and Measures of Lung Function.................................................... 176
6.3.1.1 Asthma History (ASTH89R and ASTHMA).................................................................... 179
6.3.1.2 Bronchitis History (BRONC89R and BRONC)................................................................ 181
7
6.3.1.3 Wheeze (WZY89C and WZYC)........................................................................................ 18.1
6.3.1.4 Hay Fever History (HAY89R and HAYF)......................................................................... 181
6.3.1.5 Allergy History (ALLG89R and ALLERGY).................................................................... 182
6.3.1.6 Lower Respiratory Tract Infections in Infancy (LRIPY)................................................... 182
6.3.1.7 Measures of Lung Function - Fixed Expiratory Volume in one second (FEV!)
(FEVM89C, FEVM99D and DELTA)................................................................................................... 182
6.3.2 Potential Confounding Variables..........................................................................................183
6.4 RESULTS OF TESTS FOR ASSOCIATION WITH VARIABLES..................................... 185
6.5 ADJUSTMENT FOR CONFOUNDING VARIABLES......................................................... 188
6.6 TEST FOR INTERACTION BETWEEN MUC5B AND IL13.............................................. 190
6.7 DISCUSSION................................................................................................................................. 192
7 FINAL DISCUSSION AND CONCLUSIONS...............................................................................195
APPENDICES................................................................................................................................................... 199
Appendix I -  MUC4 Biliary Tract Cancer Study ........................................................................... 199
Appendix II -  People Counts for Statistically Significant Cross Tabulations in 1946 
Birth Cohort.............................................................................................................................................. 201
REFERENCES..................................................................................................................................................203
8
LIST OF TABLES
Table 1-1 -  Classification o f genes that encode mucins................................................. 17
Table 1-2 -  Survey o f literature reporting evidence o f a change in MUC4 expression
in disease vs. normal states..................................................................................................28
Table 1-3 - Survey of literature reporting evidence o f a change in MUC5B expression
in disease vs. normal states..................................................................................................30
Table 1-4 - Examples o f studies on changes in MUC4 expression in response to
inflammatory mediators......................................................................................................42
Table 1-5 - Examples o f studies on changes in MUCSB expression in response to
inflammatory mediators.......................................................................................................44
Table 2-1 Details o f primers and conditions for PCR reactions using Taq..................79
Table 2-2 -  Details o f primers and conditions for PCR reactions using Thermo-Start
Taq..........................................................................................................................................81
Table 2-3 - List o f enzymes and conditions for restriction enzyme digests  .......83
Table 2-4 - Details of SBE primers................................................................................... 89
Table 2-5 -  Parameters for SBE Electrophoresis Run on ABI3100 ............................ 91
Table 3-1 - Individuals from fetal population initially chosen for MUC4 study and
their available tissue types................................................................................................ 103
Table 3-2 -  MUC4 genotype frequencies in fetal population..................................... 106
Table 3-3 - MUC4 SNP allele frequencies in fetal population compared to other
HapMap populations..........................................................................................................106
Table 3-4 - Measures o f linkage disequilibrium between MUC4 TR and SNP markers
.............................................................................................................................................. I l l
Table 3-5 -List o f MUC4 haplotypes and their frequencies in the fetal population. 114
Table 3-6 - RT PCR MUC4 exon expression analysis..................................................118
Table 4-1 -  Sequences o f long oligonucleotides and the SNP alleles they represent.
.............................................................................................................................................. 132
Table 4-2 - Allelic ratios from gDNA compared with allelic ratios from
oligonucleotide mixtures................................................................................................... 133
Table 5-1 - MUC5B promoter haplotypes detected by Kamio et al............................ 142
Table 5-2 -  Individuals from fetal population initially chosen for MUC5B study and
their available tissue types................................................................................................ 143
Table 5-3 -  MUCSB exonic SNP genotype frequencies in fetal population compared
with HapMap CEPH population...................................................................................... 145
Table 5-4 - Measures o f LD between MUC5B exonic SNPs in fetal and HapMap
CEPH populations..............................................................................................................146
Table 5-5 - Combined MUC5B haplotypes and their frequencies in the fetal
population............................................................................................................................150
Table 5-6 - MUCSB gDNA allelic ratio results..............................................................155
Table 5-7 -  MUCSB corrected cDNA allelic ratio results............................................157
Table 5-8 - Promoter, exonic haplotypes and averaged corrected cDNA allelic ratios
for each individual tested...................................................................................................163
Table 5-9 - 2 by 2 table showing number o f samples showing strong evidence o f  
allelic variation in MUCSB expression and whether they are heterozygous or 
homozygous for promoter haplotype.............................................................................. 164
9
Table 6-1 - MUC5B exonic SNP genotype frequencies in 1946 cohort vs. HapMap
CEPHs..................................................................................................................................174
Table 6-2 - MUCSB exonic SNP haplotype frequencies in 1946 cohort, fetal and
HapMap CEPH populations..............................................................................................175
Table 6-3 -  Respiratory outcomes and measures o f lung function examined in 1946
cohort.................................................................................................................................... 178
Table 6-4 - Potentially Confounding Variables............................................................. 184
Table 6-5 -  Results o f tests for correlation o f MUCSB with respiratory outcomes. 186 
Table 6-6 -  Results o f tests for correlation with potential confounding variables... 187 
Table 6-7 - Comparison o f results before and after adjusting for confounding
variables................................................................................................................................189
Table 6-8 - Results o f tests for association with IL13 R100Q genotypes and asthma
and allergy history variables............................................................................................. 191
Table 6-9 -  Result o f logistic regression analysis between IL13 Q carriers and
ALLERGY...........................................................................................................................191
Table 6-10 -  P values obtained for tests for interaction between MUCSB and IL13E 
influencing allergy history outcomes...............................................................................191
10
LIST OF FIGURES
Figure 1-1 -  Schematic representation o f the deduced structure o f MUC4.................19
Figure 1-2 -  Schematic Representation o f the Deduced Structure o f MUC5B protein.
 22
Figure 1-3 -  Comparison between von Willebrand Factor and four secreted mucins.
.................................................................................................................................................23
Figure 1-4 -  The Transcription Preinitiation Complex (PIC)........................................ 32
Figure 1-5 -  Core Promoter Elements...............................................................................34
Figure 1-6 - Schematic diagram o f MUC4 promoter...................................................... 37
Figure 1-7 - Schematic diagram o f MUC5B promoter....................................................39
Figure 1-8 - Strategy for detecting presence/extent o f allelic variation in mRNA
expression.............................................................................................................................. 48
Figure 1 -9 -  RFLP Method................................................................................................. 50
Figure 1-10 -  32P-based Sequencing Method................................................................. 51
Figure 1-11 -  SBE Method................................................................................................ 52
Figure 1-12 -  Pyrosequencing Method............................................................................ 53
Figure 1-13 -  MALDI-TOF MS Method......................................................................... 55
Figure 1-14 -  HaploChIP Method..................................................................................... 56
Figure 2-1 - RNA samples run on 1 % agarose gel to assess their quality................. 68
Figure 2-2 - Extracted gDNA run on a 1% agarose g e l.................................................71
Figure 2-3 - PCR Size Marker............................................................................................82
Figure 3-1 -  Known MUC4 splice variants....................................................................102
Figure 3-2 - Representative genotyping results for rs2259292 (exon 4).................... 104
Figure 3-3 - Representative genotyping results for rs2259102 (exon 6).................... 104
Figure 3-4 - Representative genotyping result for rs2550240 (exon 7)......................104
Figure 3-5 - Representative genotyping result for rs2291652 (exon 23)....................105
Figure 3-6 - Representative genotyping result for rs3205933 (exon 24)....................105
Figure 3-7 -  Photo o f gel o f Pvu //digested gDNA......................................................108
Figure 3-8 - Representative autoradiograph used to determine MUC4 TR lengths o f
individuals from the fetal population...............................................................................109
Figure 3-9 - Histogram o f MUC4 TR lengths (kb) in fetal population...................... 110
Figure 3-10 - Histogram o f MUC4 TR lengths (kb) in CEPH population.................110
Figure 3-11 -  MUC4 scale gene diagram showing LD between MUC4 TR and SNPs.
 112
Figure 3-12 - MUC4 haplotypes and their frequencies in the fetal population
determined by Phase program.......................................................................................... 113
Figure 3-13 - Representative RT PCR results showing variability in expression of
MUC4 exons in a series o f lung samples........................................................................ 116
Figure 3-14- Representative preliminary SBE results for rs2291652......................... 120
Figure 4-1 - Representative SBE traces from gDNA for rs2672785.......................... 125
Figure 4-2 -Representative SBE traces from gDNA for rs2075853............................126
Figure 4-3 - Representative SBE traces from gDNA for rs2075859.......................... 126
Figure 4-4 -  Representative comparison o f allelic ratios detected between A BI377
and ABI 3100 sequencers...................................................................................................128
Figure 4-5 - PCR template for testing rs2672785 and rs2075853 in titration 
experiments.........................................................................................................................129
11
Figure 4-6 - Graph o f peak heights/allelic ratio against amount o f template used for
rs2672785.............................................................................................................................129
Figure 4-7 -  The effect o f a segmental duplication on the measured allelic ratios
from a SBE reaction............................................................................................................131
Figure 4-8 -  Long oligonucleotide allelic ratios (T/C) for rs2075853. Oligonucelotide
mixtures run on ABI 3 7 7 ................................................................................................... 133
Figure 4-9 - Example showing difference in allelic ratios for gDNA vs. cDNA for a
single individual...................................................................................................................134
Figure 4-10 - Graph o f Allelic Ratios for rs2075853 against Allelic Ratios for 
rs2672785. Each point on graph represents the averaged allelic ratios for a different
individual.............................................................................................................................. 136
Figure 5-1 - MUC5B promoter polymorphisms identified by Kamio and colleagues.
............................................................................................................................................... 141
Figure 5-2 -  Representative MUC5B rs2672785 (exon 2) genotyping results..........144
Figure 5-3 - Representative MUC5B rs2075853 (exon 3) genotyping results 144
Figure 5-4 - Representative MUC5B rs2075859 (exon 9) genotyping results 145
Figure 5-5 -  Scale diagram showing positions o f MUC5B exonic SNPs and
associated measures o f LD in fetal population.............................................................. 146
Figure 5-6 - MUCSB Exonic Haplotype Frequencies in fetal and HapMap CEPH
populations.......................................................................................................................... 147
Figure 5-7 -  Representative electropherograms o f the MUCSB promoter sequence..
...............................................................................................................................................149
Figure 5-8 - Combined haplotypes and their frequencies in the fetal population.... 150
Figure 5-9 - Representative SBE results from MUC5B rs2672785............................ 152
Figure 5-10 - Representative SBE results from MUC5B rs2075853.........................153
Figure 5-11 - Representative SBE results from MUC5B rs2075859.........................153
Figure 5-12 - Graph o f standard deviations for SBE experiments.............................158
Figure 5-13 - Graph o f rs2075853 (T/C) allelic ratios against rs2672785 (G/A) allelic
ratios......................................................................................................................................159
Figure 5-14 - Comparison o f averaged corrected cDNA allelic ratios in individuals 
homozygous for promoter haplotype vs. individuals heterozygous for promoter
haplotype............................................................................................................................. 161
Figure 5-15 -  Comparison o f averaged corrected cDNA allelic ratios between
common diplotypes.............................................................................................................165
Figure 6-1 - Representative genotyping result from SBE multiplex...........................173
12
LIST OF EQUATIONS
Equation 2-1 - Estimation o f radionucleotide incorporation rate.................................. 74
Equation 2-2 - Method for calculating allelic ratios........................................................91
Equation 2-3 - Formula for calculating % test statistic...................................................92
Equation 2-4 -  Formula for calculating t test statistic.....................................................93
Equation 2-5 -  Formula for calculating likelihood ratio test statistic.......................... 95
Equation 4-1 - Method for calculating allelic ratios in cDNA samples using overall
gDNA allelic ratio..............................................................................................................134
Equation 4-2 - Method for calculating allelic ratios in cDNA samples using 
individualised gDNA allelic ratios.................................................................................. 135
13
CHAPTER 1
INTRODUCTION
1 INTRODUCTION
This thesis is concerned with the study of cis-acting allelic variation in mucin 
gene expression. This first chapter describes the main molecular and genetic features 
of MUC4 and MUCSB, the two mucin genes investigated in this thesis, provides a 
brief overview of mammalian gene regulation and concludes with a review of our 
current understanding of allelic variation in mRNA expression in humans.
1.1 MUCINS
1.1.1 Mucus and its Functions
Mucus is a viscous, slimy, gel-like material that covers various epithelial 
surfaces found throughout the human body, thereby forming an important interface 
between the individual and the external environment (reviewed by (Rose 1992).
Mucus performs a number of critical functions: in the respiratory system for 
example, the large airways are covered with mucus, which is continually driven 
towards the surface by ciliated cells (Sleigh 1983). This mucus layer provides a 
perpetual aqueous environment for the cells and also helps to trap foreign material 
and bacteria passing through the air passages (Lillehoj and Kim 2002). Here, mucus 
is thought to function primarily as a protective barrier against infection and 
desiccation.
In the stomach, mucus forms a buffer between the gastric lumen and mucosal 
surface, thus producing a pH gradient from highly acidic in the lumen to near neutral 
at the mucosal surface (Allen et al. 1993; Tumberg and Ross 1984). This protects the 
stomach lining from the corrosive effects of stomach acid. In addition, the mucus 
layer forms a physical barrier to the pepsin found in digestive fluid, preventing 
proteolytic digestion of the underlying epithelium (Allen et al. 1986; Kaunitz 1999). 
The mucus layer is continually renewed, thereby countering peptic erosion of the gel
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and preserving its viscoelasticity and protective properties (Slomiany and Slomiany 
1991).
Elsewhere in the digestive tract, mucus acts as a lubricant by facilitating the 
passage of food and faecal material during the process of digestion, thus protecting 
the underlying cells from mechanical damage (Allen 1981).
1.1.2 Mucus and Disease
Changes in the quality and quantity o f mucus have been observed in various 
inflammatory diseases. For example, mucus hypersecretion is often observed in 
asthmatic patients and plays a central role in the pathogenesis of severe airway 
obstruction and asphyxiation in fatal asthma attacks (Rogers 2004; Sidebotham and 
Roche 2003). Conversely, a deficiency in mucus production can lead to problems 
such as dry eye syndrome (Pflugfelder, Solomon, and Stem 2000). In intestinal 
mucosal diseases, there is evidence that the mucus layer is thinner in ulcerative 
colitis compared to controls; the opposite is true in Crohn’s disease versus controls 
(Pullanetal. 1994).
1.1.3 Mucins and the MUC  Genes
Mucus is a complex mixture, consisting of water, ions, proteins, lipids and 
glycoproteins. Mucins are the main glycoproteins components found in mucus 
(reviewed by (Boat and Cheng 1980; Strous and Dekker 1992)). Mucins are 
responsible for the viscosity of mucus and are therefore critical to its proper function 
(Gum, Jr. 1992; Vinall et al. 1998). At least 18 distinct genes encoding mucins have 
been identified so far (HUGO Committee 7 A.D.). These can be classified under two 
main categories. These are the genes that encode secreted mucins and the genes that 
encode membrane-bound mucins, as shown in Table 1-1 below (Moniaux et al. 
2001).
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Secreted Membrane-bound
MUC2 MUC1
MUC SAC MUC3A
MUCSB MUC3B
MUC6 MUC4
MUC7 MUC12
MUC19 MUC 13
MUC 15
MUC 16
MUC 17
MUC18
MUC20
Table 1-1 -  Classification of genes that encode mucins. MUC genes in bold text are gel-forming 
mucins. MUC genes in blue text form a gene complex found on Chromosome 11 p i5.5 (Pigny et al. 
1996). The complete structure and sequence of MUC8 is unknown, so that this gene cannot be 
classified yet.
Most o f the secreted mucins form gels by forming large disulphide cross- 
linked oligomers (Carlstedt, Lindgren, and Sheehan 1983; Carlstedt and Sheehan 
1984; Hovenberg et al. 1996), whereas membrane-bound mucins are monomeric and 
are anchored to the cell surface by a hydrophobic membrane-spanning domain 
(reviewed by (Fowler, Vinall, and Swallow 2001).
The MUC genes are not all members o f a single gene family although they do 
have a number of features in common. One o f the more characteristic features o f the 
MUC genes is the presence o f a large central tandem repeat (TR) region, which 
exhibits a large variation in the number (VNTR) as well as sequence o f the tandem 
repeat units (Fowler, Vinall, and Swallow 2001; Swallow et al. 1987). This VNTR is 
also reflected in mucin mRNAs and is a direct consequence of the variation observed 
at the DNA level (Debailleul et al. 1998). The TR regions typically contain a high 
percentage o f serine and threonine residues. As a result, the TR regions carry most o f  
the O-glycosylation found in mucins (Van den et al. 1998) . Hence, changes in the 
TR length are likely to affect the properties o f the mature mucins through variations 
in size as well as extent o f glycosylation. There is increasing evidence that these or 
other differences in the MUC genes influence an individual’s susceptibility to various 
diseases such as cancer and other inflammatory diseases (Kirkbride et al. 2001; Kyo 
et al. 1999; Silva et al. 2001; Vinall et al. 2000).
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The focus of this project is on MUC4 and MUC5B. These two mucins are 
therefore discussed in detail in the following sections.
1.1.4 MUC4
MUC4 encodes a large mucin with a C terminal membrane anchor and is 
expressed in numerous tissues such as the lungs, colon, cervix and salivary glands 
(Gipson et al. 1997; Liu et al. 2002; Nguyen et al. 1996; Ogata et al. 1992; Troxler et 
al. 1997). MUC4 was not detected in normal pancreas, gall bladder, biliary epithelial 
cells and the liver (Balague et al. 1994; Vandenhaute et al. 1997). In the colon, 
MUC4 is strongly expressed in columnar and goblet cells at the crypt base, but tends 
to diminish with increasing cell maturity such that expression at the surface 
epithelium becomes sporadic (Winterford et al. 1999).
MUC4 is located on chromosome 3q29 and its entire genomic organisation 
has been successfully elucidated (Moniaux et al. 1999). Figure 1-1 shows the 
deduced cDNA structure of MUC4. The characteristic mucin TR domain is located in 
exon 2 of this gene and observed tandem repeat lengths vary between 7-19 kb, 
brought about by a large variation in the number of 48 bp repeat units (Nollet et al. 
1998). As a result, the MUC4 glycoprotein can potentially extend up to 2.12 pm 
above the cell surface, making it one of the largest transmembrane mucins 
discovered so far (Moniaux et al. 1999).
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N-terminal C-terminal
978 residues
3 repeats 
126-130 residues
Tandem repeat of 16 amino acids 
2334-6334 residues
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MUC4a
M--------------------------------------------------------------------------
Signal Peptide □ Domain rich in Potential N-glycosylation Sites
Tandem Repeat □ EGF-like Domains
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Unique Sequence □ Potential Cytoplasmic Tail
Cystein-rich Domain
MUC4P
Figure 1-1 -  Schematic representation of the deduced structure of MUC4
19
The human MUC4 gene is considered to be the orthologue o f the sialomucin 
complex (SMC) or rat Muc4 (Carraway et al. 2000; Moniaux et al. 1999). SMC/Muc4 is a 
heterodimer, which is composed o f two subunits: an O-glycosylated mucin subunit ASGP- 
1, which is tightly bound to ASGP-2, a N-glycosylated transmembrane subunit (Rossi et al. 
1996). The two subunits are translated by a single unique cDNA. MUC4-like SMC/Muc4 
precursor contains a GDPH cleavage site, like that which gives rise to the two subunits 
found in SMC (Moniaux et al. 1999). This therefore suggests that human MUC4 could also 
be cleaved into two subunits, now known as M U C4a and MUC4p (Moniaux et al. 1999). 
Therefore, MUC4 could potentially exist in both soluble (M U C4a) and membrane-bound 
(MUC4P +/- M U C4a) forms.
The hydropathy profile1 o f MUC4p revealed a hydrophobic region o f about 24 
amino acid residues (Moniaux et al. 1999) which is thought to constitute a membrane- 
spanning region and hence the classification o f MUC4 as a membrane-bound mucin. In 
addition, this subunit contains three extracellular Epidermal Growth Factor (EGF) like 
domains (Choudhury et al. 2000). In other proteins, these domains can interact with 
members o f the ErbB receptor tyrosine kinase family and cause activation, thereby playing 
a role in cell signalling (Holbro and Hynes 2004). However, this association between EGF- 
like domains and ErbB receptor tyrosine kinases has only been demonstrated between the 
EGF1 domain in rat ASGP-2 and ErbB2 so far (Carraway, III et al. 1999). This binding has 
been shown to induce tyrosine auto-phosphorylation o f ErbB2, which in turn initiates 
downstream signalling pathways such as the multiple mitogen activated protein kinase 
pathways (MAPK) and the phosphtidyl 3-kinase pathway (PI3K) (Carraway et al. 2003). 
Since these pathways are involved in cell transformation, this suggests that ErbB2 plays a 
role in this process. Indeed, overexpression o f ErbB2 has been found in many cancerous 
conditions such as breast (Slamon et al. 1987; Slamon et al. 1989), colorectal (Kapitanovic 
et al. 1997), ovarian (Meden and Kuhn 1997) and non-small-cell lung (Yu et al. 1997).
1 Amino acids are hydrophobic, hydrophilic or neutral (Lodish et al. 2000). Each amino acid is assigned a 
hydropathy score, which reflects the extent o f its hydrophobicity. For a given amino acid sequence, these 
scores can be used in a hydropathy profile to predict how the protein would interact with aqueous 
environments and therefore its resultant folding pattern (Kyte and Doolittle 1982; von Heijne 1992)
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The significance o f ErbB2 (also known as HER2) overexpression has been 
particularly well studied in breast cancer. ErbB2 overexpression can upregulate MMP-9 
and MMP-2 protease activities and increase the invasiveness o f breast cancer cells (Tan, 
Yao, and Yu 1997). In addition, Erbb2 overexpression may lead to a stronger angiogenic 
response and an enhanced resistance to apoptosis (Kumar and Yarmand-Bagheri 2001; Yu 
et al. 1998). Together, these can contribute to an increased metastatic potential in breast 
cancer cells. Indeed, ErbB2 overexpressing breast tumours have been shown to be more 
resistant to various treatments, including chemotherapy and hormone therapy (Kim et al. 
2002a; Leitzel et al. 1995). As such, several therapies have been developed to target the 
expression or function o f the ErbB2 receptor (Badache and Goncalves 2006).
Although it is not known if  the EGF-like domains in human MUC4 can interact in a 
similar fashion to rat ASGP-2, the expression o f MUC4 has been found to be very similar 
to that o f ErbB2. Thus, MUC4 cell signalling may play a crucial role in cell proliferation 
and therefore be important for tumour progression.
Extensive alternative splicing o f MUC4 has been detected. This will be discussed in 
further detail in section 3.1.2.
1.1.5 MUC5B
MUC5B encodes a large secreted mucin (Van Klinken et al. 1998). MUC5B is 
expressed primarily in the bronchial glands, saliva (where it is sometimes known as MG1), 
gall bladder and endocervix (Audie et al. 1993; Audie et al. 1995; Campion et al. 1995; 
Gipson et al. 1999; Keates et al. 1997; Nielsen et al. 1997; Troxler et al. 1997; van Klinken 
et al. 1998). Like MUC4, the genomic organisation o f MUC5B is known (Desseyn et al. 
1998). The deduced protein structure inferred from cDNA is shown in Figure 1-2.
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Figure 1-2 -  Schematic Representation of the Deduced Structure of MUC5B protein. Adapted from 
(Desseyn et al. 1998). Cys: cysteine-rich subdomain; R: tandem repeat subdomain; Up: super-repeat unit.
The gene is comprised o f 48 exons and the gene possesses an unusually large 
10713 bps central exon, containing the tandem repeat domain. The central exon consists of 
19 subdomains (Desseyn et al. 1997). There are seven cysteine-rich subdomains (Cysl to 
Cys7), eight tandem repeat subdomains (R01 to RV) and four R-end subdomains (Rl-end 
to RV-end). The tandem repeat subdomains contain imperfectly conserved repeats of 87 
bps, whilst the R-end subdomains show striking sequence similarities to each other. The 19 
subdomains are arranged in a particular pattern, giving rise to four super-repeat units (UpA 
to UpD). Each o f these super-repeat units consists o f a tandem repeat subdomain, followed 
by an R-end subdomain and lastly a cysteine-rich subdomain. The central region is flanked 
by MUC1 lp l5 -like domains, which are similar to those also present in other 11 p i 5.5 
MUC genes. In contrast to the other MUC genes, MUC5B shows no evidence o f variation 
in TR length (Vinall et al. 1998).
The amino and carboxyl termini of MUC5B contain domains (D l, D2, D', D3, D4, 
B and C) that show extensive homology to the similar domains found in human pre pro- 
von Willebrand factor (Desseyn et al. 1998; Offner et al. 1998) as well as in other 1 l p l 5.5 
mucins such as MUC2 and MU5AC (see Figure 1-3).
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Figure 1-3 -  Comparison between von Willebrand Factor and four secreted mucins. Adapted from 
(Perez-Vilar and Hill 1999)
Human von Willebrand factor (vWF) is a multimeric glycoprotein found in plasma, 
where it plays a vital role in blood clotting, by stabilising clotting factor VIII and by 
mediating platelet adhesion (de Groot 2002; Perutelli, Biglino, and Mori 1997). After 
protein translocation, the signal peptide is cleaved off, leaving behind pro-vWF. Pro-vWF 
subunits then form dimers in the endoplasmic reticulum and are subsequently transported 
to the Golgi, where multimerisation takes place (Sadler 1998). The multimerisation o f 
vWF occurs via disulphide linkages between the D domains (Dong et al. 1994; Verweij, 
Hart, and Pannekoek 1987; Voorberg et al. 1990). The process is thought to involve the 
sequence CGLCG, which is similar to the sequence o f the disulphide isomerase active site 
(Mayadas and Wagner 1992). As a result, the process is self-catalysed. The CGLCG motifs 
are found in the D l, D2 and D3 domains o f  MUC5B and MUC5AC. However, the motifs 
are present only in Dl and D3 o f MUC2. In addition, sequence alignments between the 
three MUC genes show the greatest sequence identity in the D3 domains (Offner et al. 
1998), suggesting that D3 is the most likely region for the formation o f disulphide 
linkages.
The mature vWF is finally produced when the propeptide is cleaved o ff via the D' 
domain (Sadler 1998). Since MUC5B also contains a D' domain, it has been proposed that 
a similar D' cleavage event occurs in the production o f the mature MUC5B protein. 
Indeed, by using antibodies specific to D l and D2, Wickstrom et al successfully identified
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a protein fragment in salivary mucin corresponding to the size expected if  D' cleavage had 
occurred in MUC5B (Wickstrom and Carlstedt 2001).
Taken together, the current data suggests that mucin and vWF assembly might be 
conserved and that the D3 domains may play a role in MUC5B polymerisation, similar to 
that seen in vWF. Indeed, work by Perez-Vilar et al on porcine submaxillary mucin (the 
porcine homolog o f human MUC5B) demonstrated that PSM could potentially form 
disulphide-linked dimers via its N-terminal D domains (Perez-Vilar et al. 1998).
Salivary MUC5B has been shown to bind bacteria in various studies, suggesting a 
possible role in oral disease. Veerman et al demonstrated that MUC5B binds Hemophilus 
parainfluenzae but not other bacteria species such as Streptococcus and Staphylococcus 
(Veerman et al. 1995). Periodate acid treatment, partial deglycosylation, or addition of 
monosaccharides did not affect MUC5B binding to H. parainfluenzae. This indicated that 
the binding was not affected by the carbohydrate side chains but was likely instead to 
occur via a non-glycosylated domain.
In another study, Bosch et al (Bosch et al. 2000) examined the effects o f acute 
stress on the salivary levels o f the carbohydrate structure sulfo-Lewis (sulfo-Le), which is 
found on MUC5B and has been identified as an adhesion molecule for Helicobacter pylori 
(Namavar et al. 1998; Veerman et al. 1997). They successfully demonstrated a direct 
correlation between stress-mediated biochemical changes and enhanced saliva-mediated 
adherence o f H. pylori.
1.1.6 Evidence of Changes in MUC  Gene Expression in relation to Disease
A large number studies describe altered expression o f mucins in disease, in 
particular in cancer. Mucins have therefore often been considered as cancer markers. Table 
1-2 summarises the studies on MUC4 and Table 1-3 the studies on MUC5B. In some 
studies, upregulation has been shown at the RNA level while in others increased staining 
with antibodies could also reflect epitope alterations and subcellular localisation.
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In addition to those studies listed, I have m yself been involved in a study on biliary 
tract cancer, where I assisted with the western blot analysis and which is currently being 
prepared as a full manuscript. This is shown in abstract form in Appendix I. Our study 
showed evidence for upregulation o f MUC4 at the mRNA and protein levels in biliary tract 
cancer. In the case o f MUC4, the best antibodies recognise the TR domain and are 
therefore the epitopes that are at risk o f being impeded by glycosylation.
Differences in epitope specificity may account for some for the discrepancies that 
appear to be in the literature. However some discrepancies are also seen for the RNA 
studies, see for example (Nguyen et al. 1996) and (Lopez-Ferrer et al. 2001b) in Table 1-2.
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Disease Type of Evidence Observation and Conclusions Reference
Colon
cancer
mRNA (northern blots) MUC4 mRNA at comparable or higher levels compared to normal. (Ogata et al. 1992)
Protein
(immunohistochemistry)
In 50% of the hyperplastic 
polyps, MUC4 was reduced but 
in the remaining cases was 
similar to normal. Loss of MUC4 
expression was observed in all 
serrated adenomas.
(Biemer-Huttmann 
et al. 1999)
Pancreatic
cancer
mRNA (northern blots)
Enhanced expression of MUC4 in 
pancreatic cancer compared to 
normal.
(Balague et al. 
1994)
mRNA (northern blots) High levels of MUC4 mRNA expression in pancreatic cancer.
(Hollingsworth et 
al. 1994)
mRNA
(in-situ hybridisation)
MUC4 undetectable in normal 
pancreas but detected in 
pancreatic cancer.
(Balague et al. 
1995)
mRNA (slot blots)
MUC4 expressed in pancreatic 
cancer but not in chronic 
pancreatitis and normal pancreas 
samples.
(Andrianifahanana 
et al. 2001)
mRNA
{In-situ hybridisation) 
and Protein
(immunohistochemistry)
Highly increased expression was 
observed in late pancreatic 
intraepithelial neoplasia (PanlN- 
3, pre-cursor lesions) and 
infiltrating ductal 
adenocarcinoma of the pancreas 
compared to normal tissue.
(Park et al. 2003)
Downregulation of MUC4 
using cell transfection 
experiments and anti­
sense RNA. Results 
confirmed with western 
blots and
immunofluorescence
analyses.
Anti-sense transfected cells 
exhibited diminished growth, 
diminished clonogenic ability and 
3-fold decrease in motility 
compared to controls. 
Demonstrates direct association 
of MUC4 mucin with the 
metastatic pancreatic cancer 
phenotype.
(Singh et al. 2004)
Invasive
ductal
carcinoma
of the
pancreas
(IDC)
Protein
(immunohistochemistry)
MUC4 expression significantly 
correlated with poor prognosis.
(Saitou et al. 
2005)
Intraductal 
papillary 
mucinous 
neoplasms 
(IPMNs) of 
the pancreas
Protein
(immunohistochemistry)
Expression of MUC4 found in 
cancerous lesions of IPMNs, but 
undetectable in normal and 
hyperplastic lesions.
(Kanno et al. 
2006)
Gastric
cancer mRNA (northern blots)
Increased levels of MUC4 mRNA 
in gastric cancer compared to 
normal.
(Ho et al. 1995)
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Disease Type of Evidence Observation and Conclusions Reference
Lung cancer
mRNA (northern blots)
Raised levels o f MUC1, MUC3 
and MUC4 mRNA in cancerous 
tissue.
Lung squamous-cell, 
adenosquamous, and large-cell 
carcinomas were characterized 
by increased levels of MUC4 
alone.
(Nguyen et al. 
1996)
mRNA (semi- 
quantitative RT PCR)and 
protein
(immunohistochemistry)
Reduced expression o f MUC4, 
MUC5AC, and MUC8 was 
observed in non-small cell 
carcinomas vs. normal tissue.
(Lopez-Ferrer 
et al. 2001b)
mRNA (northern blots)
Intensity of expression of MUC1 
and MUC4 was always superior 
in cancer vs. normal tissue.
(Seregni et al. 
1996)
mRNA (northern blots)
44% of the cell lines and 72% of 
the tumour samples tested 
showed high levels of MUC4 
mRNA expression
(Hanaoka et 
al. 2001)
Protein
(Immunohistochemistry)
High MUC4 expression in small­
sized lung adenocarcinomas 
correlates significantly with poor 
prognosis.
(Tsutsumida 
et al. 2007)
mRNA (RT PCR, in-situ 
hybridisation) and 
protein
(immunohistochemistry)
MUC4 expressed at protein and 
mRNA levels only in lung 
adenocarcinomas and not in 
malignant or benign mesothelial 
cells. Potential as specific 
marker for lung cancer.
(Llinares et al. 
2004)
Biliary tract 
cancer
mRNA (in-situ 
hybridisation)
Increased expression of MUC4 
and MU5AC of mRNA found in 
cholangiocarcinomas and the 
biliary epithelium, especially for 
dysplastic cells of stone- 
containing intrahepatic bile ducts 
compared with normal controls.
(Lee and Liu 
2001a)
Extrahepatic 
bile duct 
carcinoma
Protein
(immunohistochemistry)
High MUC4 expression 
associated with poor prognosis.
(Tamada et al. 
2006)
Salivary gland
mucoepidermoid
carcinoma
Protein
(immunohistochemistry)
Significant trend towards 
reduction in MUC4 antigen 
expression in high-grade 
tumours compared with low- 
grade and intermediate-grade 
tumours.
(Weed et al. 
2004)
Protein
(immunohistochemistry)
MUC4 expression associated 
with lower grade tumours and 
better prognosis.
(Alos et al. 
2005)and 
(Handra-Luca 
et al. 2005)
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Disease Type of Evidence Observation and Conclusions Reference
Ovarian cancer mRNA (northern blots)
Significant decrease in 
expression of MUC3 and MUC4 
with increasing cancer stage. 
Trend toward improved patient 
survival occurred with increased 
expression of MUC4.
(Giuntoli et 
al. 1998)
Protein
(Immunohistochemistry)
MUC4 expression detected in 
ovarian cancer samples but not or 
weakly detected in normal 
controls.
(Chauhan et 
al. 2006)
Prostate cancer
Protein from tissue 
(immunohistochemistry) 
mRNA from cell lines 
(semi-quantitative RT 
PCR)
Expression of MUC4 
significantly down regulated in 
prostate cancer tissues and cancer 
cell lines vs. normal/benign 
tissue and normal prostate 
epithelial cell lines.
(Singh et al. 
2006)
Barrett's
oesophagus
(pre-cancerous)
mRNA (in-situ 
hybridisation)
Upregulation of MUC4 and 
MUC1 expression in severely 
dysplastic and neoplastic 
oesophageal tissue. Possible use 
as markers o f early progression 
to oesophageal cancer.
(Arul et al. 
2000)
mRNA (semi-quantitative 
RT PCR)
MUC4 levels were significantly 
higher in high-grade 
intraepithelial neoplasia and 
adenocarcinoma, than in 
Barrett’s oesophagus, which was 
in turn lower than in normal 
squamous epithelium.
(Bax et al. 
2004)
Cervical
Dysplasia
(pre-cancerous)
mRNA (in-situ 
hybridisation) and protein 
(immunohistochemistry, 
western blots)
MUC4 was strongly detected in 
dysplastic cervical epithelia but 
was absent in normal stratified 
cervical epithelium.
(Lopez-Ferrer 
et al. 2001a)
Crohn’s disease mRNA (dot-blots)
Expression levels of MUC3, 
MUC4, and MUC5B significantly 
lower in both healthy and 
involved ileal mucosa of patients 
with Crohn's disease compared to 
controls.
(Buisine et al. 
1999a)
Cap polyposis mRNA {in-situ hybridisation)
MUC4 was overexpressed in cap 
polyposis compared to normal.
(Buisine et al. 
1998a)
Chronic sinusitis mRNA (semi-quantitative RT PCR)
Upregulation of MUC4, 
MUC5AC, MUC5B, MUC7, and 
MUC8 compared to normal.
(Jung et al. 
2000)
Black-pigment
gallstones
mRNA {In-situ 
hybridisation)
Presence of MUC2, MUC4, and 
increased expression of MUC1, 
MUC3, MUC5B and MUC6 in 
black stone-containing 
gallbladders vs. gall bladders 
with no stones.
(Lee and Liu 
2001b)
Table 1-2 -  Survey of literature reporting evidence of a change in MUC4 expression in disease vs. 
normal states.
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Disease Type of Evidence Observation and Conclusions Reference
Asthma
Protein
(immunohistochemistry)
In mild asthmatics, large amounts of 
MUC5B, but not MUC5AC, 
positive extracellular mucus was 
found in the airway lumen as plugs. 
Similar MUC5B positive mucus 
plugs were not detected or observed 
in normal controls.
(Groneberg et 
al. 2002)
Protein (western blots)
Significant increase in MUC5B and 
MUC5AC in sputum from 
asthmatics vs. normal controls.
(Kirkham et 
al. 2002)
Chronic
obstructive
pulmonary
disease
(COPD)
Protein
(immunohistochemistry)
COPD specifically associated with 
increased expression of MUC5B in 
bronchiolar lumen and increased 
expression of MUC5AC in 
bronchiolar epithelium vs. normal 
controls.
(Caramori et 
al. 2004)
Chronic
rhinosinusitis
(CRS)
mRNA (semi- 
quantitative RT PCR)
Expression levels of MUC5B and 
MUC5AC in CRS significantly 
increased compared to in normal 
sinus mucosa.
(Kim et al. 
2004)
Protein (ELISA)
MUC5B secretion was significantly 
upregulated in CRS compared with 
normal controls.
(Viswanathan 
et al. 2006)
Protein
(immunohistochemistry)
MUC5AC and MUC5B expression 
was significantly increased in the 
sinus mucosa of CRS patients vs. 
normal sinus mucosa.
(Ding and 
Zheng 2007)
Cystic
fibrosis (CF)
Protein
(immunohistochemistry)
In epithelium of patients with cystic 
fibrosis, MUC5B and MUC5AC- 
staining was significantly increased 
compared to normal controls. 
Staining for MUC5B and MUC5AC 
also increased in airway lumens.
(Burgel et al. 
2007)
Nasal polyps 
(NP)
mRNA (in-situ 
hybridisation) and 
protein
(immunohistochemistry)
MUC5B expression raised in 
bilateral NP, NP from CF patients 
and antrochoanal (AC) polyps vs. 
normal nasal mucosa.
(Martinez- 
Anton et al. 
2006)
Chronic otitis 
media (COM) 
and mucoid 
otitis media 
(MOM)
mRNA (northern blots, 
in-situ hybridisation) 
and protein (western 
blots, ELISA)
MUC5B and MUC4 were 
upregulated 4.2-and 6-fold, 
respectively, in middle ears with 
COM or MOM. Upregulation of 
mucin genes was accompanied by 
increase of MUC5B and MUC4 
producing cells in middle ear 
mucosa.
(Lin et al. 
2001)
Mucoid otitis
media
(MOM)
mRNA (northern blots, 
in-situ hybridisation) 
and protein (western 
blots, ELISA)
5-fold and 6-fold increase in 
MUC5B and MUC4 expression 
respectively in middle ears with 
MOM vs. normal controls.
(Lin et al. 
2003)
Otitis media 
with effusions 
(OME)
mRNA (semi- 
quantitative RT PCR)
MUC5B and MUC5AC expression 
increased 2-3 folds in OME vs. 
normal controls.
(Elsheikh and 
Mahfouz 
2006)
29
Disease Type of Evidence Observation and Conclusions Reference
Lung cancer mRNA (slot blots)
MUC5B was overexpressed in 
cancerous vs. normal tissue. 
Overexpression of MUC5B 
correlated with increased risk of 
post-operative relapse.
(Yu et al. 
1996)
Endometrial
cancer mRNA (slot blots)
Endometrial tumours showed 
increased expression of MUC1, 
MUC5B and MUC8 over normal 
tissues.
(Hebbar, 
Damera, and 
Sachdev 
2005)
Breast cancer Protein(immunohistochemistry)
MUC5B was overexpressed in breast 
cancer but was generally undetected 
in normal breast epithelium.
(Sonora et al. 
2006)
Gallstones mRNA {in-situ hybridisation)
Stronger and more extensive 
expression of MUC5B, MUC3 and 
MUC6 in stone-containing 
gallbladders vs. normal gallbladder.
(Lee and Liu 
2002)
Table 1-3 - Survey of literature reporting evidence of a change in MUC5B expression in disease vs. 
normal states.
1.2 CONTROL OF GENE EXPRESSION
Control o f gene expression is clearly central to the generation o f tissue and 
developmental specificity as well as to disease related changes such those as seen in the 
previous section. This section describes the mechanisms that are responsible for the 
regulation o f gene expression.
1.2.1 Restriction of Gene Expression
1.2.1.1 Spatial Restriction
The so-called housekeeping genes encode products that are required for key 
cellular processes such as translation and metabolism and are found in all cells o f the body 
(Watson JD et al. 1965). Other genes exhibit spatial restriction and show differential 
expression depending on their location. This leads to phenomena such as tissue-specific 
and intracellular-specific gene expression (Durkin et al. 1997; Hughes 1997; Lauffart et al. 
2006; Saito-Hisaminato et al. 2002).
The MUC genes exhibit an extensive range o f cellular and tissue-specific 
expression. MUC1 is perhaps the most widely expressed mucin. It is found in tissues as
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diverse as the stomach, ocular surface and the reproductive tract (Gipson et al. 1997; Ho et 
al. 1993; Inatomi et al. 1995; Watanabe 2002). Other mucins have a more limited range o f 
expression. MUC7 for example, is mainly found on epithelial surfaces o f the respiratory 
system (Biesbrock, Bobek, and Levine 1997).
1.2.1.2 Temporal Restriction
Temporal restriction o f genes is also a common occurrence: this includes 
developmental stage-specific, cell differentiation stage-specific and cell cycle stage- 
specific expression (Cox and Hirsh 1985; Dutcher and Hartwell 1983; Gober et al. 1991; 
Kok et al. 1993; Porter et al. 2005).
The most studied form o f temporal restriction in the MUC genes is that of 
developmental-stage specific expression. Various studies have looked at the expression of 
mucins in different organ systems during development (Buisine et al. 1998b; Buisine et al. 
1999b; Buisine et al. 2000; Reid, Gould, and Harris 1997; Reid and Harris 1998). They 
compared the expression o f various MUC  genes in tissue originating from fetuses of 
different gestational ages as well as tissue from adults. Certain o f the MUC  genes, such as 
MUC5AC  in the trachea (Reid, Gould, and Harris 1997) and MUC4 in the colon (Reid and 
Harris 1998) were expressed in fetuses but were subsequently absent in the same tissue 
taken from adults. In other cases, such as MUC4 in the trachea, there was the opposite 
pattern, with a gradual increase in expression level that eventually reaches a maximal level 
in adults (Buisine et al. 1999b).
1.2.2 Levels of Gene Regulation
Regulation o f mammalian gene expression occurs at two broad levels. These are:
• Transcriptional regulation, which can be further subdivided into the 
following:
o Epigenetic mechanisms and long range control of gene expression 
by chromatin structure, which are methods o f  gene regulation not 
attributed directly to DNA sequence. These include processes such as
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histone acetylation and methylation o f genes (Robertson 2002; Sharma 
et al. 2005; Sproul, Gilbert, and Bickmore 2005). These mechanisms 
affect chromatin structure, physically controlling access o f  the 
transcription machinery to genes, 
o Control of transcription initiation, which involves the binding o f  
transcription factors to DNA regulatory sequences (Maston, Evans, and 
Green 2006; Villard 2004). The vast majority o f  gene regulation is 
believed to occur at this level (Mitchell and Tjian 1989).
• Post-transcriptional regulation, which includes processes such as alternative 
splicing, mRNA transport and stability, and translation efficiency (Audic and 
Hartley 2004; Bevilacqua et al. 2003; Blobe et al. 1993; Day and Tuite 1998; 
Ren and Stiles 1994; Shim and Karin 2002).
The focus o f  this project is on variation in transcription regulation o f the MUC 
genes. Hence, the other levels o f  gene regulation will not be discussed in detail.
1.2.3 An Overview of the Control of Transcription Regulation -  Cis vs. 7>fl/is-acting
Eukaryotic transcription is initiated by the assembly o f a transcription preinitiation 
complex (PIC), consisting o f RNA polymerase II and other general transcription factors, 
such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH (see Figure 1-4) (Conaway and 
Conaway 1993; Tang et al. 1996). The complex directs RNA polymerase II to the 
transcription site start and is responsible for the basal transcription (low-level expression) 
o f a gene.
D ouble­
s tran d ed
DNA RNAPI1
W Start
I
PIC ► transcription
Figure 1-4- The Transcription Preinitiation Complex (PIC). Adapted from (Zawel and Reinberg 1992)
The basal expression levels o f a gene can be increased or decreased by the binding 
o f sequence-specific transcription factors (activators or repressors, respectively) to various 
regulatory sequence elements, such as proximal promoter elements, enhancers and 
silencers (Villard 2004). Thus, transcriptional regulation is based on controlling the 
binding o f trans-acting transcription factors to c/s-acting regulatory sequences:
Transcription factors are usually transcribed from a distantly located gene(s), after 
which they migrate to their site o f action. Since these factors act on distantly located 
targets, they are said to be trans-acting. Indeed, these factors can potentially act on 
multiple regulatory sequences situated at a great distance from their site o f origin as well as 
on both homologues o f a target gene(s) (Griffiths et al. 1999; Strachan and Read 2000)
Conversely, the regulatory elements they bind to tend to be located within the 
vicinity o f the gene being regulated. These sequences are physically on the same DNA 
molecule as the gene being regulated and only influence the expression o f that gene and 
indeed that homologue. Hence, these regulatory elements are said to be cis-acting 
(Griffiths et al. 1999; Strachan and Read 2000).
1.2.4 Classes of C/s-acting Regulatory Elements involved in Transcriptional 
Regulation
The various classes o f c/s-acting regulatory elements are briefly discussed in this
section.
1.2.4.1 Core Promoter Elements
Core promoters are sequence elements on which the PIC assembles and are 
therefore found in the immediate vicinity o f the transcription start site (Smale and 
Kadonaga 2003). Figure 1-5 shows some o f the core promoter elements found in humans.
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Figure 1-5- Core Promoter Elements. Adapted from (Maston, Evans, and Green 2006)
• BRE (TFIIB recognition elements) are recognised by TFIIB (see Figure 1-5). In 
comparison, the other core promoter elements described to date are TFIID 
interaction sites (Smale and Kadonaga 2003). The BRE was originally identified as 
an element that had a positive effect on transcription in vitro, using purified basal 
factors (Lagrange et al. 1998). It has since been shown in vitro using crude nuclear 
extracts and in vivo to repress basal transcription, thereby increasing the amplitude 
o f transcriptional stimulation in the presence o f  an activator (Evans, Fairley, and 
Roberts 2001).
• TATA (TATA Boxes) are short and highly conserved sequences comprised solely 
o f Thymines and Adenines. These are located approximately 26-31 bps upstream o f 
the start site and are bound by the TATA-box-binding protein (TBP) subunit o f 
TFIID (Thomas and Chiang 2006).
• Inr (Initiators) are found in some eukaryotic genes as an alternative to TATA 
boxes (Smale and Baltimore 1989; Weis and Reinberg 1992). In comparison to 
TATA boxes, these are much less conserved.
• MTE (Motif Ten Elements) are a recently discovered class o f  core promoter 
element. The MTE can promote transcription by RNA polymerase II in conjunction 
with the Inr but independently o f  the TATA-box or DPE and can therefore 
compensate for the loss o f  either o f  the two elements (Lim et al. 2004).
• DPE (Downstream Promoter Elements) are, as the name suggests, located 28-32 
bps downstream o f  the transcription start site (Burke and Kadonaga 1997). These 
are thought to be the downstream counterparts o f TATA boxes and appear to be 
conserved from drosophila to humans. This observation suggests an important role 
in basal transcription.
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1.2.4.2 Proximal Promoter Elements
Proximal promoter elements tend to be located 100-200 bps from the start site 
(Anthony J.F.Griffiths et al. 1999; Griffiths et al. 1999). Notable sequence elements falling 
under this classification include:
• GC Boxes, which have the consensus sequence GGGCGG and are usually found 
within 100 bps o f the start site. These bind the Spl transcription factor and 
modulate the basal transcription o f the core promoter (Li et al. 2004).
• API (Activator Protein 1) Sites have the consensus sequence TGAC and bind the 
transcription factor Activator Protein 1. API is a heterodimer o f c-Jun and c-Fos 
both o f which are also transcription factors.API has been shown to play an 
important role in signalling, cell proliferation and apoptosis (Karin, Liu, and Zandi 
1997).
1.2.4.3 Enhancers
Enhancers are sequence elements that enhance the basal transcription level o f genes 
(Khoury and Gruss 1983; Serfling, Jasin, and Schaffner 1985). They differ in terms o f their 
location from proximal promoter elements that also up-regulate gene transcription (i.e. 
activator-binding sites). Whereas proximal promoter elements are always upstream o f the 
transcription initiation site, enhancers can theoretically be found at a great distance from 
the genes they affect. They can be located upstream of, downstream o f or even within the 
genes themselves (Lettice et al. 2003). Unlike core promoter elements, enhancers can exert 
their influence irrespective o f their orientation (Blackwood and Kadonaga 1998).
1.2.4.4 Silencers
Silencers function in the opposite way to enhancers -  they decrease the basal 
transcription level o f genes, thereby silencing their expression (Brand et al. 1985). They 
are thus repressor-binding sites. They share similar characteristics in terms o f location and 
orientation, although some position-dependent silencers, known as Negative Regulatory 
Elements (NRE) have been discovered (Ogboume and Antalis 1998).
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1.2.4.5 Response Elements
Response elements are an interesting class o f cis-acting regulatory element. As 
their name implies, these elements allow the level o f transcription o f a gene to be 
modulated in response to specific external stimuli. They tend to be situated within 1 kb 
upstream of the start site (Kobayashi et al. 1997; Strachan and Read 2000). Some examples 
o f response elements include those that activate transcription in response to specific 
hormones such as glucocorticoids and growth hormones and intracellular secondary 
messengers such as cyclic AMP (Bergad, Towle, and Berry 1999; Hayashi et al. 2004; 
Verma, Blass, and Davidson 1997).
1.2.5 Transcriptional Regulation of MUC4 and MUC5B Expression
This section summarises current knowledge on the promoters o f MUC4 and 
MUC5B and reviews the various studies so far on the regulation o f MUC4 and MUC5B 
expression using experimental systems such as ALI cultures. Schematic diagrams o f the 
promoters, with the relative positions o f putative ds-acting regulatory sequences 
(described in section 1.2.4), are shown on the following pages.
1.2.5.1 MUC4 Promoter
A schematic diagram o f the MUC4 promoter is shown in Figure 1-6. This diagram 
was constructed using information from the work o f Perrais and colleagues (Perrais et al. 
2001b).
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Figure 1-6 - Schematic diagram of MUC4 promoter. Positions of putative transcription factor binding sites (cis regulatory elements, determined computationally) relative 
to start of translation from exon 1. Sites in red have been validated experimentally to bind their associated transcription factors (Perrais et al. 2001b) Diagram not to scale.
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1.2.5.2 MUC5B Promoter
A schematic diagram o f the MUC5B promoter is shown in Figure 1-7. This 
diagram was constructed using information primarily from the work o f Van 
Seuningen and colleagues (Chen et al. 2001; Perrais et al. 2001a; Van, I et al. 2000).
A notable feature o f the MUC5B promoter region is the presence o f a putative 
distal TATA box, in addition to the proximal TATA box first described (Van, I et al. 
2000). This suggested that MUC5B transcription could be initiated from two 
different locations. In order to address this, Perrais and colleagues performed primer 
extension experiments using a reverse primer located 131 bps downstream o f the 
distal TATA box (Perrais et al. 2001a). They successfully obtained a specific 
extension product o f 109 bps, corresponding to a transcription start site located 23 
bps downstream o f the distal TATA box, implying that transcription could indeed be 
initiated from the distal TATA box.
To complement this finding, RT PCR experiments on total RNA from KATO 
III gastric cancer cells were carried out, using a pair o f primers that encompassed the 
distal TATA box, the proximal promoter and the proximal transcription start site. 
PCR products o f the expected sizes were obtained, showing that the entire region 
was transcribed and that both distal and proximal TATA boxes were active.
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Figure 1-7 - Schematic diagram of MUC5B promoter. Positions of putative transcription factor binding sites (c/s-acting regulatory elements, determined computationally) 
relative to start of transcription from proximal TATA box are shown. Sites in red have been validated experimentally to bind their associated transcription factors (Perrais et 
al. 2001a; Van, I et al. 2000)). Diagram not to scale.
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1.2.5.3 Evidence of changes in MUC4 and MUC5B Expression in Response to 
Inflammatory Mediators
Numerous studies have investigated the transcriptional regulation o f MUC4 
and MUC5B expression, often by using Normal Bronchial Epithelial Cells (NHBE) 
grown at the Air Liquid Interface (ALI) as a model system. These have been used 
widely for the study o f respiratory epithelium because cells grown in this manner 
have been shown to retain many morphological and functional properties o f in vivo 
airway epithelial cells (Gray et al. 1996) and have been shown to express mucins 
(Bemacki et al. 1999). Such cells can be treated various inflammatory mediators and 
the change in mucin expression studied.
Examples o f experimental evidence o f changes in MUC4 and MUC5B 
expression in response to inflammatory mediators are summarised in Table 1-4 and 
Table 1-5 respectively.
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Inflammatory 
Mediator Tested Rationale Experimental system used Conclusions from Study Reference
Estrogen
Dexamethasone
Progesterone
Steroid hormones.
mRNA levels quantified by 
slot blotting using 
radiolabelled oligonucleotide 
probes and NHBE cells.
MUC4 expression levels raised 3-4 fold by 
estrogen, 1.5-2 fold by dexamethasone. No 
effect with progesterone but interferes with 
upregulation by estrogen.
(Gollub et al. 
1995)
Tumour necrosis 
factor-alpha (TNF-a)
Interferon gamma 
(INF-y)
Proinflammatory cytokines
MUC4 Transfection assays 
using CAPAN-1 and 2 
pancreatic cell lines.
Mild effect when TNF-a or INF-y used alone. 
Synergistic effect (10-12 fold activation) when 
used together or when INF-y used with 
transforming growth alpha (TGF-a) in CAPAN- 
2 cells.
(Perrais et al. 
2001b)
Neutrophil Elastase
Inflammatory protease. In COPD, 
airway epithelium permanently 
exposed to neutrophil elastase.
Steady state mRNA levels in 
NHBE cells measured by RT 
PCR. MUC4 protein levels 
measured by western blotting.
Neutrophil elastase increased MUC4 expression 
in time and dose dependent manner, and raised 
MUC4 glycoprotein levels.
(Fischer et al. 
2003)
Bile Acids
Abnormal gastro-oesophageal 
reflux and bile acids have been 
linked to the presence of Barrett's 
oesophageal premalignant lesion 
associated with an increase in 
mucin-producing goblet cells and 
MUC4 gene overexpression.
Luciferase reporter assays 
containing MUC4 promoter 
sequences.
Taurocholic, taurodeoxycholic, 
taurochenodeoxycholic and glycocholic bile 
acids and sodium glycocholate strongly activate 
MUC4 expression.
(Mariette et 
al. 2004)
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Inflammatory 
Mediator Tested Rationale Experimental system used Conclusions from Study Reference
Interleukin-4 (IL4)
Inflammatory cytokines
Real-time PCR using mRNA from 
NCI-H650 cell lines. MUC4 
glycoprotein levels quantified by 
western blotting.
IL4 and IL9 upregulate MUC4 mRNA and 
protein levels in a time and concentration 
dependent manner.
(Damera, Xia, 
and Sachdev 
2006)
Interleukin-9 (IL9) (Damera et al. 2006)
IL-1 beta
Lipopolysaccharide
(LPS)
Previously shown to induce 
MUC2 and MUC5AC expression 
(Kim et al. 2002b).
Level of MUC4 mRNA measured 
by RT PCR and the amount of the 
MUC4 mucin glycoprotein 
estimated by ELISA using cultured 
nasal polyps obtained from chronic 
rhinosinusitis patients.
IL-1 beta and LPS upregulate MUC4 
expression at mRNA and protein levels.
(Bai, Song, and 
Kim 2007)
Table 1-4 - Examples of studies on changes in MUC4 expression in response to inflammatory mediators
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Inflammatory 
Mediator Tested Rationale Experimental system used Conclusions from Study
Reference
Bacterial
Lipopolysaccharides
(LPS)
Bacterial inflammation in mucosa 
is accompanied by morphological 
and proliferative changes in goblet 
cells and mucin hypersecretion
RT PCR and ELISA using total 
RNA and secretions from 
HT29-MTX cells, a human 
colon carcinoma derived, 
mucin-secreting goblet cell line
LPS (100 ng/ml) increased MUC5B mRNA 
expression 2.1 fold and stimulated a 31% 
increase in MUC5B secretion.
(Smirnova et 
al. 2003)
Acrolein
Acrolein is an aldehyde in tobacco 
smoke that could cause/exacerbate 
respiratory diseases such as 
bronchitis and asthma, where there 
is mucus hypersecretion.
Steady state mRNA levels in 
NCI-H292 human lung cancer 
cells measured by RT PCR
MUC5B expression unaffected by exposure, 
suggesting MUC5B is constitutively expressed 
in cells tested.
(Borchers, 
Carty, and 
Leikauf 
1999)prostaglandin E2 
TNF-alpha
Eicosanoid inflammatory 
mediators associated with acrolein 
exposure
Interleukin 4 
(IL-4)
IL-4 was shown to dramatically 
upregulate 15-LO expression and 
production of 15-LO metabolites 
(Jayawickreme et al. 1999), which 
is in turn thought to stimulate 
mucin secretion (Marom et al. 
1983)
RT PCR using total RNA 
extracted from NHBE cells in 
ALI culture
IL-4 unexpectedly reduced MUC5B expression. 
Results from Marom and colleagues may have 
differed because bronchial explants in their 
studies contained not only a variety of 
mesenchymal cells but also inflammatory cells, 
which might when exposed to 15-LO 
metabolites stimulate the release of mucin.
(Jayawickre 
me et al. 
1999)
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Inflammatory 
M ediator Tested Rationale Experimental system used Conclusions from Study Reference
Human neutrophil 
defensins (human 
neutrophil peptides 1-3 
[HNP1-3])
Known to induce airway 
epithelial cell proliferation and 
therefore might play important 
role in wound repair
MUC5BmKNA levels in NCI- 
H292 human lung cancer cells 
measured by RT PCR
HNP1-3 increased MUC5B mRNA 
expression, suggesting a role for defensins in 
mucous cell differentiation
(Aarbiou et 
al. 2004)
phorbol 12-myristate 
13-acetate (PMA)
Known inflammatory mediator 
(protein kinase C activator), 
which initiates signalling 
cascades that lead to a variety of 
cell events, including gene 
expression, cell differentiation, 
cell proliferation, and respiratory 
secretions.
Steady state mRNA levels in 
NCI-H292 human lung cancer 
cells measured by RT PCR
ALI cultures using NHBE cells, 
an immortalized NHBE cell 
line HBE1, and human lung 
cancer cell line A549. Real­
time RT PCR and ELISA 
performed.
MUC5B expression unaffected by exposure, 
suggesting MUC5B is constitutively 
expressed in cells tested.
PMA induced MUC5B mRNA in all primary 
NHBE, HBE1, and A549 cells in a time and 
dose dependent manner. MUC5B secretions 
also increased.
(Borchers, 
Carty, and 
Leikauf 
1999)
(Yuan-Chen 
et al. 2007)
Table 1-5 - Examples of studies on changes in MUC5B expression in response to inflammatory mediators. Discrepancy in results between studies on PMA and its effect 
on MUC5B expression might be due to different cell lines used.
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1.3 ALLELIC VARIATION IN GENE EXPRESSION
Allele-specific differences (allelic variation) in levels o f gene expression are 
known to exist in humans. The following sections discuss this phenomenon in detail:
1.3.1 Causes of Allelic Variation in mRNA Expression
1.3.1.1 Genomic Imprinting and X-chromosome Inactivation
Classical M endelian inheritance is obeyed when genes located on paternally 
and maternally inherited chromosomes are equally expressed. This is now 
understood to be an overly simplistic view o f what happens in reality and that 
exceptions exist.
For example, genomic imprinting results in monoallelic expression o f a gene, 
depending on which parent that allele was inherited from (Brannan and Bartolomei 
1999). Examples o f imprinted genes include insulin-like growth factor-2, IGF2, 
which exhibits parental imprinting, and PEG1, which is paternally imprinted in 
fetuses, whereas both alleles are expressed in adults (Ekstrom 1994; Kobayashi et al. 
1997; Reik et al. 2000; Riesewijk et al. 1997).
Another example o f monoallelic expression is that o f X-chromosome 
Inactivation, which results in the random inactivation o f one o f the two X 
chromosomes in the cells o f a female (Lyon 1999; Migeon 1994). This provides a 
mechanism for controlling gene dosage and compensates for the fact that males have 
a single X chromosome compared to females (Lyon 1989).
1.3.1.2 Regulatory Polymorphisms
DNA polymorphisms are defined as DNA sequence variations that occur at a 
frequency o f at least 1% in a particular population. The most frequent type o f 
polymorphism is the Single Nucleotide Polymorphism or Simple Nucleotide
45
Polymorphism (SNP), which is so called because it involves a single-base change 
(Human Genome Project Information 2006). These are thought to occur very often 
throughout the human genome, at a typical rate o f one SNP per 1000 bases (Zhao et 
al. 2003). Other polymorphisms include various types o f repeat number variations 
(VNTR) such as mini and microsatellites, as well as insertions and deletions (indels).
Broadly speaking, polymorphisms fall under two main categories: coding and 
regulatory. Coding polymorphisms occur in the coding regions o f  genes and are 
therefore limited to the exons. These can cause non-synonymous amino acid 
changes, frame shifts and premature stop codons, and have been the focus o f most 
genetic studies concerning association with function (Cargill et al. 1999). This is 
because o f the possibility o f  such changes in amino acid sequence affecting the 
structure and consequently, the function o f  a protein o f interest.
On the other hand, regulatory polymorphisms are located within the various 
non-coding cis elements described in section 1.2.4. These variations can affect the 
complex interactions between trans-acting factors and ds-acting regulatory 
sequences, thus affecting transcriptional regulation. This could in turn influence the 
level o f gene expression.
Regulatory polymorphisms thus give rise to an added degree o f sophistication 
to the expression o f genes, allowing control o f the quantity o f encoded proteins 
produced by an individual, in addition to the quality, as determined by differences in 
amino acid sequence, caused by coding polymorphisms. Thus, differences in gene 
expression levels could potentially account for a major part o f the variation found 
between individuals and indeed in between species (Rodriguez-Trelles, Tarrio, and 
Ayala 2003).
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1.3.2 Methods for Detecting Allelic Variation in mRNA Expression due to e x ­
acting Regulatory Polymorphisms 
1.3.2.1 In Vitro Methods
In vitro approaches most commonly involve reporter assays (Alam and Cook 
1990). These monitor the transcriptional activity o f a synthetic reporter construct 
using a quantifiable reporter protein (such as luciferase) and usually involve the 
putative promoter and upstream regions o f  the gene studied. Such assays can be used 
to compare the relative transcriptional activities o f allele-specific constructs, 
revealing the presence o f allelic variation (Coleman et al. 2002).
An alternative in vitro approach for detecting allelic variation utilises 
Electrophoretic Mobility Shift Assays (EMSA) (Kako et al. 1998). Each allele in an 
individual heterozygous for the gene o f  interest is used as a probe. These are tagged 
with radioactive or fluorescent labels to allow detection. The probes are then 
incubated with nuclear extracts from relevant cell types and then analysed on 
polyacrylamide gels. Non-specific binding is controlled for by introducing a non­
specific competitor DNA at increasing concentrations. Protein-bound DNA will 
migrate more slowly through the gel and show up as a higher molecular weight band 
(called a ‘shift’) compared to unbound DNA. The intensity o f this band indicates the 
stability o f the binding. Thus, the demonstration o f differential transcription binding 
between the two alleles indicates the presence o f allelic variation (Mottagui-Tabar et 
al. 2005).
1.3.2.2 In Vivo Methods
The general strategy used for quantifying relative allelic expression in vivo is 
depicted in Figure 1-8. In this example, the G allele results in strong binding o f a 
trans-acting regulatory protein such as a transcription factor to the cis-acting DNA 
regulatory element. This results in high expression. Conversely, the A allele results 
in weaker binding o f the regulatory protein and results in lower expression.
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Figure 1-8 - Strategy for detecting presence/extent of allelic variation in mRNA expression
Individuals heterozygous for the gene being studied are used. A marker SNP 
is used to distinguish between the two alleles. For most o f the following methods, the 
marker SNP is exonic, because it needs to be transcribed in order to be detected in 
the processed mRNA.
These methods usually begin with obtaining total RNA from an individual 
heterozygous for the gene o f interest. RT PCR is performed using primers 
encompassing a region containing the marker SNP. The RT PCR product contains 
allele-specific PCR fragments, representative o f the different relative amounts o f 
allelic transcripts in the starting total RNA. By determining the relative abundance o f 
each allelic transcript, the presence and extent o f allelic variation in mRNA 
expression can be determined.
The key to these methods is to replicate the procedure in gDNA as well as in 
cDNA, from individuals heterozygous for the gene o f interest. The gDNA results act 
as a reference since the results obtained represent a 1:1 ratio o f  each allele 
(important: assuming there is no gene duplication). This in principle corrects for any 
bias in representation o f one allele over another.
The comparison o f  different alleles within the same individual provides a 
number o f benefits: firstly, both gene copies originate from the same tissue source, 
which controls for tissue and developmental-stage-specific differences; secondly,
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since both gene copies come from the same individual, the different alleles would 
have been exposed to the same environmental influences and trans-acting factors. 
Hence, the detection o f allelic variation in mRNA expression in such individuals can 
be attributed to c/s-acting sequence differences and/or epigenetic effects.
1.3.2.2.1 Early methods
Previously in this lab, three different genotyping methods were successfully 
employed to detect allelic variation in the expression o f lactase (W ang et al. 1994; 
Wang et al. 1995). All the methods generate visible allele-specific bands. A 
significant difference in relative intensity o f the allele-specific bands in cDNA 
compared to that observed in the genomic DNA indicates that allelic variation is 
present.
1.3.2.2.1.1 Restriction Fragment Length Polymorphisms (RFLP) and Single­
strand Conformation Polymorphism (SSCP)
PCR is performed to obtain a product containing an exonic SNP in gDNA. 
An enzyme digestion is carried out and the restriction fragments are analysed by gel 
electrophoresis to identify heterozygous individuals. The process is then repeated 
using cDNA from these heterozygous individuals.
In Figure 1-9, individuals 4 and 5 show a substantially lower expression o f 
the -  allele compared to the + allele in the cDNA. In contrast, individual 6 shows an 
equal expression o f both alleles and therefore a lack o f allelic variation.
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Figure 1 -9 -  RFLP Method. Adapted from (Wang et al. 1995)
The same approach was also taken for SSCP.
1.3.2.2.1.2 33P-based Sequencing
gDNA and cDNA from individual heterozygous for the gene o f interest 
(lactase) were sequenced by a 33P-based method.
In Figure 1-10 below, individuals 43 and 26 are shown with their respective 
gDNA and cDNA autoradiographs. Both individuals are heterozygous (CT) at locus 
666, as indicated by the blue boxes. The C and T bands are o f the same relative 
intensities. A similar result is seen in the cDNA results for individual 26. In 
comparison, the cDNA result for individual 43 shows much higher expression of the 
C allele than T allele, indicating an allelic difference in mRNA expression.
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cDNA 
A C G T
43 -* -C /T
Figure l-10-32P-based Sequencing Method. Adapted from (Wang et al. 1995)
1.3.2.2.2 More Recent methods
1.3.2.2.2.1 Single-base Extension (SBE)
Single-base extension, also known as primer extension or minisequencing, 
has been used in various allelic variation studies (Bray et al. 2003; Yan et al. 2002).
Figure 1-11 shows how the procedure works.
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Figure 1-11 -  SEE Method
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1.3.2.2.2.2 Pyrosequencing
Pyrosequencing is similar to SBE in that a primer is extended by a single 
base, but the method o f detection is markedly different (Ahmadian et al. 2000).
1. The reaction mixture consists o f  RT PCR products from an individual 
heterozygous for the SNP o f  interest, a primer that anneals to the sequence 
and terminates just 5' o f  the marker SNP, DNA polymerase, ATP sulfurylase, 
luciferase and apyrase.
2. Unlabelled ddNTPs are added one at a time to the reaction mixture (Zhou et 
al. 2005). It is unnecessary to add all 4 kinds o f  ddNTPs; only the ddNTPs 
corresponding to the possible SNP alleles are required. DNA polymerase 
incorporates a single ddNTP and pyrophosphate (PPi) is released as a by­
product.
(primer)n + ddNTP polymerase ( (p rim erV i + PPi
3. The released pyrophosphate is then converted to ATP by ATP sulfurylase. 
Luciferase then utilises the ATP to produce light. The amount o f  light 
produced is detected by the pyrosequencing machine.
Suldiryl-ase
T S r ***
A P S + P P i ATP 
luciferin  oxyluciferin
Luciferaserv
ATP L ig h t
n u c le o t id e  in co rp o ra tio n  g e n e r a t e s  lig h t  
s e e n  a s  a p ea k  in th e  pyrogram
Figure 1-12 -  Pyrosequencing Method
4. Excess ATP is removed by apyrase.
ATP Apyrase „ ADP + AM P + phosphate
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5. The next ddNTP is now added and the detection procedure is repeated. The 
relative amounts o f each allelic transcript can then be inferred by comparing 
the amount o f light produced when each ddNTP was added.
1.3.2.2.2.3 SBE with MALDI-TOF MS
M atrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) in conjunction with SBE has been successfully developed into a 
high throughput technique for studying allelic variation by Ding et al (Ding and 
Cantor 2003).
Figure 1-13 shows how this method works. A SBE reaction is carried out, 
similar to that described in section 1.3.2.2.2.1. However, the crucial difference is that 
the reaction contains three different ddNTPs, with the remaining base as a dNTP. In 
addition, none o f the nucleotides are dye-labelled. The dNTP chosen must be a base 
complementary to one o f the two SNP alleles (dGTP in Figure 1-13). This modified 
SBE reaction results in either a single-base or a double-base extension. The different 
sized allele-specific products can then be resolved by MALDI-TOF MS and 
quantified.
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Figure 1-13 -  MALDI-TOF MS Method. Adapted from (Ding and Cantor 2003)
1.3.2.2.2.4 HaploChIP
The main limitation o f the above methods is the requirement for the marker 
SNP to be transcribed. It is not always possible to find such a SNP within a gene o f 
interest and this somewhat limits the usefulness o f the aforementioned techniques.
The Haplotype-specific chromatin immunoprecipitation (HaploChIP) method 
overcomes this limitation (Knight et al. 2003). A marker SNP is still required but that 
SNP in theory can be located anywhere in the gene. The method discriminates 
between the two alleles based on differential initiation o f transcription from genomic 
DNA.
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The first step in this method involves adding formaldehyde to cells, which 
causes protein-DNA cross-linking to occur. Since the initiation o f  transcription o f  a 
gene involves the binding o f  RNA polymerase II to its promoter, this therefore 
excludes non-transcribing alleles.
Next, the cells are lysed and the chromatin is sonicated, producing chromatin 
fragments. After this, the chromatin is immunoprecipitated (ChIP) using an antibody 
specific to a phosphorylated residue (Ser5) in the C-terminal domain o f  RNA 
polymerase II. Phosphorylation o f Ser5 correlates with the transition from initiation 
to elongation o f the nascent transcript. Hence, only the chromatin-bound RNA 
polymerase II will be immunoprecipitated.
The cross-linking is then reversed and the proteins (RNA polymerase II) are 
digested. SBE followed by MALDI-TOF (see section 1.3.2.2.2.3) is then applied to 
the ChlPs to quantify the relative abundance o f  each allele.
pronor DNA crosslnkr< ; ,tt wvd
immurwpnjcpliibon vrtft artjbody 
spoeafc  to DNfc-& rcing prctiHn
reversal of crD&sJrfcs. d p es lio n  &  
protein
nrwaw-re relaravs a d j^ d a n ce  c l a M e s  cl5*:nrr<naled 
fly irtjrfcHr yrrs*r Hafurwrri w (t <
spectrorrefry of PCR am plffcd irrnunoprcdpA aK d  
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Figure 1-14 -  HaploChIP Method (Knight et al. 2003)
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1.3.2.3 In Silico Methods
The prediction o f  genes showing allelic variation in mRNA expression has 
been performed using computers. An example o f this in silico approach is the work 
by Ge and colleagues:
They employed a novel approach o f using the dbEST and HapMap databases 
to detect allelic variation (Ge et al. 2005). First, the HapMap database was used to 
determine the expected allele frequencies for a set o f SNPs, which were common in 
the four distinct populations available from the database. Next, they compared these 
allele frequencies to the allele counts obtained from dbEST for the set o f SNPs. The 
rationale behind their strategy was as follows:
If  a marker SNP in observed ESTs is in linkage disequilibrium with an 
unknown ds-acting regulatory SNP, which gives rise to allelic variation, the allelic 
distribution in the ESTs will deviate significantly from the allelic distribution 
observed in the genomic DNA. Hence, significant differences in SNP allele 
distribution between the EST and HapMap data are indicative o f allelic variation in 
the associated genes.
Using this method, Ge and colleagues identified 976 SNPs which showed 
significant indications (p<0.05) o f allelic variation. To complement their data, Ge 
and colleagues sought to validate some o f  their findings through experimental means. 
They selected 40 genes based on two criteria: first, that they were expressed in 
lymphoblastoid cell lines (LCLs); second, that they showed more significant 
differences in allelic distribution between the EST and HapMap CEPH data. The 
LCL panel included the CEPH individuals from the HapMap database, allowing the 
selection o f individuals heterozygous for the relevant SNPs.
Using DNA sequencing and in-house software, the allele predicted to be over 
expressed matched their experimental results in 242 cases, the alleles were found to 
be equally expressed or undefined in 348 cases and the opposite allele was
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overexpressed in 105 cases. Overall, despite differences between the experimentally 
validated and the predicted findings, the in silico method Ge and colleagues 
employed resulted in the production o f a list o f genes enriched for allelic variation.
1.3.3 Evidence Suggesting that MUC Gene Expression may be Influenced by
Regulatory Polymorphisms
This section presents the arguments to suggest that it would be worthwhile to 
explore the possibility that MUC gene expression may be affected by regulatory 
polymorphisms and hence exhibit allelic variation in mRNA expression.
1.3.3.1 Heritable Differences in Gene Expression Levels are Common in the 
Human Genome
Firstly, a number o f studies in the last few years have indicated that 
genetically determined differences in gene expression are widespread. One such 
study used cDNA microarrays to study genes expressed in lymphoblastoid cells, 
which were derived from 35 unrelated individuals from the Centre d ’Etude du 
Polymorphisme Humain (CEPH) Utah pedigrees (Cheung et al. 2003).
The hybridisation signal intensities o f each individual were compared against 
a reference sample, pooled from 10 individuals for 813 genes. O f the 813 genes, 40 
genes that showed the greatest variation in expression levels between the 35 
individuals were selected. These 40 genes included several that were already known 
to be highly variable amongst individuals, such as HLA-DRB1 and drug metabolising 
genes like CYP3A4 and DHFR, supporting the validity o f their results.
Cheung and colleagues sought to investigate the genetic basis o f the variation 
in gene expression observed by selecting five genes from the 40 highly variable 
genes and examining their transcript levels in three groups o f people -  49 unrelated 
individuals, 35 offspring from 5 CEPH families and 10 pairs o f monozygotic twins. 
Results from quantitative real-time PCR experiments indicated that for all five genes,
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the expression levels were least variable in monozygotic twins and most variable 
amongst the unrelated individuals.
Although subsequent F tests showed that the difference in variance for the 
unrelated individuals versus the monozygotic twins was only marginally significant, 
the results suggest that inter-individual differences in gene expression are widespread 
throughout the genome and that these differences are due at least in part to 
underlying genetic differences.
A study by Morley and colleagues supported this conclusion.(Morley et al. 
2004). They also used microarrays to measure the baseline expressions levels o f 
genes in immortalised B cells from 94 CEPH grandparents. From the 8500 or so 
genes on the microarrays, 3554 genes which showed greater variance in expression 
levels between individuals than between replicate measurements (within individuals) 
were chosen for further study.
Genotypes for SNPs were obtained from the SNP consortium (Matise et al. 
2003) and used to carry out genome-wide linkage analysis for the 3554 expression 
phenotypes in 14 CEPH families. This allowed the authors to isolate expression 
phenotypes with ‘regulators’, which were gene regions that were found to be 
significantly linked to the expression levels when a lod score o f ~3.4 was used. 984 
expression phenotypes with ‘regulators’ were identified, suggesting that a large 
proportion o f human quantitative traits were subject to gene regulation and are 
influenced by underlying genetic determinants.
1.3.3.2 Allelic Variation in Non-imprinted Autosomal Genes - A Heritable and 
Common Occurrence in the Human Genome
The evidence that much o f this variation in gene expression is allele-specific 
first came from the study o f individual genes:
A recent study o f allelic variation in mRNA expression was by Yan and 
colleagues (Yan et al. 2002). They investigated 13 genes for allelic variation in
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mRNA expression in 96 CEPH families using mRNA from lymphoblastoid cell lines 
and the SBE method. They detected significant differences in relative expression 
levels for six o f the 13 genes examined. The extent o f the differences varied amongst 
the heterozygotes, ranging from a 1.3-4.3 fold difference depending on the gene. 
Next, they re-examined these six genes in nine families where a member o f  each 
family had previously exhibited allelic variation. In three o f the families, they 
showed that altered allelic expression levels were consistently inherited together with 
a single haplotype, providing convincing proof that the allelic variation was caused 
by c/s-acting inherited polymorphisms.
Since half the genes examined in this study exhibited allelic variation in 
mRNA expression, the authors proposed that this phenomenon might be a relatively 
common occurrence in humans and this led to a follow-up genome-wide survey. 
Affymetrix HuSNP chips were used to analyse 1063 SNPs, each o f which were 
located in transcribed regions (Lo et al. 2003). A computational method was 
developed to extract the fluorescent intensity o f the allele-specific probes and to 
quantify the relative levels o f expression o f  each allele present. cDNA from seven 
fetal tissues sources such as kidney and liver was used.
There were significant differences in allelic expression for 326 o f the 602 
(54%) genes studied. In about 28% o f the genes, this difference was greater than 
four-fold. Genes known to be imprinted and genes subjected to X-chromosome 
inactivation showed monoallelic expression, just as expected.
In order to substantiate these results, allele-specific real-time quantitative 
PCR was performed on a sample set o f seven genes; two genes were known to be 
imprinted, one gene was shown to have equally expressed alleles, according to the 
HuSNP experiments, whilst the remaining four genes showed allelic variation in 
gene expression. With one exception, the results were concordant with the HuSNP 
findings.
A study by Bray and colleagues examined 15 genes that are expressed in the 
brain using mRNA derived from post-mortem brain (Bray et al. 2003). Their purpose 
was to investigate the extent to which Yan and colleagues’ findings could be
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extrapolated to native human tissue. Polymorphisms located within the 15 genes 
were selected and used to identify an average o f 19 heterozygote individuals per 
polymorphism. These were then used to compare the relative expression levels o f the 
different alleles by SBE. They found that seven o f the 15 genes showed significant 
differences in allelic expression in one or more individuals - approximately half o f 
the genes, as was also reported by Yan and colleagues in their study (Yan et al. 
2002).
A final piece o f evidence supporting the notion that allelic variation is 
widespread throughout the genome was an extensive literature survey o f in vitro 
allelic variation studies up to the year 2002. This survey revealed that 107 genes 
found throughout the human genome exhibited allelic variation (Rockman and Wray 
2002). From reporter assay experiments, 63% o f these 107 genes showed allelic 
differences o f two-fold or greater. However, since most o f the genes tested had been 
pre-selected, based on prior evidence o f probability or functionality, this high 
proportion is unlikely to be a true reflection o f the entire genome.
1.4 HYPOTHESIS AND AIMS OF THE PROJECT
1.4.1 Hypothesis
Mucins have been shown to be aberrantly expressed in a wide variety o f 
inflammatory diseases and types o f cancer (see section 1.1.6). There is also research, 
which shows that mucin expression levels are altered at both mRNA and protein 
levels in response to inflammatory mediators (see section 1.2.5.3). Finally, there is 
evidence, particularly in the case o f MUC5B (see section 5.1.1), to suggest that these 
changes in expression may be due at least in part to inherited regulatory 
polymorphisms affecting transcriptional regulation o f the MUC  genes (see section
1.3.3). Hence, allelic variation in MUC mRNA expression could be important in the 
study o f complex diseases that involve inflammation and mucin alterations. Thus:
We hypothesise that cis-acting regulatory polymorphism is likely to cause 
allelic variation in mRNA expression o f  the MUC genes. This may affect the quantity
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o f particular mucins produced by an individual and thus the properties o f  the mucus 
and also the cellular response to inflammation. This in turn is likely to influence 
susceptibility to disease and disease severity.
1.4.2 Aims of Project
The main aims o f  this project were as follows:
•  To establish an effective method for determining the presence and 
extent o f  allelic variation in mRNA expression o f the MUC  genes.
Two genes were selected as examples: MUC4, which is membrane- 
associated and MUC5B, which is secreted and gel-forming.
• To determine the influence o f template length (due to VNTR) on the 
level o f MUC4 mRNA expression.
• To investigate the presence and degree o f constitutive allelic variation 
in MU5B and MUC4 mRNA expression.
• To test for association between MUC5B genotypes/high expressing 
haplotypes and respiratory outcomes in a longitudinal birth cohort.
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CHAPTER 2
MATERIALS AND METHODS
2 MATERIALS AND METHODS
2.1 SAMPLES
2.1.1 Human Fetal Samples
The human fetal samples were taken from o f 117 aborted fetuses from which 
one or more o f the following tissue types were collected: lung, trachea, salivary 
glands, stomach, gall bladder, liver and intestine. The cohort comprises o f tissue 
originating from both male and female fetuses (although the sex was not determined 
in a large majority o f individuals), with menstrual ages ranging from 11 to 20.4 
weeks. Information regarding the method o f  abortion was also recorded.
The samples were collected over a 7-year period, from 1997 to 2004, by the 
former MRC Tissue Bank at Hammersmith hospital, London. Fully informed consent 
for all the samples was obtained from the respective mothers and ethical approval 
was obtained (Ethical approval reference: UCL/UCLH 04/0011).
Each sample was labelled with an identifier consisting o f a unique number 
representing the individual, followed by a single letter: G (gall bladder), I (intestine, 
both large and small), L (lung), LV (liver), S (stomach), SG (salivary gland) and T 
(trachea), representing the tissue o f origin.
2.1.2 MRC National Survey of Health and Development (NSHD) - 1946 
Longitudinal Birth Cohort)
Details o f this cohort are described in chapter 6 (see section 6.1).Blood and 
buccal samples were collected (Ethical approval reference MREC no 98/2/121) from 
the cohort at age 53 and used to extract genomic DNA (gDNA), giving a total o f 
2939 members represented. Plated buccal gDNA was available for this project (-30  
ng per well) and epidemiological information was available though NSHD.
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2.2 LIST OF BUFFERS AND SOLUTIONS
• 5 X T B E
0.44 M Tris, 0.44 M Boric acid, 12.5 mM EDTA, pH 8.2-8.4
•  Sample loading buffer for agarose gel electrophoresis
0.25 % Bromophenol blue, 0.25 % Xylene Cyanol FF, 15 % Ficoll.type- 
400
• Back Extraction buffer
4 M Guanidine Thiocyanate, 50 mM sodium citrate, 1 M Tris
• Devurinating solution 
0.25 M HC1
• Denaturing solution
1.5 M N aC l, 0.5 M NaOH
• Neutralising solution
1.5 M NaCl, 0.5 M Tris HC1, 0.001 M EDTA, pH 7.2
• Denhardts solution (TOO X)
2 % (w/v) Ficoll type-400, 2 % (w/v) Bovine Serum Albumin (BSA), 2% 
(w/v) Polyvinylpyrrolidone (PVP), filtersterilised with a 0.2 pM  membrane
• Pre-hybridisation solution
60 ml 20 X SSC, 120 ml dH20 , 10 ml Denhardts (100 X), 10 % (w/v) SDS
• 20 X SSC (Sodium Chloride. Sodium Citrate)
3 M NaCl (Sodium Chloride), 0.3 M Na3C6H 50 7 .2H20  (Sodium Citrate), 
pH 7.0
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• ‘Home-made’ Microclean solution
1 M NaCl, 2 mM Tris-HCl, 0.2 mM EDTA, 40 % PEG-8000 (polyethylene 
glycol), 3.5 mM MgCl2
• ‘Home-made’ Better Buffer solution 
200mM Tris-HCl (pH 9.0), 5 mM MgCl2
• AB2ene PCR Buffer IV  (\ OX concentration)
1.25 ml o f 750 mM Tris-HCl (pH 8.8 @ 25 °C), 200 mM (NH4)2S 0 4, 0.1 % 
(v/v) Tween 20®, 15 mM MgCl2
• NEBuffer 2
10 mM Tris-Hcl, 10 mM Mg Cl2, 50 mM NaCl, 1 mM dithiothreitol (pH
7.9 @ 25 °C)
•  NEBuffer 3
50 mM Tris-Hcl, 10 mM Mg Cl2, 100 mM NaCl, 1 mM dithiothreitol (pH
7.9 @ 25 °C)
• NEBuffer 4
20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 
1 mM dithiothreitol (pH 7.9 @ 25 °C)
2.3 RNA/DNA EXTRACTION FROM FETAL TISSUE
2.3.1 Tissue Homogenisation
All fetal tissue samples were stored at -70 °C. All equipment (pestles, 
mortars, and forceps) were cleaned with Presept solution and baked at 180 °C for 6 
hours in order to denature any nucleases. The RNA and DNA extraction protocols 
are optimised for samples ranging from 10-60 mg in weight. Hence, a mallet was 
used to break off a suitably sized piece o f tissue whenever a sample was estimated to 
exceed the 60 mg limit. Otherwise, the entire sample was used.
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First, the piece o f tissue was transferred using forceps into a cyrotube. The 
cyrotube was then dropped into a container filled with liquid nitrogen to keep the 
tissue frozen. Liquid nitrogen was poured into a mortar and a pestle was placed 
inside in order to pre-chill both the mortar and pestle. A separate mortar and pestle 
was used for each sample. Meanwhile, the cryotube was weighed using a balance and 
its weight taken as soon as the reading stabilised. The sample was then emptied into 
the mortar containing liquid nitrogen. The empty cryotube was weighed and the 
difference between the readings gave an estimate o f the weight o f the tissue.
The sample was homogenised with the pestle and mortar, using liquid 
nitrogen.
2.3.2 RNA Extraction
The RNA extraction method employed was the RNA Bee (Biogenesis Ltd) 
extraction solution, which is based on the phenol-chloroform extraction method 
developed by Chomczynski (Chomczynski 1993).
After the sample was completely homogenised, 20 pi o f RNA Bee per mg o f 
tissue was added directly to the mortar. The pestle was used to mix the RNA Bee with 
the sample and the resultant semi-frozen mixture left to thaw.
Once the mixture had thawed completely, it was transferred to a clean 1.5 ml 
microcentrifuge tube using a pipette. The pipette was also used to estimate the total 
volume o f mixture recovered (some o f the mixture was left behind on the mortar). 
Only filtered pipette tips were used from this point forth. Next, 1 pi o f chloroform 
for every 5 pi o f mixture was added to the tube. The tube was then shaken vigorously 
for 30 sec, before it was placed on ice and left to stand for five min.
Next, the tube was centrifuged at 12000 rpm (MSE Micro Centaur centrifuge) 
for 15 min at 4 °C. The aqueous phase containing RNA was then transferred into a 
clean 1.5 ml microcentrifuge tube. Great care was taken not to disturb the interface 
and risk contaminating the aqueous phase with DNA whilst doing so. Thus, in
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practice, not all o f the aqueous phase was recovered, in order to leave a safety buffer 
between the interface and aqueous phase. Next, 500 pi o f isopropanol was added in 
order to precipitate the RNA. The sample was left to stand for 10 min at room 
temperature before it was centrifuged at 12000 rpm (MSE Micro Centaur centrifuge) 
for 15 min at 4 °C. The tube containing the organic phase was stored at -70 °C for 
gDNA extraction later on.
The supernatant was removed and care was taken not to lose the RNA pellet. 
75 % ethanol equal in volume to that o f the starting mixture was added, making sure 
that the pellet was dislodged from the tube wall. The sample was then centrifuged at 
7000 rpm (MSE Micro Centaur centrifuge) for 5 min. Finally, the supernatant was 
removed and the pellet was re-suspended in 50 pi o f  RNase-free dE^O via gentle 
pipetting.
Optical density o f the total RNA was measured and its concentration 
estimated from the A260/A280 ratios. The concentration was adjusted to 200 ngpl'1 
and the sample was stored at -70 °C.
1 pi o f total RNA was checked on 1 % agarose gels and deemed as good 
quality if  the 18s and 28s ribosomal RNA bands were visible.
28s rRNA ---------- ►
18s rRNA -----------►
Figure 2-1 - RNA samples run on 1 % agarose gel to assess their quality
Samples checked
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2.3.3 gDNA Extraction following RNA Extraction
The organic phase left behind during the RNA extraction procedure (see 
section 2.3.2) contains gDNA and proteins. The following procedure was used to 
extract the gDNA from the mixture:
First, the microcentrifuge tube containing the mixture was allowed to defrost 
completely. Then the tube was inverted a few times to mix its contents and 
centrifuged at 12000 rpm (MSE Micro Centaur centrifuge) for 10 min at 4 °C to re­
establish the various separation phases. After this, the remaining aqueous phase was 
removed, thereby reducing any RNA contamination o f  the gDNA.
0.5 X the volume o f RNA Bee used (see section 2.2.2) o f back extraction 
buffer was added. Next, the tube was shaken vigorously for 30 sec and then stored 
for 10 min at room temperature. Then, the tube was centrifuged at 12000 rpm (MSE 
Micro Centaur centrifuge) for 15 min at 4 °C.
The supernatant was discarded and 1 ml o f 75% ethanol was added to the 
pellet. The mixture was stored at room temperature for 10 min and mixed 
periodically by inversion. Next, the sample was centrifuged at 2000 rpm (MSE 
Micro Centaur centrifuge) for 5 min at 4 °C. The ethanol was removed and the pellet 
was allowed to briefly dry for 3 min at room temperature. The pellet was dissolved in 
50 pi o f  8mM NaOH solution by gentle pipetting. Finally, 8.6 pi o f  0.1 M HEPES 
buffer was added to bring the pH o f the gDNA down to 8.4, a pH more suitable for 
PCR reactions.
2.3.4 gDNA Extraction for Southern Blots
Genomic DNA for Southern blots needs to be o f high quality, so for this 
purpose the gDNA was extracted directly from fetal tissue, rather than as a by­
product from the RNA extraction, as described in the previous section.
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An aliquot o f Cell Lysis Solution (Puregene DNA Purification Kit) was 
placed into the water bath set at 53 °C and allowed to warm up. This prevents the 
SDS from precipitating out o f the Cell Lysis Solution at low temperatures. 
Meanwhile, a piece o f fetal tissue was homogenised under liquid nitrogen as 
described in section 2.2.1 and was left at room temperature for 10 min. Next, 600 pi 
o f  the pre-warmed Cell Lysis Solution was added to the mortar and mixed thoroughly 
with the ground tissue before the lysate was transferred to a clean 1.5 ml 
microcentrifuge tube using a pipette.
600 pi o f Cell Lysis Solution is suitable for tissues weighing 10-20 mg. If  the 
piece o f tissue greatly exceeded 20 mg, an additional 600 pi o f Cell Lysis Solution 
was added and the total volume o f the lysate was divided into two microcentrifuge 
tubes. The tubes were henceforth treated like two separate samples for the rest o f the 
extraction.
3 pi o f Proteinase K (20 mg/ml) solution was then added to the tube and its 
contents were mixed by inverting the tube 25 times. The mixture was left to incubate 
overnight in the 55 °C water bath.
The following morning, the sample was cooled to room temperature and 200 
pi o f Protein Precipitation Solution (Puregene DNA Purification kit) was added to 
the lysate. The tube was vortexed at high speed for 20 sec, thoroughly mixing its 
contents before it was centrifuged at 7200 g (Fisher Scientific Force 7 centrifuge) for 
5 min. A protein pellet should be visible at his stage. If  not, the tube was re-vortexed, 
placed on ice for 5 min and the centrifugation step repeated.
The supernatant was transferred into a clean 1.5 ml microcentrifuge tube 
containing 600 pi o f 100% isopropanol (2-propanol) and its contents mixed by 
inverting gently 50 times. The tube was then centrifuged at 7200 g (Fisher Scientific 
Force 7 centrifuge) for 2 min. The supernatant was poured o ff and the tube was 
drained on clean absorbent paper. 600 pi o f 70% ethanol was added and the tube was 
inverted several times to wash the DNA pellet. Following this, the tube was 
centrifuged at 7200 g (Fisher Scientific Force 7 centrifuge) for 2 min. The ethanol
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was discarded, ensuring that the DNA pellet was not lost. The tube was inverted, 
drained on a clean piece o f absorbent paper and allowed to air dry for 10-15 min.
Lastly, the pellet was re-suspended in 100 pi o f DNA Hydration Solution 
(Puregene DNA Purification Kit) before the tube was left on a rocker at 4 °C 
overnight. The gDNA was stored at 4 °C.
1 pi o f gDNA was checked on 1% agarose gels. If no band was visible, 
(sometimes because the DNA pellet was not completely dissolved) the sample was 
incubated at 37 °C for 2 hours and rechecked.
M arker^________ Samples checked
Figure 2-2 - Extracted gDNA run on a 1% agarose gel
2.3.5 Reverse T ranscrip tion  (Single-stranded cDNA Synthesis)
The extracted RNA was converted to cDNA using the following method:
For each sample, 2 pi (-400 ng) o f total RNA was put into two 0.2 ml 
microcentrifuge tubes (Eppendorf), one tube as a + RT and the second as a -  RT 
control. A master mix comprising o f 8 pi o f dfLO, 2 pi o f 10 X dNTPs and 0.5 pi 
(0.25 pg) o f random hexamers was added to each tube. The tubes were heated at 65 
°C for 5 min in a thermocycler (MJ).
Next, a master mix containing 4 pi o f 5 X buffer (provided with Moloney 
Murine Leukemia Virus (MMLV), Invitrogen), 2 pi o f 0.1 M DTT (Invitrogen) and
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0.5 pi o f RNaseOut RNase inhibitor (Invitrogen) was added to both tubes. 1 pi (200 
units) o f MMLV (Invitrogen) was added to the + RT tube whilst 1 pi o f d t^ O  was 
added to the -  RT tube.
Reverse transcription was performed in a thermocycler using the following 
conditions: 37 °C for 2 min, then 25 °C for 10 min, followed by 37 °C for 50 min 
and finally 70 °C for 15 min. Lastly, the cDNA was diluted 1:10 in dLLO and stored 
as smaller aliquots at -20 °C.
2.4 DETERMINATION OF TANDEM REPEAT LENGTHS USING 
SOUTHERN BLOTTING
2.4.1 Digestion of DNA Samples
In order to determine the MUC4 tandem repeat (TR) lengths for an 
individual, gDNA from that individual (obtained by the method described in section
2.3.4) was digested using Pvu II. This enzyme has recognition sites relatively close 
to both 5' and 3' ends o f the MUC4 TR (as well as elsewhere throughout the 
genome), but crucially does not cut within the TR itself. Hence, digestion with this 
enzyme will result in gDNA fragments containing the entire MUC4 TR, for both 
alleles, which can be subsequently detected and sized.
For each sample, 12 pi o f gDNA was digested with a master mix composed 
o f the following: 1.7 pi (17 units) o f Pvu II  (New England Biolabs), 1.7pl o f 
NEBuffer 2 (New England Biolabs), 0.6 pi (0.1M) o f Spermidine (Promega, 
Southampton, UK) and 1 pi o f dH20. The samples were incubated at 37 °C 
overnight.
2.4.2 Gel Electrophoresis
5 pi o f ficoll loading buffer was added to each sample, before they were 
loaded onto a 0.8% agarose gel (2.4 g o f agarose in 300 ml o f 1 X TBE and 3 pi o f
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EtBr (5 m g.m l'1). In addition to the samples, 15 pi o f Raoul Molecular Weight 
Marker was run in the first and last lanes o f the gel. Two digested genomic controls 
o f known molecular size were run as well. The first control is a genomic sample 
prepared from the cell line Caco-2 whilst the second is a mixture o f  two genomic 
samples (180/210). Electrophoresis was performed in 2 litres o f  1 X TBE at 50V, 
50mA for 24 hours. After this, the gel was visualised under UV light with a ruler 
lined up next to the Raoul marker bands and a photo was taken.
2.4.3 Southern Blotting
The gel was subjected to Southern blotting using a VacuGene XL Vacuum 
Blotting Unit (Amersham Pharmacia Biotech). The gDNA fragments were vacuum 
blotted onto a Hybond N+ nylon transfer membrane (Amersham Biosciences) using 
a pressure o f 75 millibars. The following solutions were used as transfer buffers in 
this specific order: first, the depurinating solution for 30 min, next the denaturing 
solution for 30 min, then the neutralising solution for 30 min and finally 20 X SSC 
for 2 hours.
The membrane was placed between two pieces o f 3mm filter paper 
(Whatman) and dried by baking in an oven at 80 °C for two hrs before it was stored 
in a cool dark place.
2.4.4 Radioactive Detection of DNA Fragments
After the Southern blotting was complete, the membranes were ready to be 
probed in the following fashion:
2.4.4.1 Membrane Pre-hybridisation
200 ml o f pre-hybridisation solution was brought up to 65 °C, poured into a 
large clean plastic box and the membranes were added one at a time into the box. 
The box was swirled after each membrane was added to ensure that a layer o f
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solution was between each membrane. Then the box was placed in the water bath at 
65 °C and incubated with agitation for four hrs.
2.4.4.2 Labelling of Probe
The probe was radiolabelled as follows: 6 pi (25-50 ng) o f  a MUC4 TR 
specific cDNA probe (JER64) (Porchet et al. 1991), 54 pi o f d t^ O  and 10 pi o f 
random primers from the Megaprime DNA Labelling System (Amersham 
Biosciences) were combined in a 1.5 ml microcentrifuge tube. The mixture was 
denatured at 95 °C for 5 min and snap cooled on ice. 20 pi o f labelling buffer 
(Megaprime DNA Labelling System), 6 pi o f Redivue 5 '[a32P]dCTP (370 MBq/ml, 
GE Healthcare Life Sciences) and 4 pi o f Klenow (Megaprime DNA Labelling 
System) was added. The mixture was then incubated at 37 °C for 30 min.
Following this, the labelled probe was purified using a Nick column 
(Amersham Biosciences) to remove the unincorporated nucleotides. The reaction 
mixture was applied to the top o f the column and eluted with 400 pi o f  3 X SSC. 
This ‘void’ volume was collected in a 15 ml centrifuge tube and kept aside. The 
labelled probe was then recovered by adding another 400 pi o f 3 X SSC to the 
column. The unincorporated radionucleotides are left behind, within the column 
itself.
The efficiency o f  the radionucleotide incorporation was estimated by 
measurements with a Geiger counter, using the following formula:
counts per minute (cpm) of the labelled probe
Incorporation rate (%) = --------------------------------------------------------------- X 100
cpm of the labelled probe + cpm of the
unincorporated radionucleotides (column)
Equation 2-1 - Estimation of radionucleotide incorporation rate
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The probe was used only if  the incorporation rate was above 50%. Otherwise, 
the labelling procedure was repeated. This procedure labels enough probe to test up 
to five membranes.
2.4.4.3 Probing of Membrane
50 pi o f Herring Sperm DNA (10 mg/ml, Promega) was then added to the 
probe to block non-specific hybridisation o f the probe to the membrane and the 
mixture was boiled for 5 min. The box containing the membranes and 
prehybridisation solution was retrieved from the water bath and the membranes were 
removed. The probe was then introduced into the prehybridisation solution and the 
membranes were returned one at a time to the solution. Lastly, the box was placed 
back in the water bath and incubated with agitation at 65 °C overnight.
2.4.4.4 Washing of Membranes
The next morning, the prehybridisation solution was discarded and the 
membranes were washed to remove any unbound probe. Three wash solutions were 
used consecutively; all contained 0.1% (w/v) SDS but had decreasing amounts o f 
SSC (2%, 0.2% and 0.1% SSC) such that the solutions were o f increasing stringency. 
(2% solution for 30 min, and the duration o f the washes for the 0.2% and 0.1% 
solutions was dependent on Geiger counter readings performed after each wash, the 
goal being to wash o ff as much unbound probe as possible, without washing o ff too 
much o f the bound probe in the process.) All washes were carried out at 65 °C in a 
water bath.
2.4.4.5 Probe Detection
The membranes were wrapped in cling film and placed in a Fuji FG-8 film  
cassette (Fuji film) together with a piece o f Super HR-E30 Fuji medical X-ray film  
(Fuji film). The X-ray films were exposed to the membranes overnight in a -70 °C 
freezer and the autoradiographs developed the following day using a Compact X2
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automatic X-ray film  processor (Xograph Imaging Systems Ltd). Depending on the 
results obtained, longer or shorter exposure times were used for subsequent pieces o f 
film, to obtain the best results possible.
2.4.4.6 Tandem Repeat Size Determination
Once the best possible autoradiograph was obtained for a particular 
membrane, it was scanned using the Grab-IT 2.59 (Ultra-Violet Products) computer 
program. The digital image o f the autoradiograph was then processed using the 
GelWorks ID Intermediate v4.01 (Ultra-Violet Products) software package. This 
software package uses the bands o f known size from the Raoul markers to plot a 
curve o f  size (kb) against distance migrated (cm). This curve is then used to 
determine the size o f  the other bands on the autoradiograph. There are two main 
advantages o f using this system, rather than sizing the bands by hand. The first is that 
the process is faster and more accurate. The second is that the program can take into 
consideration distortions in the gel run (such as if  the DNA fragments did not 
migrate in a straight line during electrophoresis) by using the Caco-2 and 182/210 
samples as internal controls.
2.5 POLYMERASE CHAIN REACTION (PCR)
Two different protocols were used, depending on whether normal Taq 
polymerase or Thermo-Start Taq was used. Following PCR, the products were 
subjected to electrophoresis on 2% agarose gels and visualised under UV light to 
ensure that the PCR products were o f  the expected sizes.
2.5.1 Taq polymerase PCR
A 10 pi reaction was carried out, using 2 pi o f gDNA (-30  ng), 1 pi o f each 
primer (5 pM ), 1 pi o f 10 X Buffer IV (containing M gCl2, ABgene), 1 pi o f 10 X 
dNTPs (200 pM ), 0.05 pi o f Taq polymerase (0.25 units, ABgene) and 3.95 pi o f 
dH20 .
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A standard PCR cycling program was used, although the annealing 
temperature as well as number o f cycles was adjusted depending on the particular 
PCR reaction, as shown in Table 2-1.
95 °C initial denaturation for 5 min, followed by 30 sec o f  denaturation at 95 
°C, 30 sec at the annealing temperature (dependant on the primers used) and 30 sec 
o f extension at 72 °C. These last three steps were repeated up to 35 times (depending 
on the PCR) and were followed by a final 5 min extension at 72 °C.
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Purpose Primer Name Sequence of Primer (5' to 3 ') Product Size (bp)
Annealing 
Temp (°C)
No. of 
Cycles
MUC4 rs2259292 genotyping
MUC4 Ex4 For DNA 
MUC4 Ex4 Rev DNA
TCGGGGAACACAGGACAG
CGTCTCGAAGCAGGAGAGAG
318 63 32
MUC4 rs2259102 genotyping
rs2259l02 Forward Exonic 
rs2259102 Reverse Exonic
ATGGTGAACACAGCCTGCTA
TCCACTGGGCAGGATAGG
132 58 30
MUC4 rs2550240 genotyping
MUC4X7F
MUC4I7R
AACACCTACCAAGCCATCCTC
GGAGTCAGCGTGAGTCAGAAG
263 65 31
MUC4 rs2291652 genotyping
rs2291652 For DNA/cDNA 
rs2291652 rev DNA
CGACGTGGTCTTCCAGCCGAT
TGCTGGCTGCTCCTGCTCTC
282 61 32
MUC4 rs3205933 genotyping
MUC4exon24-F
MUC4exon24-R
TTCATCGGTTGCTTTCTGTG
GGCAGGTTCCTTGTCATCTC
475 58 30
MUC4 rs2291652 gDNA allelic MUC4 cDNA Forward CGGTGGTGGAGGCGTTCT 278 61.4 32ratios rs2291652 For DNA/cDNA CGACGTGGTCTTCCAGCCGAT
MUC5B rs2075859 RFLP 
genotyping
rs2075859 For DNA 
rs2075859 Rev DNA
CAGCGCGCGCAGCACTG
CCTCCCAGCCAGTGCCCTTC
204 62 32
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Purpose Primer Name Sequence of Primer (S' to 3 ') Product Size (bp)
Annealing 
Temp (°C)
No. of 
Cycles
MU5AC rsl 132440 multiplex 
genotyping
MUC5AC rsl 132440 F  
MUC5AC rsl 132440 R
ACACCGAGGTGGAAGAGTGC
CTGGACAGGGGCACAAGTTC
243
61 32
IL4 rs2070874 multiplex 
genotyping
IL4 rs2070874 F  
IL4 rs2070874 R
CTCATTTTCCCTCGGTTTCA
GAAGCAGTTGGGAGGTGAGA
150
IL13 rs l800925 multiplex 
genotyping
IL13 rsl800925 F  
IL13 r s l800925 R
TGACATCAACACCCAACAGG
CACCAGTCTCTGCAGGATCA
201
MUC5B rs2672785 multiplex 
genotyping + gDNA allelic ratios
rs2672785 Multiplex For gDNA 
rs2672785 Rev DNA
CATTCCCTCTTCCCACAGAG
GGGTGCTGGGTATTGTCCT
222
MUC5B rs2075853 multiplex 
genotyping + RFLP genotyping + 
gDNA allelic ratios
rs2075853 For DNA 
rs2075853 Rev DNA
GGGAGGGTGTCTCTGCTTC
GGCAGCATCTGCTTACGG
151
MUC5B rs2075859 multiplex 
genotyping + gDNA allelic ratios
rs2075859 Multiplex For gDNA 
rs2075859 Multiplex Rev gDNA
ACATGCAGCACCAGGAGTGT
GCATGAGGGGCTCTGCTT
207
MUC5B loci 6, 7, 8 sequencing
5BpromFl
5BpromR2
CCACGGAGCATTCAGGAC
CTCAGTCTGGGTGGCTTGTG
576 61 32
MUC5B loci 9, 10, 11 sequencing
5BpromF2
5BpromRl
CACAAGCCACCCAGACTG
GAGCCAACACCAGCGTC
585 61 32
Table 2-1 - Details of primers and conditions for PCR reactions using Taq
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2.5.2 Thermo-Start Tag Polymerase
For some PCRs and all RT PCRs, to reduce the spurious annealing o f the 
primers, Thermo-Start Taq was used:
A 10 pi reaction was carried out, using 3 pi o f gDNA (-3 0  ng) or cDNA, 1 
pi o f  each prim er (5 pM), 1 pi o f Thermo-Start buffer (ABgene), 1 pi o f M gC^ 
(25mM), 1 pi o f  10 X dNTPs (200 pM), 0.05 pi o f Thermo-Start Taq polymerase 
(0.25 units, ABgene) and 1.95 pi o f dH20.
The following cycling program was used: (As was the case with normal Taq 
polymerase PCR, the number o f cycles and annealing temperature was dependent on 
the particular PCR. These details are shown in Table 2-2.)
95 °C initial denaturation for 15 min, followed by 30 sec o f denaturation at 
95 °C, 30 sec at the annealing temperature (dependant on the primers used) and 30 
sec o f  extension at 72 °C. These last three steps were repeated up to 35 times 
(depending on the PCR) and were followed by a final 5 min extension at 72 °C.
The initial denaturing step is 10 minutes longer than that for the normal Taq 
PCR (see section 2.5.1). Thermostart Taq is a chemically modified form o f the 
normal Taq polymerase and an extended heating time is needed to activate the 
enzyme. The principle behind this is that the Taq will not be able to function whilst 
the PCR reactions are being set up and before the reaction mixture has reached 95 
°C, thereby minimising the initial formation o f spurious PCR products that could be 
amplified in the cycling steps.
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Purpose Primer Name Sequence of Primer (5' to 3 ') Product Size (bp)
Annealing 
Temp (°C)
No. of 
Cycles
MUC5B rs2672785 Tetra
rs2672785 FI DNA 
rs2672785 RO DNA
CCCTGTGGAGCCGAGCTGTGA
GTCAGACGCATGGCTGCTTGGAG
296
62 32ARMS genotyping rs2672785 RIDNA 
rs2672785 FO DNA
CAT GGT GT GCCCTGCATGCC 
TTT CC AT AGC ATT G AGC AGG AGCCG
149
MUC5B rs2672785 + 
rs2075853 cDNA allelic 
ratios
MUC5B El-2 For cDNA 
rs2075853 Rev cDNA
GACGCTGGTGTTGGCTCTG 
GCTC AGGCTGGGG AAG AC A
175 59.2 35
MU5B rs2075859 cDNA 
allelic ratios
MUC5B E8-E9 boundary 
rs2075859 Rev cDNA
CTCTGCCCCCGGACCT
AGCCAGAGTGCGTGATGTC
165 60.1 35
MUC4 E3-E4 cDNA
MUC4 E4 For Out cDNA 
MUC4 E4 Rev Out cDNA
GACAGACGGTGGGAGACGCA 
T AGAGGG AATC ACGGAG AGAGG AGC
264 62 35
MUC4 E5-E7 cDNA
MUC4X5F 
MUC4 Ex6 Rev cDNA
GACGATGCTGACTTCTCCAC
ATCCCACCGCTCTGGTAG
277 61 35
MUC4 E7-E9 cDNA
MUC4X7F AACACCTACCAAGCCATCCTC
251 60 35
MUC4X9R CGGTGTAGCCTGTAGAACTGC
MUC4 E23-E24 cDNA
MUC4 cDNA Forward 
MUC4 E24 Rev cDNA
CGGT GGT GG AGGCGTTCT 
CC AGGT CGT AGCCCTTGT AGC
168 57 35
MUC4 E24-25 cDNA
MUC4 E24 For CDNA CTTCAGATGCGATGGCTACA
207 58 35
MUC4 E25 Rev cDNA GCGTCGAGTTTCATGCTCA
Ribosomal RNA controls
Ribol
Ribo2b
CCTGGTT CT GGGG ACCT GG AC 
CAGGTCCAGGGGTCTTGGTCC
144 65 26
Table 2-2 -  Details of primers and conditions for PCR reactions using Thermo-Start Taq
For RT PCR, the primers either spanned intron-exon boundaries or were 
located in exons with large introns in between so that only cDNA and not 
contaminating gDNA produced an amplicon. If  this happened, products amplified 
from contaminating gDNA could be easily identified from their large size.
As an added precaution, whenever RT PCR was carried out on a sample for 
the first time, the PCR was also performed for its -  RT control and checked to ensure 
that a product was not obtained.
2.5.3 S tandard  P rocedure for A garose Gel E lectrophoresis
A standard size marker was run with all agarose gels. The size markers were 
made in the lab using PCR products o f known sizes, as shown in Figure 2-3.
800 bp 
500 bp 
400 bp 
300 bp 
250 bp 
210 bp 
150 bp
100 bp
Figure 2-3 - PCR Size Marker
(w/v) agarose gels were typically used with 50 ml 1 X TBE as the 
buffer. 1 pi o f EtBr (5 mgml"1) was added to the gels and to the 
running buffer. Gel electrophoresis was carried out at 60 mA / 60 V for 30-45 mins 
before the gels were visualised using a UV transilluminator (Ultra Violet Products, 
Cambridge).
1 to 3 % 
gel and running
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2.6 GENOTYPING
Throughout this project, the polymorphisms were typed as inferred 
genotypes: i.e. phenotypes C, CT and T were assumed to be genotypes CC, CT and 
TT.
2.6.1 Restriction Enzyme Digestion
The MUC4 SNPs and the MUC5B rs2075853 and rs2075859 SNPs were 
genotyped by restriction fragment length polymorphism (RFLP). Table 2-3 shows 
the enzyme required to genotype each SNP, the type o f NEB enzyme buffer, the 
volume o f enzyme, enzyme buffer and dFEO required, and the expected sizes o f the 
allele-specific bands. 3 pi o f PCR product was digested in all the assays and 0.15 pi 
Bovine Serum Albumin (BSA) was added to each sample for rs2075859 genotyping.
Gene SNP Enzyme
Vol of 
Enzyme
(MO
NEBuffer
Vol of 
Buffer 
(Ml)
Vol of 
dH20  (pi)
Alleles and 
Band sizes (bp)
MUC4 rs2259292 Sfo I 0.75 2 1 5.25 A = 318 G = 177, 141
MUC4 rs2259102 Mbo I 1 3 1.5 9.5 C = 132 G = 79, 53 
C =  105, 104,
MUC4 rs25 50240 ScrFI 0.5 4 1 5.5 32, 22
G = 209, 32, 22
MUC4 rs2291652 Mbo I 1 4 1.2 6.8 C = 261, 21 T = 282
MUC4 rs3205933 AlwNI 0.5 4 1.2 7.3 A = 475 G = 292, 183
MUC5B rs2075853 Msp I 1 2 1.5 9.5 C = 88, 66 T =  151
MUC5B rs2075859 Bts I 1 4 1.5 9.35 C =  187, 17 T = 204
Table 2-3 - List of enzymes and conditions for restriction enzyme digests
The digest reactions were then left overnight at 37 °C in an incubator. All 15 
pi o f each sample was subjected to electrophoresis the next day on a 3 to 4% agarose 
gel (depending on the particular assay) and visualised using a UV transilluminator.
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2.6.2 Tetra-ARMS Allele Specific PCR (Ye. Humphries, and Green 1992)
The MUC5B rs2672785 SNP was genotyped using this method, which uses 
allele-specific primers. This method uses four primers in a PCR reaction. These are 
the Forward Outer (FO), Reverse Outer (RO), Forward Inner (FI) and Reverse Inner 
(RI) primers. FO and RO are non allele-specific primers that flank the region 
surrounding the SNP to be genotyped. FI and RI are allele-specific primers (for allele 
1 and allele 2, respectively) whose 3' ends terminate at the SNP o f interest. In 
addition, the inner primers have a mismatch mutation at the third base from their 3' 
ends. This mutation helps to make the primers more allele-specific.
Depending on the alleles present in an individual, different PCR products will 
be generated. FO and RO will always generate a product, because these primers are 
non allele-specific. FI and RO will only generate a product if  allele 1 is present, 
whereas FO and RI will generate a product only when allele 2 is present. Hence, a 
homozygote for allele 1 will have the FO-RO and the FI-RO products, a homozygote 
for allele 2 will have the FO-RO and FO-RI products, whilst a heterozygote will have 
all three possible PCR products. These products are differentiated by gel 
electrophoresis. It is therefore vital to design the primers such that the products are 
sufficiently different in size from one another.
A 10 pi PCR reaction was carried out and consisted o f the following: 2 pi o f 
gDNA (~30 ng), 1 pi o f each primer (5 pM), 1 pi o f Thermo-start buffer (ABgene), 
1 pi o f M gCl2 (25mM), 1 pi o f 10 X dNTPs (200 pM), 0.05 pi o f Thermo-Start Taq 
polymerase (0.25 units, ABgene) and 0.95 pi o f d ^ O .
The PCR conditions described in section 2.5.2 were used. All 10 pi o f the 
PCR products were subject to gel electrophoresis and genotyped under UV light.
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2.6.3 Sequencing
2.6.3.1 Purifying PCR Products
15 pi o f PCR product was prepared for each sample using PCR plates 
(ABgene). Next, 5 pi o f the product was run on an agarose gel to check that the 
amplification was successful. The remaining 10 pi o f  PCR product was purified by 
adding 20 pi o f ‘home-m ade’ Microclean and 10 pi o f  dE^O. The plates were 
covered and the samples were thoroughly mixed by running the plates against the 
edge o f a lab bench. The plate was centrifuged at 145 g (MSE Mistral 2000 
centrifuge) for 45 min. Next, the plate lids were removed, the plates inverted, placed 
on pieces o f  paper towel and centrifuged for 1 min at 20 g, in order to remove the 
supernatant.
After this, 150 pi o f 70% EtOH was added to each sample. The plates were 
covered and centrifuged for 25 min at 145 g. As before, the plate lids were removed, 
the plates were inverted, placed on paper towel and centrifuged for 1 min at 20 g. 
Lastly the samples were allowed to air-dry for 15 min at room temperature before the 
DNA pellets were resuspended in 10 pi o f dELO.
2.6.3.2 Sequencing Reaction
3 pi o f purified PCR sample was subjected to electrophoresis on an agarose 
gel and checked under UV light. Depending on the intensity o f the product, 3 to 7 pi 
o f PCR product was subsequently used. The following was added as a master mix to 
each sample: 5 pi o f ‘home-m ade’ Better Buffer, 1 pi o f Big Dye vl. 1 Terminator 
Mix (Applied Biosystems), 0.48 pi o f primer (5 pM ) and enough dL^O to make up 
the volume o f reaction to 15 pi.
The sequencing reaction was carried out as follows: 96 °C for 1 min, 96 °C 
for 10 sec, 50 °C for 5 sec, and 60 ° C for 4 mins. The last three steps were repeated 
for 25 cycles.
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2.6.3.3 Sequencing Reaction Clean-up
Following the sequencing reactions, 80 pi o f 80% isopropanol was added to 
each sample. The plates were covered and run across the edge o f the lab bench to 
mix the samples thoroughly. The samples were left at room temperature for 10 min. 
After this, the plates were centrifuged at 2500 rpm for 45 min (MSE M ISTRAL 2000 
centrifuge). The supernatant was removed in an identical fashion to that used in the 
PCR purification step (see section 2.6.3.1) Then 150 pi o f 70% ethanol was added to 
each sample and the plates were centrifuged at 2500 rpm for 15 min. The supernatant 
was removed in the same way as before. Finally, the sample pellets were allowed to 
air dry at room temperature for 10 min.
2.6.3.4 Electrophoresis and Detection of Sequencing Products
The samples were resuspended in 10 pi o f Hi-Di formamide and run on an 
ABIPRISM  3730XL Genetic Analyser (Applied Biosystems) using a 50 cm array and 
POP-6 polymer (Applied Biosystems). Hi-Di formamide was used in place of 
standard de-ionised formamide because the low conductivity o f  Hi-Di formamide 
aids in the efficient transfer o f samples onto the sequencer’s capillaries. A standard 
Big Dye v l . l  specific run module was used. The results were analysed using 
Sequencing Analysis v5.1.1 (Applied Biosystems)
2.6.4 Multiplex Single Base Extension (SBE)
SBE was used to genotype all three MUC5B SNPs for the work described in 
chapter 6, as well as 3 other markers that formed part o f another project. The method 
uses the SNaPshot Multiplex kit (Applied Biosystems) and reduces genotyping cost 
and time by multiplexing at both the PCR and SBE stages.
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2.6.4.1 Multiplex PCR
Six different sets o f  primers were multiplexed together in the following 
fashion:
A 10.05 pi PCR reaction was carried out, comprised o f  the following: 2 pi o f 
gDNA (-3 0  ng), 0.5 pi (18 pM ) o f rs2672785 Multiplex For gDNA ver 2 primer, 0.5 
pi (18 pM) o f rs2672785 Rev DNA primer, 0.5 pi (7 pM ) o f rs2075853 For DNA 
primer, 0.5pl (7 pM ) o f rs2075853 Rev DNA primer, 0.5 pi (4 pM ) o f  rs2075859 
Multiplex For gDNA primer, 0.5 pi (4 pM ) o f rs2075859 Multiplex Rev gDNA 
primer, 0.5 pi (10 pM) o f  MUC5AC rsll32440 F primer, 0.5 pi (10 pM) o f 
MUC5AC rsl 132440 R primer, 0.5 pi (10 pM ) o f IL13 rsl800925 F primer, 0.5 pi 
(10 pM ) o f IL13 rs l800925 R primer, 0.5 pi (10 pM ) o f IL14 rs2070874 F primer, 
0.5 pi (10 pM ) o f IL14 rs2070874 R primer, 1 pi o f Buffer IV (ABgene), 1 pi o f 10X 
dNTPs (200 pM ) and 0.05 pi o f  Taq polymerase (0.25 units, ABgene).
The following PCR conditions were used: 95 °C initial denaturation for 5 
min, followed by 30 sec o f denaturation at 95 °C, 30 sec o f annealing at 61 °C and 30 
sec o f extension at 72 °C. These last three steps were repeated for 31 cycles and were 
followed by a final 5 min extension at 72 °C.
2.6.4.2 PCR Product Purification
Excess primers and dNTPs from the multiplex PCR reactions had to be 
removed in order to prevent them from interfering with the subsequent SBE 
reactions. Shrimp Alkaline Phosphatase (SAP) was used to remove the 5’-phosphates 
from dNTPs, rendering them useless and Exonuclease I (Exo I) functions as a 3' —► 5' 
single strand exonuclease, thereby removing any excess primers left over from the 
multiplex PCR. SAP was used rather than any other sort o f phosphatase because it 
inactivates fully when heated at 75 °C.
1.33 units o f SAP and 0.8 units o f Exo I (made up as a master mix) were 
added to 4 pi o f PCR product. The PCR products were placed in a thermocycler and
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the following program was run: 37 °C for 60 min, then 75 °C for 15 min and finally a 
4 °C hold. If the SBE reaction was not carried out immediately, the samples were 
stored at - 20 °C.
2.6.4.3 SBE
For each sample, 1.67 pi o f SNaPshot Multiplex Ready Reaction Mix 
(Applied Biosystems) and 0.66 pi o f primer mix consisting o f the following: 0.75 
pM  o f rs2075853 PE primer, 3.6 pM  o f rs2672785 PE primer, 3 pM  o f rs2075859 
PE primer, 1.8 pM  o f PE MUC5AC FORWARD rsl 132440 primer, 0.2 pM  o f PE 
IL13 rsl800925 primer and 2.4 pM  o f PE IL4 rs2070874 primer, was added as a 
master mix to 1 pi o f purified PCR product.
The samples were placed in a thermocycler and the following program was 
run: 96 °C for 10 sec, followed 50 °C for 5 sec, then 60 °C for 30 sec. These three 
steps were repeated for 25 cycles before a final 4 °C hold.
2.6.4.4 Post-extension Treatment
The post-extension treatment removes the 5'-phosphoryl groups from the 
unincorporated ddNTPs and alters their migration, preventing them from co- 
migrating with the fragments o f interest during the electrophoretic run and interfering 
with the interpretation o f results. The post-extension treatment was performed by 
adding 1 pi o f a master mix consisting o f 0.33 pi o f calf intestinal phosphatase (CIP) 
(1 unit/pl), 0.43 pi o f 10X CIP buffer and 0.23 pi o f dE^O to each sample. Next, the 
samples were placed in a thermocycler and the following program was run: 37 °C for 
60 min, followed by 75 °C for 15 min and a 4 °C hold.
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2.6.4.5 Electrophoresis and Detection of SBE Products
2 pi o f  each sample was combined with 10 pi o f  Hi-Di formamide and 0.25 
pi o f  Genescan LIZ 120 size standard. The size standard acts as an internal control. 
This circumvents the problem o f  slight variations in the migration rates o f  identically 
sized products between different capillaries and allows samples run in different 
capillaries to be sized accurately for comparison with each other.
The samples were denatured at 95 °C for 5 m in before they were snap-cooled 
on ice. The samples were then run on an ABI PRISM 3730XL Genetic Analyser 
(Applied Biosystems) using the built-in run module for SNaPshot products. 
Genemapper version 4.0 (Applied Biosystems) was used to analysis the data 
generated from the run. Bins for each marker were assigned. These are a set o f  
instructions that tell the software what size a particular SBE primer should be, the 
colours o f  the peaks expected, and the alleles those colours represent. Once this was 
completed, the genotypes could be called automatically by the software, based on the 
size and colours o f  the peaks.
Table 2-4 shows details o f  the SBE primers, as well as the expected coloured 
peaks and the SNP alleles they represent.
Alleles
Primer Name Sequence (5' to 3') Orientation and Peak 
colours
rs2291652 PE GGTCTTCCAGCCCAT Sense Black = CRed = T
rs2672785 PE GTGTGGCCTGCATTC Anti-sense Red = A Black = G
rs2075853 PE AACAAAGCTCACGCGCC Anti-sense Blue = C Green — G
rs2075859 PE CAGCGCGCGCAGCACTG Sense Black = CRed = T
PEMUC5AC Black = C
Blue = GFORWARD AAAAAAAAAAGCTCGGCGCAGGGCA Sensersl132440
PEIL4
rs2070874 GATATGCAGTGAGAATGTGAG Anti-sense
Blue = C 
Green = T
PEIL13
rs!800925 TTTTTTTTGCCTTTTCCTGCTCTTCCCTC Anti-sense
Blue = C 
Green = T
Table 2-4 - Details of SBE primers
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2.7 TESTING FOR ALLELIC VARIATION IN mRNA EXPRESSION
USING SBE
For the purpose o f  detecting and determining the extent o f allelic variation, 
SBE was used. The primary difference between the SBE method used here and that 
described in section 2.6.4 is that the PCRs and SBEs are all carried out as 
singleplexes.
2.7.1 PCR and PCR Product Cleanup
The relevant PCRs were performed on individuals known to be heterozygous 
for the relevant SNPs, using the conditions and procedures described in section 2.5.2.
After the PCRs were complete, 3 pi o f each sample was subject to gel 
electrophoresis on a 2 % agarose gel. The PCR products were checked to ensure that 
bands o f the expected size were clearly visible. The PCR products were purified 
using the procedure described in section 2.6.4.2.
2.7.2 SBE and Post-extension Treatment
Each reaction was set up in the following manner: 1 pi o f cleaned up PCR 
sample, 0.66 pi o f the relevant extension primer (all at lpM ) and 1.67 pi o f 
SNaPshot Multiplex Ready Reaction Mix (Applied Biosystems).
The samples were then placed in a thermocycler and the program described in 
section 2.6.4.3 was used. After the SBE was complete, the post-extension treatment 
described in section 2.6.4.4 was performed.
2.7.3 Electrophoresis, Detection of SBE Products
16 pi o f Hi-Di formamide was added to each sample. The samples were then 
denatured at 95 °C for 5 min before they were snap-cooled on ice. The SBE products
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were run on an ABI PRISM 3100 Genetic Analyser (Applied Biosystems) using a 50 
cm array and POP-6 polymer (Applied Biosystems). Dye set E was used in 
conjunction with a GeneScan run module, which encodes the parameters shown in 
the table below:
Run Temperature 60 °C
Cap Fill Volume 184 Steps
Current Tolerance 100 pAmps
Run Current 100 pAmps
Voltage Tolerance 0.6 kV
Pre-run Voltage 15 kV
Pre-run Time 180 sec
Injection Voltage 3 kV
Injection Time 22 sec
Run Voltage 15 kV
Number of Steps 10
Voltage Step Interval 60 sec
Data Delay Time 600 sec
Run Time 3000 sec
Table 2-5 -  Parameters for SBE Electrophoresis Run on ABI 3100
The results were then analysed using GeneScan Analysis Software version 3.7 
(Applied Biosystems).
The different alleles are distinguishable by the colour o f their peaks. The peak 
heights are representative o f the abundance o f a particular allele-specific product. 
Hence, the relative abundance o f one allele-specific product compared to the other, 
was calculated as follows:
Allelic Ratio of Sample X Peak Height of Allele 1 of SNP A for Sample X
for SNP A “  peak Height of AUele 2 of SNp A for Sample x
Equation 2-2 - Method for calculating allelic ratios
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2.8 STATISTICAL ANALYSIS
2.8.1 v2 (Chi-Square) Test
•y  -y
Pearson’s x  test, commonly referred to as the % test, is a statistical 
hypothesis test in which the test statistic is evaluated with reference to the %2
<y
distribution. The formula for calculating the x test statistic is as follows:
2 _  V '  "  £ • )
\ n —1 /  v
*=1 E i
Equation 2-3 - Formula for calculating x2 test statistic. Oj = an observed frequency; Ej = an 
expected (theoretical) frequency, asserted by the null hypothesis; n = the number o f possible outcomes 
of each event.
•y
In this thesis, the % test is used as a test for independence in two main ways: 
Firstly, to evaluate the deviation from the expected Hardy W einberg distribution o f a 
population and secondly, to evaluate the statistical significance o f correlations from 
cross tabulations and logistic regression analyses.
2.8.2 Fisher’s Exact Test
Fisher's exact test is a statistical significance test used in the analysis o f 
categorical data where sample sizes are small. The test is used to examine the 
significance o f the association between two variables in a 2 x 2 contingency table.
'y
Although a x  Test could be used in such a situation, Fisher’s exact test has two main
•y
advantages over the x Test. Firstly, it can used when any o f the cell values in the 
contingency table is below 10 and secondly, when the data is very unevenly 
distributed within the contingency table (for example, a value o f  1000 in one cell and 
a value o f  5 in another). The sampling distribution o f  the test statistic only
9 9approximates a % distribution in such cases, making the x test unsuitable.
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2.8.3 Student’s t Test
There are a number o f  uses o f the t test, including determining whether the 
mean o f a normally distributed population has a value specified in a null hypothesis. 
However, in this thesis, the t test was used to test if  the means o f two groups were 
significantly different from each other (see section 5.7). There are different forms o f 
the t-test depending on whether two groups o f equal size are compared and if  the data 
is paired. For the data analysed in this thesis, two unpaired, unequal sized groups 
were compared and the calculation used is as follows:
t -  * '  ~ X ‘- where ( 1  + 1
Sx t_x2 V m  +  n 2 - 2  \ m  n 2
Equation 2-4 -  Formula for calculating t test statistic. 1: first group; 2: second group; s: standard 
deviation; n: number of samples; X  : mean o f group
2.8.4 Bayesian Algorithm
The Bayesian algorithm is used by the Phase program (Scheet and Stephens 
2006; Stephens, Smith, and Donnelly 2001) to infer the haplotypes and their 
probabilities in an individual. As the name suggests, this algorithm is based on Bayes 
theorem, which relies on conditional probabilities.
The algorithm begins by making an initial guess o f the haplotypes, based on 
the allele frequencies. It then resolves all the unambiguous haplotypes (such as those 
in an individual homozygous at all the loci tested). Next, it randomly selects an 
individual from amongst the ambiguous samples and makes an estimate o f the 
probability o f the haplotypes in this individual, under the assumption that all the 
other haplotypes are correct. This process is repeated continuously (as a Markov 
Chain Monte Carlo method) until stable probabilities are obtained.
The method relies on the assumption that an unresolved haplotype should 
most likely resemble a resolved haplotype, on the evolutionary basis that haplotypes 
are derived from other haplotypes.
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2.8.5 Exact Test of Population Differentiation Based on Haplotype
Frequencies (Goudet et al. 1996)
This is a test o f  non-random distribution o f haplotypes into population 
samples under the hypothesis o f panmixia. It is similar to the Fisher’s exact test 
where a 2 x 2 contingency table is constructed, except here a k x  r table is 
constructed instead, where k  is the number o f haplotypes and r the number o f 
populations.
In this thesis, this test is used to determine if  the haplotype distribution is 
significantly different between two different populations, although the test can 
accommodate more than two populations.
2.8.6 Cross Tabulations
Cross tabulations (or crosstabs for short) are essentially contingency tables 
and show the distribution o f two or more variables simultaneously. They are often 
used for a number o f reasons, including ease o f use and because they can be used 
with any level o f data: nominal, ordinal, interval, or ratio.
In this thesis, cross tabulations in conjunction with % tests are mainly used to 
test for significant associations between MUC5B genotypes/haplotypes and various 
respiratory outcomes (see section 6.4)
2.8.7 Analysis of Variance (ANOVA)
In general, the purpose o f  analysis o f variance (ANOVA) is to test for 
significant differences between the means o f two or more groups. In this thesis, 
ANOVA is used primarily to test for significant correlations between MUC5B 
genotypes/haplotypes and measures o f lung function (continuous data in the form o f 
FEVi readings, see section 6.4). It was used in preference to the Student t test since
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more than two groups were compared; this becomes computationally more difficult 
for t tests and greatly increases the chance o f type I errors due to multiple pairs o f 
comparisons.
2.8.8 Likelihood Ratio Test
A likelihood-ratio test is a statistical test in which a ratio is calculated 
between the maximum probabilities o f a result under two different hypotheses. The 
general form o f the test statistic (S) is as follows:
f 1 ^
S  = -21n ^HO
\ ^ h  j
Equation 2-5 -  Formula for calculating likelihood ratio test statistic. LHo: maximum probability of 
an observed result under the null hypothesis; LH: maximum probability o f an observed result under the 
alternative hypothesis
This test statistic approximates to a % distribution, which can be used test for 
a statistically significant difference in likelihood between the two hypotheses. In this 
project, the likelihood ratio test is used primarily to compute a P value for the 
adjusted logistic regressions (see section 6.5)
2.8.9 Logistic Regression
Logistic regression is a variation o f ordinary regression, which is used when 
the dependent variable is a dichotomous variable (such as ‘yes’ or ‘no’ for a disease).
In particular, logistic regression allows one to calculate the odds ratios for a 
variety o f individual risk factors that may be contributing to the occurrence o f a 
disease. The odds ratios represent the risk o f disease for those with the exposure 
being studied (MUC5B in this thesis), relative to the risk o f disease among those 
without the exposure —  adjusted to remove the effects o f all other confounding 
variables.
95
For the work described in this thesis, logistic regression was used in 
conjunction with the likelihood ratio test to compare an unadjusted model vs. an 
adjusted model (adjusted for confounding variables) and generate an overall P value 
for assessing statistical significance o f MUC5B with a respiratory outcome (see 
section 6.5).
2.9 COMPUTER SOFTWARE
• LDmax (Abecasis and Cookson. 2000) 
http://www.sph.umich.edu/csg/abecasis/GOLD/
Part o f GOLD software package. Uses the Slatkin and Excoffler (1995) 
algorithm to analyse genotype data.
• Phase v2.1 (Scheet and Stephens 2006: Stephens. Smith, and Donnelly 
2001)
http://stephenslab.uchicago.edu/software.html
Uses Bayesian algorithm to infer haplotype distributions.
• Arlequin v3.11 (Excoffier, L. G. Laval, and S. Schneider (2005) 
http://cmpg.unibe.ch/software/arlequin3
Integrated software package for population genetics data analysis.
• GeneScan Analysis Software version 3.7 (Applied Biosvstems) 
https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=:catNavi 
gate2&catID=601382
Software package for general fragment analysis. (Discontinued)
• Genemapyer Software v4.0 (Applied Biosvstems) 
https://products.appliedbiosvstems.eom/ab/en/US/adirect/ab?cmd=catNavi 
gate2&catID=600798
Genotyping software package.
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Sequencing Analysis Software v5.1.1 (Applied Biosvstems)
https://products.appliedbiosystems.com/ab/en/US/adirect/ab7cnKNcatNavi
gate2&catID=601780
Software for base calling and sequence analysis.
• Grab-IT 2.59 (Ultra-Violet Products)
Software for capturing images o f gels/autoradiographs. (Discontinued)
• Gel Works ID Intermediate v4.01 (Ultra-Violet Products)
Software for analysing images o f gels/autoradiographs. (Discontinued)
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CHAPTER 3
STUDY OF ALLELIC VARIATION 
IN MUC4 EXPRESSION
3 STUDY OF ALLELIC VARIATION IN MUC4 EXPRESSION
3.1 INTRODUCTION
This chapter is concerned with the study o f  c/s-acting allelic variation in 
MUC4 mRNA expression. MUC4 was chosen for two reasons: it is an example o f a 
membrane-associated mucin and because it is clearly overexpressed in disease, for 
example in pancreatic cancer (Andrianifahanana et al. 2001; Balague et al. 1994; 
Kanno et al. 2006) and biliary tract cancer, as found in a parallel study that I was 
involved in (see Appendix I). This particular property o f MUC4 makes it an 
attractive diagnostic marker for pancreatic cancer (Andrianifahanana et al. 2001). 
The upregulation o f MUC4 in these conditions appears to occur at the mRNA level 
and is most probably a change in gene regulation in these diseases. As such, it was o f 
interest to question whether there is any evidence o f inter-individual differences in 
this response.
In order to test for the presence/extent o f constitutive allelic variation in 
MUC4 mRNA expression, the SBE method was chosen (see section 1.3.2.2.2.1). 
This was for a number o f reasons, including the relatively low cost and successful 
use by other researchers to detect allelic variation in mRNA expression (Cheung et 
al. 2003; Y anet al. 2002)
Two potential confounders/limitations to this study needed to be addressed 
first; these are tandem repeat length variation and alternative splicing in MUC4.
3.1.1 Tandem Repeat Length Variation in MUC4
MUC4 TR length varies highly between individuals and this could influence 
allelic variation in MUC4 gene expression; the idea being that alleles with longer TR 
lengths would take more time to transcribe and hence longer TR length transcripts 
would be less abundant than short TR length transcripts. Thus, one o f the major aims
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of this project is to investigate the influence o f TR length on allelic variation in 
MUC4 expression.
3.1.2 Alternative Splicing in MUC4
It has been known for some time that MUC4 undergoes extensive alternative 
splicing. 24 distinct transcripts o f MUC4 have been reported (Escande et al. 2002; 
Moniaux et al. 2000). These are generated by different combinations o f alternative 
splicing, such as the alternative use o f  exons and the use o f cryptic donor/acceptor 
splice sites as shown in Figure 3-1. The splice variants are named svO-MUC4 to 
sv21-MUC4, MUC4/X and MUC4/Y. svO-MUC4 is the predominant spliceoform 
and encompasses the full M UC4 cDNA sequence. M UC4/X and MUC4/Y are 
unique in that they have a complete deletion o f exon 2 and hence if  at all translated, 
will result in proteins totally lacking the O-glycosylated TR region (Moniaux et al. 
2000). Other splice variants result from different combinations o f splice events and 
these transcripts are shorter than svO-MUC4.
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Figure 3-1 -  Known MUC4 splice variants. Clear and shaded boxes denote constitutive and deleted exons respectively. Extended boxes indicate insertions; reduced boxes 
deletions. The side of the box extended or deleted indicates the involvement of a cryptic acceptor site (left) or cryptic donor site (right). 5’ is a cassette exon. Not to scale.
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Because o f the alternative splicing in MUC4, the first aim o f this work was to 
identify SNPs for use in SBE experiments, avoiding regions o f known splicing 
variation, although at the outset o f the project it was thought likely that these 
alternative spliceoforms would only represent a small fraction o f the transcripts.
3.2 INITIAL SELECTION OF SAMPLES
MUC4 has been detected in fetal stomach (8 to 18 weeks gestation) (Buisine 
et al. 2000), fetal trachea (10.5 weeks onwards) (Buisine et al. 1999b), fetal bronchi 
(12 weeks onwards) (Buisine et al. 1999b) and fetal bronchioles (13 weeks onwards) 
(Reid, Gould, and Harris 1997). Hence, individuals from the fetal population with 
stomach, trachea or lung samples were initially selected for this study. Table 3-1 
provides a summary o f the individuals chosen and the tissues types available.
Lungs Stomach trachea No. of Individuals (n=51)
Average
Gestational 14.0 ± 1.9 13.9 ± 1.9 15.0 ± 2 .2
Age (weeks)
*
0/
4
3
✓ 34
✓ * 2
✓ ✓ 6
✓ ✓ ✓ 2
Total number
of samples 
(n=97)
46 38 13
Table 3-1 - Individuals from fetal population initially chosen for MUC4 study and their 
available tissue types
3.3 GENOTYPE ANALYSIS
RNA and gDNA were extracted from the fetal samples using the methods 
described in sections 2.3.2 and 2.3.3. The extracted gDNA was used to genotype the 
fetal individuals for five MUC4 SNPs: rs2259292 found in exon 4, rs2259102 in
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exon 6, rs2550240 in exon 7, rs2291652 in exon 23 and rs3205933 in exon 24. These 
SNPS were chosen because they had been successfully validated either in the 
HapMap databases or in previous work, could be used as markers for allelic variation 
expression analysis since they were exonic (see section 1.3.2.2) and because they 
were located in exons which were usually not spliced out (see Figure 3-1). 
Representative genotyping results for the five SNPs are shown in Figure 3-2, Figure 
3-3, Figure 3-4, Figure 3-5 and Figure 3-6.
318 b p s____
177 b p s----- ►
141 bps *
M arker AA GG AA AA AG AA AG AG AG 
Figure 3-2 - Representative genotyping results for rs2259292 (exon 4). Digested using Sfo I.
132 b p s____^
79 b p s ------ ►
53 bps *
M arker CG CC GG GG GG CG GG CG CG 
Figure 3-3 - Representative genotyping results for rs2259102 (exon 6). Digested using Mbo I.
209 b p s ^
 ►
1 0 5 ,1 0 4  bps
M arker GG CG CG CG CC CC GG CG GG 
Figure 3-4 - Representative genotyping result for rs2550240 (exon 7). Digested using ScrF I.
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282 bps____
261 bps- — ►
M arker CT CT CT CT CT CT CT CC 
Figure 3-5 - Representative genotyping result for rs2291652 (exon 23). Digested using Mbo I.
475 bps____
292 bps---- ►
183 bps *
M arker GG GG AG GG AGGG GG GG AG 
Figure 3-6 - Representative genotyping result for rs3205933 (exon 24). Digested using AlwN I.
The genotype frequencies were determined for each MUC4 SNP and these 
are shown in Table 3-2. x2 tests were performed for each SNP to test for deviation 
from expected Hardy-Weinberg frequencies.
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SNP Genotypes Fetal Genotype Freq
H W x 1 
P Value
rs2259292 
(exon 4)
AA
AG
GG
0.300(15) 
0.600 (30) 
0.100 (5)
0.210
rs2259102 
(exon 6)
CC
CG
GG
0.020 (1) 
0.314(16) 
0.667 (34)
0.852
rs2550240 
(exon 7)
CC
CG
GG
0.340(17) 
0.460 (23) 
0.200(10)
0.909
rs2291652 
(exon 23)
CC
CT
TT
0.373 (19) 
0.431 (22) 
0.196(10)
0.736
rs3205933 
(exon 24)
AA
AG
GG
0.000 (0) 
0.143 (7) 
0.857 (42)
0.865
Table 3-2 -M UC4  genotype frequencies in fetal population
The MUC4 SNPs allele frequencies in the fetal population were compared 
with other populations in the HapMap database: Centre d ’Etude du Polymorphisme 
Humain (CEPH) samples, Han Chinese from Beijing (CHB), Japanese from Tokyo 
(JPT) and Yoruba (YOR) from Nigeria. The results are shown in Table 3-3:
SNP Allele Allele FrequenciesFetal CEPH CHB JPT YOR
rs2259292 G 0.400 0.356(exon 4)
” “ ”
rs2259102 
(exon 6) 
rs2550240
C 0.176 0.108 0.344 0.261 0.000
0.444 0.318(exon 7) 
rs2291652
G 0.441 0.533 0.875
0.578 0.689(exon 23) 
rs3205933
T 0.412 0.542 0.025
(exon 24) A 0.071 " " '
Table 3-3 - MUC4 SNP allele frequencies in fetal population compared to other HapMap 
populations. Allele shown for each SNP is the minor allele in fetal population. -: Data not available
The allele frequencies in the fetal population are the most similar, for the 
three SNPs for which there are data, to those from the HapMap CEPHs. The 
HapMap CEPH samples were collected in the 1980s in the US from individuals with 
western and northern European ancestry. Unfortunately, information regarding the
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ethnicity o f the fetal samples was not available, but it is likely that the majority o f the 
individuals from the fetal population are o f northern/western European ancestry, 
although the sample set, collected from the London area, undoubtedly includes 
representatives o f non-European groups.
There is however no significant deviation from Hardy-W einberg equilibrium, 
suggesting no very serious problem with population admixture.
3.4 DETERMINATION OF MUC4 TANDEM REPEAT LENGTH
In order to conserve fetal lung, stomach and trachea samples for RNA 
extraction, genomic DNA was extracted (using the method described in 2.3.4) from 
intestine or liver samples whenever these were available.
MUC4 tandem repeat allele lengths were determined by Southern blotting. 
Figure 3-7 shows a photo o f one o f  the gels taken before blotting (see section 2.4.2) 
whilst Figure 3-8 shows its matching autoradiograph. The distance from the wells o f 
each Raoul marker band was determined from the photo and their positions were 
marked on the autoradiographs. The MUC4 TR bands were then sized using the 
method described in section 2.4.4.6.
107
Raoul
1
Raoul
I
18520 bps (6.5 cm) 
14980 bps (7.4 cm) 
10600 bps (9.0 cm)
9007 bps (10.5 cm) 
7378 bps (12.7 cm)
5634 bps (16.2 cm) 
4360 bps (20 J  cm)
Figure 3-7 -  Photo of gel of Pvu / /  digested gDNA. Size of Raoul marker bands and distance from 
wells indicated.
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Raoul
18520 bps 
(6.5 cm)
14980 bps 
(7.4 cm)
10600 bps 
(9.0 cm)
9007 bps 
(10.5 cm)
>
7378 bps ____
(12.7 cm)
Caco2
180/210R a o u l
Test samples
>
^____  Position of
wells
<4____ 18520 bps
M  14980 bps
10600 bos
9007 bps
7378 bps
Figure 3-8 - Representative autoradiograph used to determine MUC4 TR lengths of individuals 
from the fetal population. Horizontal bars show positions of Raoul marker bands. Sizes and distance 
from wells indicated.
Figure 3-9 is a histogram o f the MUC4 TR lengths detected in the fetal 
population, whilst Figure 3-10 shows the distribution o f MUC4 TR lengths in a UK 
population studied previously by Vinall and colleagues (Vinall, Pratt, and Swallow 
2000).
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Figure 3-9 - Histogram of MUC4 TR lengths (kb) in fetal population
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Figure 3-10 - Histogram of MUC4 TR lengths (kb) in UK population (Vinall, Pratt, and Swallow 
2000)
As can be seen, in both cases, the TR lengths appear to fit a tri-modal 
distribution with three main groups o f TR lengths, the first ranging from 7.5 to 9.5 
kb, the second ranging from 10 to 14 kb and the third most distinct group from 14.5 
to 19.5 kb. Thus, in order to better analyse TR lengths in relation to SNP markers
1 1 0
within the MUC4 gene, TR lengths less than 14.5 kb were reclassified as ‘short’ (S) 
alleles and TR lengths greater than 14.5 kb as Tong’ (L) alleles (see Figure 3-9).
3.5 ANALYSIS OF LINKAGE DISEQUILIBRIUM BETWEEN MUC4 
POLYMORPHISMS
At the outset o f this project, it was not known whether LD could be detected 
between MUC4 TR and SNPs either side o f the TR domain. Thus, the pattern o f 
linkage disequilibrium between the TR region and all five SNPs was examined. This 
would also help to make an informed selection o f a SNP to test for allelic expression 
by providing information on phase.
The MUC4 SNP genotypes and TR LS length alleles were used to calculate 
D' values between each marker and a x2 test P value, which indicates whether there is 
significant linkage disequilibrium between any two given markers. The results o f the 
analysis are shown in Table 3-4.
Pair-wise Comparisons X2 P value Lewontin D'
TR vs. rs2259292 0.00005 0.577
TR vs. rs2259102 0.00956 0.692
TR vs. rs2550240 0 0.758
TR vs. rs2291652 0.00088 0.509
TR vs. rs3205933 0.73496 0.153
rs2259292 vs. rs2259102 0 1
rs2259292 vs. rs2550240 0.00058 0.681
rs2259292 vs. rs2291652 0.00159 0.655
rs2259292 vs. rs3205933 0.06089 1
rs2259102 vs. rs2550240 0.02017 0.768
rs2259102 vs. rs2291652 0.13935 0.512
rs2259102 vs. rs3205933 0.6144 0.647
rs2550240 vs. rs2291652 0 0.620
rs2550240 vs. rs3205933 0.01688 1
rs2291652 vs. rs3205933 0.31702 0.495
Table 3-4 - Measures of linkage disequilibrium between MUC4 TR and SNP markers.
Significant LD (P value <0.05) between markers shown in bold.
I l l
The degree o f linkage disequilibrium (LD) between each o f the MUC4 
markers is depicted in a graphical form in Figure 3-11. The diagram is to scale and 
provides an indication o f the physical distance between each marker.
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Figure 3-11 -  MUC4 scale gene diagram showing LD between MUC4 TR and SNPs. Red lines 
indicate significant x P values (<0.05). Dotted lines indicate D' values less than 1.
There seems to be a striking degree o f  LD within the MUC4 gene. The most 
prominent associations appear to be those between the TR domain and the five SNP 
markers. With the exception o f rs3205933, which is some 30 kb (possibly much 
further depending on the actual number o f  TR units) away, all the other SNPS exhibit 
a statistically significant association with the TR domain. The breakdown o f  LD 
between the TR domain and rs3205933 is probably due to recombination between 
rs2291652 and rs3205933, as evident from the lack o f association between these two 
SNPs. There also appear to be significant associations between many pairs o f SNPs, 
although the D' values suggest that the strength o f  these associations varies quite a 
bit.
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3.6 HAPLQTYPE ANALYSIS
Given that rs2259292, rs2259102, rs2550240 and rs2291652 were 
significantly associated with the TR domain, genotype data from these four SNPs 
and the TR domain were used to construct haplotypes using the Phase v2.1 program. 
Figure 3-12 shows the frequency o f each haplotype within the fetal population whilst 
Table 3-5 shows the actual alleles in each haplotype and its associated frequency.
0.300
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« 0.100
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2 3 4 5 6 7 8 9 10 11 12 13 14 151
Figure 3-12 - MUC4 haplotypes and their frequencies in the fetal population determined by 
Phase program
113
Haplotype
Identifier
£
H
rs
22
59
29
2
rs
22
59
10
2
rs
25
50
24
0
rs
22
91
65
2
Haplotype
Freq
1 S G G C C 0.147
2 s G G c T 0.020
3 s G C G C 0.010
4 s G C C C 0.127
5 s G c c T 0.020
6 s A G G T 0.039
7 s A G C C 0.098
8 L G G G c 0.020
9 L G G G T 0.010
10 L G G C C 0.029
11 L G C C C 0.020
12 L A G G C 0.069
13 L A G G T 0.284
14 L A G C C 0.069
15 L A G C T 0.039
Table 3-5 -List of MUC4 haplotypes and their frequencies in the fetal population
There are four common haplotypes (shown in bold): 1, 4, 7 and 13 in the fetal 
population. O f particular note is haplotype 13, which is the only one o f  the four 
common haplotypes that carries the Tong’ (L) allele. If  this haplotype is compared 
with the other three common haplotypes, it seems that the rs2550240 and rs2291652 
SNPs could function effectively as tags for the TR domain (G associated with L for 
rs2550240 and T with L for rs2291652).
3.7 RT PCR MUC4 EXON EXPRESSION ANALYSIS
The next task was to amplify the regions in MUC4 cDNA containing the 
SNPs selected - regions that had been selected in order to avoid alternative splicing. 
Early results showed that products were not obtained in all cases. Thus, there was an 
indication o f alternative splicing in these regions o f MUC4 as well. In order to gain a 
better understanding o f the extent o f alternative splicing o f these regions in fetal 
tissue, all samples (not just heterozygotes) were amplified for all five SNP regions.
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RT PCR using ribosomal RNA specific primers were used as positive 
controls for cDNA quality, since rRNA should be constitutively expressed. RT PCR 
was conducted using a certain number o f rounds o f amplification in order to keep the 
reaction as far as possible in the linear range (35 rounds for the test PCRs and 26 
rounds for the rRNA controls). Figure 3-13 is a representative result from a selection 
o f lung samples and shows significant differences in relative expression o f the 
various exons in different individuals.
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Samples Tested 
Marker <--------------------------------------------►
264 bps
277 bps
MUC4 E3-E4
MUC4 E5-E7
251 bps
M UC4 E7-E9
168 bps
M UC4 E23-E24
207 bps
MUC4 E24-E25
144 bps
rRN A  C ontrol
Figure 3-13 - Representative RT PCR results showing variability in expression of MUC4 exons 
in a series of lung samples. 10 pi o f RT PCR product electrophorised for each sample.
1 1 6
The results o f the RT PCRs are tabulated in Table 3-6. The numbers give an 
indication o f the strength o f  the PCR product (estimated from the gel) obtained per 
RT PCR reaction. The differences in relative efficiencies o f the different RT PCR 
reactions make comparisons across different reactions complicated, so strengths were 
estimated by comparing the relative product strength for different regions using the 
same cDNA and the differences between samples by making comparisons o f the 
different samples amplified in the same PCR experiments.
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SA
M
PL
ES
Lungs Stomach Trachea
Target SNP rs2259292 rs2259102 rs2550240 rs2291652 Rs3205933 rs2259292 rs2259102 rs2550240 rs2291652 rs3205933 rs2259292 rs2259102 rs2550240 rs2291652 rs3205933
RT PCR Ex3-4 Ex5-7 Ex7-8 EX23-24 Ex 23-25 Ex3-4 Ex5-7 Ex7-8 Ex23-24 Ex23-25 Ex3-4 Ex 5-7 Ex7-8 Ex23-24 Ex 23-25
4 0 2 0 2 1 2 3 4 3 4 - - - - -
8 - - - . . - . - - - 3 4 4 4 4
22 0 0 3 2 3 - 1 2 3 3 - - - - -
23 - 0 0 3 3 - 0 0 4 4 - - - - -
25 0 0 0 2 3 3 0 4 4 4 - - - - -
27 3 3 4 3 4 4 4 4 4 4 - - . - -
28 0 0 0 0 0 4 4 0 4 0 - - . - -
30 - - - . . 0 4 4 4 3 - 4 4 4 4
31 0 - 0 1 2 - - - - 3 3 4 4 3
32 - - - - - - - - . 4 2 4 4 4
36 0 1 0 4 4 0 0 4 0 . - . - -
39 0 0 0 0 0 0 4 0 2 3 . - - - -
40 - 4 4 4 4 4 4 0 3 4 . - - - -
49 0 0 1 2 1 0 0 2 2 . - - - -
50 0 0 2 2 2 0 1 3 3 . . . - -
51 0 0 1 0 2 0 4 3 4 . . - - -
54 - 3 4 3 0 2 4 4 3 4 - - - -
57 0 4 0 0 0 4 4 4 4 4 . . - - -
58 0 2 0 0 3 1 4 3 4 . . - - -
60 1 3 4 3 4 1 4 4 2 3 . . . - -
63 - 3 4 3 1 - 2 3 4 3 3
64 0 1 3 3 3 - 4 4 3 3 . . . - -
66 0 1 1 3 3 - 4 4 4 . . . - -
67 0 0 2 1 3 2 4 4 4 4 . . . - -
68 - 0 0 2 1 0 . 2 . _ . . - -
69 0 0 0 0 - 1 4 . 3 . . . . - -
71 0 - 2 2 2 2 1 2 1 . . - -
72 0 0 0 1 1 4 4 4 . . . . - -
73 - 0 2 4 3 0 1 3 4 . . . - -
74 0 0 0 2 1 0 0 3 4 . . - - -
82 - - 0 3 4 3 4 4 4 4 . - - - -
83 0 4 0 0 0 0 4 4 4 4 . . . - -
85 - 0 0 0 0 0 1 4 3 4 . . - - -
86 1 0 3 2 3 . - . . . . 2 4 4 4
87 - - - - - - - - . 4 4 4 4 4
88 0 - 1 3 2 - - - . . 4 4 4 4 4
89 - - - - - - - - . . 0 3 4 3 1
90 - 0 1 - 2 - - - 4 4 . . . - -
91 1 2 2 3 3 0 0 2 3 3 . . - -
92 0 0 1 2 1 0 0 0 0 0 . . - - -
94 0 0 1 4 2 - - - . . 4 4 4 4 4
95 - 0 0 0 0 0 0 0 0 0 _ . . - -
97 0 0 1 2 3 - - - . . _ . . . -
98 0 - 0 2 3 1 2 3 3 3 4 3 4 4 4
100 0 0 2 2 - - - 2 3 _ . . -
103 - - 0 2 0 - - - . . 3 0 3 3 3
104 0 0 0 3 3 3 4 4 4 4 . . . - -
110 - 0 0 0 1 0 3 3 3 4 . . . -
112 0 0 0 1 1 - - - . . . . . -
115 - 0 0 0 0 - - - . . _ _ . -
116 - 0 0 2 1 - - - - - - - - - -
Table 3-6 - RT PCR MUC4 exon expression analysis. 0: no visible product; 1: trace; 2: clearly visible product; 3: strong product; 4: very strong product; sample not available or 
not tested
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As can be seen, there is a great deal o f inter-sample variability in MUC4 
exonic expression. In general, the trachea samples tended to produce strong products 
across all five RT PCR reactions. The expression in stomach was more varied, with 
some samples producing strong products for some exons and weak or undetectable 
products in others. The lung samples showed large inter-individual variability and 
had the weakest expression o f MUC4 overall, with many o f  the samples failing to 
produce any detectable products for the majority o f the RT PCR reactions. In 
addition, there seemed to be relatively lower expression o f  the 5' exons, with the 3' 
exons being expressed more frequently and often more strongly, although it is hard 
to exclude this being due to relative differences in PCR efficiency o f the different 
reactions. There was no correlation between gestational age and the RT PCR 
products obtained.
However, the lack o f expression o f some exons, but strong expression o f 
others in some o f the individuals provides clear evidence o f additional previously 
unreported alternative splicing in MUC4, which is different in different samples and 
therefore suggests inter-individual variability in this.
3.8 TESTING FOR ALLELIC VARIATION IN MUC4 mRNA 
EXPRESSION BY SBE METHOD
Using the information from the work described in the preceding sections o f 
this chapter, rs2291652 was chosen as best marker SNP for testing for allelic 
variation in MUC4 gene expression. This SNP was chosen for the following reasons: 
it appeared as though RT PCR templates would be obtainable for all samples; it has a 
high heterozygosity, increasing the number o f informative individuals available for 
testing by SBE (see section 3.3); it is in significant LD with the TR domain (see 
section 3.5) and can function as a tag for the Tong’ TR allele (see section 3.6).
The initial strategy was to compare rs2291652 heterozygotes with two long 
TR alleles or two short alleles against rs2291652 heterozygotes with both L and S 
TR alleles.
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If the TR length were having a substantial effect, we would expect to see a 
greater difference in allelic expression in the TR LS individuals compared to the TR 
homozygotes.
Given that the T allele o f  rs2291652 is associated with the ‘long’ TR allele, 
the hypothesis at this stage was that if  TR length were exerting a strong influence on 
MUC4 mRNA allelic variation, the SBE experiments would show that the C allele 
(associated with ‘short’ TR alleles) was usually expressed at a higher level than the T 
allele.
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Figure 3-14- Representative preliminary SBE results for rs2291652. Four different cDNA samples 
from heterozygous individuals shown.
Preliminary SBE results showed an imbalance o f  allelic expression with the C 
allele more highly expressed in some samples but the opposite effect observed in a 
few others (examples shown in Figure 3-14). In a few o f the samples, there was 
almost mono-allelic expression. The allelic differences observed were much greater 
than that expected for allelic variation due to TR length differences or even 
regulatory polymorphism.
1 2 0
On completion o f the general semi-quantitative RT PCR, which was done 
whilst this was in progress, it became clear that in a few cases, no PCR product was 
obtainable for this fragment (Ex 23-24, see Table 3-6) even though other regions o f 
MUC4 were expressed.
Both these observations therefore suggested that there is genetic variation in 
alternative splicing o f MUC4 that is influencing allelic variation in MUC4 mRNA 
expression.
It was also clear from the results however, that there were issues with the 
quantitation (as was also being observed for MUC5B) and with the reproducibility o f 
the results. This issue is addressed in more depth in the next chapter.
3.9 DISCUSSION
The first aim o f this chapter was to examine the effect o f TR length on levels 
o f MUC4 allelic expression. As background to this, the extent o f LD was examined 
between exonic SNPs selected for the expression study and the TR domain, 
expressed as ‘Long’ (L) and ‘Short’ (S) alleles. Significant LD was detected between 
the TR domains and SNPs 3 ' o f  the TR domain. Analysis o f HapMap LD plots 
shows that there is also LD between polymorphisms either side o f the MUC4 TR 
domain. This suggests that, as is also the case for MUC1 (Pratt, Islam, and Swallow 
1996), variation o f  the TR domains did not arise because o f unequal reciprocal 
recombination at meiosis, but rather by non-reciprocal events.
The work in this chapter highlights the challenges faced when investigating 
allelic variation in gene expression, in particular the difficulties posed by alternative 
splicing.
MUC4 had been reported to exhibit a high degree o f alternative splicing; this 
was determined using RT PCR on cDNA derived from pancreatic cancer cell lines 
(Choudhury et al. 2000; Moniaux et al. 2000) as well as from epithelial tissue
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obtained from stomach, trachea, salivary glands and other organs (Moniaux et al. 
2000). Spliceoforms were identified by using different primers spanning the length 
o f the gene and by comparing the products obtained to the genomic sequence. 
However, it was not clear that these alternative spliceoforms were major components 
o f the MUC4 transcriptome.
Here we found evidence o f even more extensive MUC4 alternative splicing, 
obtained by RT PCR using primers specifically chosen to avoid regions o f known 
splicing. There were slight differences between the different tissues examined, but 
more note-worthy was the large inter-sample variability in MUC4 exon expression, 
suggesting the possibility o f  inter-individual differences. The 3' most end o f the 
MUC4 transcript was less affected by splicing than the rest o f the regions examined 
and was therefore selected for the mRNA allelic variation studies. Nevertheless, 
there was some variability in expression and the idea that there was c/s-acting 
variation in splicing was strongly suggested by these experiments.
Although the SBE results were encouragingly interesting, the technical 
difficulties encountered, plus the fact that there were four potential genetic sources o f 
variation: cis-acting regulatory polymorphism; TR; possible tissue-specificity and 
alternative splicing, led us to conclude that untangling the relative roles o f these 
different effects would be very difficult, and that this might be better done with 
different sample sets and by using a different approach. For example, alternative 
splicing in MUC4 could be further studied by using microarrays and allelic variation 
in mRNA expression by a method that does not rely on RNA, such as HaploChIP 
(see section 1.3.2.2.2.4). In view o f the extreme complexity o f MUC4, the rest o f the 
work described in this thesis is focussed on MUC5B.
As to whether TR length influences MUC4 expression, it seems that this 
question is unanswerable at present in view o f the extensive alternative splicing 
observed. It is relevant to note that in another parallel study in the group, the effect o f 
TR length on MUC1 expression was addressed and there was no apparent correlation 
between the two (Ng 2007).
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The significance o f the large number o f different MUC4 splice variants is 
subject to speculation. Many o f the MUC4 splice events reported previously result in 
the introduction o f stop codons and thus if  translated, many o f the different 
spliceoforms would produce an identical apomucin. This limits the total number o f 
different putative M UC4 proteins. It is possible that the potential diversity o f 
transcripts could help to modulate the properties o f MUC4. Alternatively, the various 
spliceoforms might serve to reduce the level o f  expression o f the main svO-MUC4 
isoform.
As for MUC4, a number o f splice variants have been reported for MUC1 
(reviewed in (Imbert et al. 2006) and some are directly influenced by a single exonic 
SNP 8 nucleotides from the start o f exon 2 (Ng 2007). In addition, some variation in 
the levels o f  these transcripts was observed. It could well be that there are such 
variations in MUC4. At present our limited observations were from fetal tissue and 
may not apply to adults, but these suggest that this is something to be watchful for in 
disease studies.
Whatever the situation, it seems hardly surprising that there have been 
difficulties in getting good antibody reagents and that there are discrepancies in 
expression studies for MUC4. This issue needs to be fully understood if  MUC4 is to 
be a good disease marker.
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CHAPTER 4
DEVELOPMENT OF SINGLE-BASE EXTENSION 
METHOD FOR DETECTING ALLELIC 
DIFFERENCES IN mRNA EXPRESSION
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4 DEVELOPMENT OF SINGLE-BASE EXTENSION METHOD 
FOR DETECTING ALLELIC DIFFERENCES IN mRNA 
EXPRESSION
4.1 IN TRO DU CTION
This chapter is concerned with the development o f the single-base extension 
(SBE) method to test for allelic variation in mRNA expression o f the MUC genes.
Preliminary experiments showed that there was an allelic bias in the 
representation o f the different alleles in the gDNA o f heterozygous individuals, 
specifically, an over representation o f  A over G in marker SNP rs2672785, T over C 
in rs2075853 and C over T in rs2075859. Representative SBE traces are shown in 
Figure 4-1, Figure 4-2 and Figure 4-3.
GG G Sample 112L
homozygote T V
l Y m L O B U a / □  H  IR 112L 0  E2 f u  /
AG G A Sample 74L
heterozygote A
2Y :M l D S . f n  / U  a  2R 74L D E  I n  /
A
AA A Sam ple 88T
homozygote
/ \ Artifact
.... ............ ........................../  ..................................... _
1Y.S8TB E2.fsa /  H I  3R 88T 0  E  lsa  /
Figure 4-1 - Representative SBE traces from gDNA for rs2672785. One example of each genotype 
shown, confirming that SBE was detecting the alleles accurately. Samples run on ABI3100.
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C T
homozygote
Sam ple 94T
CC
homozygote
Sam ple 53L
Artifact T T
homozygote
Sam ple 49L
3ft « 3 lD E 3 f* > / 3G 631 0  0  tsa /
Figure 4-2 -Representative SBE traces from gDNA for rs2075853. One example of each genotype 
shown, confirming that SBE was detecting the alleles accurately. Samples run on ABI3100.
T
I
TT
homozygote
1
Sam ple 3SG
2Y 3SO  0  EO.C04_00.fM 1 ■ ■  2R 3SG O BB.C04_oe.fM /
CT
homozygote
C T
Sam ple 5S
1JL.J _  _______________
3Y : 88 D BO .004.08 f s j / ■ ■  3R :6S D a_004_08.fsa /
CC
homozygote Sam ple 23L
________1Y : 23L D BB_BM.10.fM /
X: 1900 Y : 289 4
■ ■  1R 23L D E9 ED410 fsa i
Figure 4-3 - Representative SBE traces from gDNA for rs2075859. One example of each genotype 
shown, confirming that SBE was detecting the alleles accurately. Samples run on ABI 3100.
Previously, three technical sources o f  unequal representation o f allele-specific 
products had been highlighted (Moskvina et al. 2005). These are unequal detection o f
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the different fluorescent dyes during electrophoresis o f SBE products, differential 
efficiencies o f  nucleotide incorporation during SBE reactions and unequal 
amplification o f the different alleles during PCR. This chapter addresses these issues.
There are two ways o f  determining the relative allelic ratios using data 
generated from the SBE method -  the measurement o f peak heights or the 
measurement o f peak areas. In all experiments, both values were recorded and used 
to calculate allelic ratios. The results were similar, so peak heights were used to 
calculate allelic ratios (see Equation 2-2) since other researchers have used peak 
heights in their work.
4.2 DETECTION OF FLUORESCENT DYES
At first sight, it appeared that dye detection was not a major issue because 
different relative signal strengths were obtained for different SNPs, even when the 
same dyes were involved.
However, over the course o f this work, dye detection did appear to be a 
significant factor influencing the relative peak heights obtained. Early experiments 
were conducted using an AB I 577 sequencer (Applied Biosystems), whilst later 
experiments were conducted using an ABI 3100 sequencer (Applied Biosystems). 
When the same samples were run on both sequencers, the allelic ratios obtained were 
different, although the extent o f the difference was the same across the samples (see 
Figure 4-4).
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Figure 4-4 -  Representative comparison of allelic ratios detected between ABI 377 and ABI 3100 
sequencers. Same sample run on both machines. Separation of dyes and relative peak heights 
different between sequencers for SNP marker rs2075853.
It was thus clear that the use o f  the machines was not interchangeable and for 
the remainder o f  this project (Chapter 5), only the ABI 3100 was used for detecting 
allele-specific differences in mRNA expression.
4.3 NUCLEOTIDE INCORPORATION
Two factors that might affect nucleotide incorporation were investigated. In 
each case, three MUC5B SNPs were tested using two compound heterozygotes.
4.3.1 Template Concentration
Figure 4-5 shows the electrophoresis o f 3 pi o f PCR product using gDNA 
from two MUC5B compound heterozygotes with different levels o f  MUC5B 
expression. These two rather different samples were used to explore the effect o f a 
greater range o f PCR product concentrations on the allelic ratios measured.
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Marker 43L 67S
222 bps
Figure 4-5 - PCR template for testing rs2672785 and rs2075853 in titration experiments
Serial dilutions were prepared from both samples and used for SBE reactions. 
Figure 4-6 shows a representative result from one o f  the samples for rs2672785.
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0.52000
0.4
o> 1500 
a>I
« 1000 4>a.
500
0.3
0.2
0.125 0.25 0.5 1
o
on
o
a>
<
Amount of template added  (ul)
Figure 4-6 - Graph of peak heights/allelic ratio against amount of template used for rs2672785
The experiments showed that for both samples and for all three SNPs that the 
strength o f the signal (peak height) is increased with the amount o f  template used, 
suggesting that SBE is quantitative. Importantly, the amount o f  template added does 
not significantly alter the allelic ratios obtained. These results suggested that careful 
control o f the amount o f template used for the SBE reactions would not be necessary.
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In practice, 3 pi o f PCR product from every sample was run on an agarose 
gel. If a faint but clear band was visible (such as sample 43 in Figure 4-5), the sample 
was deemed usable for SBE reactions. Some PCR products from gDNA were 
stronger than sample 67 in Figure 4-5 but all PCR products derived from cDNA were 
as strong or weaker than sample 67.
4.3.2 Primer Concentration Titration
A similar experiment was conducted to that described in section 4.3.1. This 
time the amount o f  template was fixed at 1 pi, but the concentration o f primer used 
varied from 0.25 pM  to 2 pM. Increasing the primer concentration resulted in higher 
peak heights just as was observed when template concentration was raised. Again, 
the allelic ratios measured did not change significantly throughout the range o f 
primer concentrations tested for all three MUC5B SNPs (data not shown).
1 pM  was chosen as the optimum primer concentration because o f the strong 
signal produced and because this concentration was the maximum primer 
concentration recommended by the SNaPshot manufacturers.
4.4 UNEQUAL PCR AMPLIFICATION
One way in which there might be an allelic bias in PCR amplification is the 
presence o f unknown polymorphisms located in the PCR primer annealing sites. 
Thus, all PCRs were designed such that there were no known SNPs in their annealing 
sites and that the SNP being tested was well spaced from the PCR primers.
4.5 THE POSSIBILITY OF SEGMENTAL GENE DUPLICATIONS OF 
THE SBE PRIMER ANNEALING SITE
Allelic imbalance in gDNA could also be due to the existence o f variable 
number o f copies o f  target sequence due for example to segmental duplications as
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has been recently reported to be widespread in the genome (Conrad and Antonarakis 
2007; Freeman et al. 2006).
An important assumption made when using SBE for detecting allelic variation 
is that the SBE primer anneals only once for every allele. If  segmental duplications 
exist, the PCR product used as template for the SBE reactions may contain more than 
one SBE primer-annealing site. For example:
Allele 1 
Allele 2
CT
heterozygote
T/C
Copy 1 
T/C
- j \A A A A A A -
Copy 1
- |\A A A A A A -
Copy 2
c
Copy 2
TT
homozygote
CC
homozygote
4 C : 0 T3C : IT 2 C : 2 T
No apparent allelic 
bias
C allele over­
represented in 
gDNA allelic ratio
Homozygous 
individual not 
suitable for SBE 
experiments
Figure 4-7 -  The effect o f a segmental duplication on the measured allelic ratios from a SBE 
reaction.
In this example, copy 1 o f  the gene contains a SNP, whereas that SNP is non- 
polymorphic in copy 2. In the case o f a true heterozygote, the C allele will be over­
represented, since copy 2 will always produce two extra C allele primer-annealing 
sites. This will result in an allelic ratio overly biased for the C allele. In the case o f a 
TT homozygote, the 1:1 ratio o f each allele is fortuitously preserved. Whilst the 
allelic ratios obtained would certainly represent the results expected when an equal 
number o f copies o f each allele were present, it would be inappropriate to use that 
individual’s cDNA since he/she is really a homozygote.
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If  the segmental duplications are polymorphic (i.e. there is copy number 
variation (CNV)), some individuals will have only one copy o f the gene (and the 
allele it carries) whilst others might have multiple copies. In such a case, one would 
observe significant inter-individual differences in the allelic ratios and would be 
alerted to the possibility o f segmental duplications complicating the investigation.
To test whether the detected allelic imbalances reflects the existence o f 
multiple copies o f the gene or CNV, we had to use a template for which we knew no 
duplications were present. Thus, two long oligonucleotides were designed for every 
SNP tested. Each oligonucleotide was 29-30 bps long and contained the SBE primer- 
annealing site, but had a different SNP allele. Table 4-1 shows the sequences o f the 
long oligonucleotide used and the SNP alleles they represent.
SNP ID Sequence 5' to 3' AlleleRepresented
rs2672785 AGCT GGG GGAAT GC AGGGC AC ACC AT GG AT G
rs2672785 AGCTGGG/4 G AAT GC AGGGC AC ACC AT GG AT A
rs2075853 CCCACCCGGCGCGTGAGCTTTGTTCCACCC C
rs2075853 CCCACCJGGCGCGTGAGCTTTGTTCCACCC T
rs2075859 TCCTC GCAGAGCT GC GCGCGCT GGGGGTT C
rs2075859 TCCTG4CAGAGCTGCGCGCGCTGGGGGTT T
Table 4-1 -  Sequences of long oligonucleotides and the SNP alleles they represent. Position of 
SNP in sequence shown in bold italics.
These were made up to equimolar concentrations (0.5 pM) using the 
manufacturers’ directions. Equal volumes o f each allele-specific oligonucleotide 
could then be mixed together to artificially create a heterozygote with a perfect 1:1 
representation o f each allele that could be used for SBE reactions.
Figure 4-8 shows a typical result when different proportions o f the two alleles 
were mixed in a titration experiment. The titration experiments demonstrate that 
there is a linear relationship between the allelic ratio determined and the proportion 
o f the oligonucleotides in the mixture tested. This meant that SBE was quantitative 
and could be used to measure allelic ratios.
132
Amount of T Oligo vs C Oligo (T/C)
Figure 4-8 -  Long oligonucleotide allelic ratios (T/C) for rs2075853. Oligonucelotide mixtures run 
on ABI 377
Crucially, the 1:1 mixtures gave results that were similar to those obtained 
from heterozygous individuals for all three MUC5B markers (see Table 4-2).
Allelic Ratios rs2672785 (G/A) rs2075853 (T/C) rs2075859 (T/C)
Averaged gDNA 
Averaged 
Oligonucleotide 
Mixtures
0.699 ±0.021 
0.789 ±  0.023
0.634 + 0.059 
0.620 ±0.038
0.669 ±  0.050 
0.579 ±0 .042
Table 4-2 - Allelic ratios from gDNA compared with allelic ratios from oligonucleotide mixtures.
All samples were run on ABI 3100. Averaged allelic ratio results for oligonucleotide mixtures 
obtained from three replicates for each SNP. gDNA from a small number o f individuals were initially 
tested for comparison with the oligonucleotide mixture allelic ratios. The averaged gDNA allelic 
ratios shown here however were derived from the complete sample set described in Chapter 5, in 
order to give a more complete representation.
These results suggest that imbalance in detection is not due to segmental 
duplications but rather difference in labelled nucleotide incorporation. It therefore 
follows that in the absence o f  large inter-individual differences in gDNA allelic 
ratios, segmental duplications are unlikely to be an issue.
4.6 CALCU LA TIN G  A L L E L IC  R A TIO S IN cDNA
Because o f the imbalance in allelic detection observed in gDNA from 
heterozygotes, there is therefore a need to adjust the calculated allelic ratios from
cDNA, in order to take into account the degree o f allelic bias in a particular SBE 
reaction (see Figure 4-9).
EM
94T gDNA |  
I 1
rs2075859 
T/C  Allelic Ratio 
= 0.668
■■ 1R : 1_HT_0_B_FD3_11 t n  / 3100 _Prc*ci2
94T cDNA
rs2075859 
\ T /C Allelic Ratio 
= 1.126
1
Figure 4-9 - Example showing difference in allelic ratios for gDNA vs. cDNA for a single 
individual.
For the work described in chapter 5, normalisation o f  the cDNA allelic ratios 
for each SNP was conducted using an overall gDNA allelic ratio obtained from all 
the samples tested for that SNP (see Equation 4-1). Allelic ratios for the cDNA 
samples were also normalised using individualised allelic ratios derived from their 
corresponding gDNA samples (see Equation 4-2). Very little difference was 
observed between the two correction methods and the rationale for using these two 
methods will be discussed later in Chapter 5.
Corrected cDNA Allelic Ratio 
of Sample X for SNP A
cDNA Allelic Ratio of Sample X for SNP A 
Overall gDNA Allelic Ratio for SNP A
Equation 4-1 - Method for calculating allelic ratios in cDNA samples using overall gDNA allelic 
ratio
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cDNA Allelic Ratio of Sample X for SNP A
Corrected cDNA Allelic Ratio ---------------------------------------------------------------
of Sample X for SNP A = Mean gDNA Allelic Ratio o f Sample X for SNP A
Equation 4-2 - Method for calculating allelic ratios in cDNA samples using individualised gDNA 
allelic ratios
4.7 ADDRESSING THE ISSUE OF DIFFERENT ALLELIC RATIOS 
FROM THE SAME INDIVIDUAL WHEN DIFFERENT MARKER 
SNPS ARE USED
Since rs2672785 and rs2075853 are located in adjacent exons, it was possible 
to use a single PCR product to test for both markers in cDNA. Hence, although the 
allelic ratios for the two marker SNPs might be different when gDNA from a double 
heterozygote individual is tested (see section 3.2.3), one would expect the corrected 
cDNA allelic ratios to be very similar, assuming that the alleles are in phase. 
However, discrepancies between the rs2672785 and rs2075853 allelic ratios were 
noted when five compound heterozygotes were tested for both SNPs.
Nonetheless, when the averaged corrected cDNA allelic ratio values (derived 
from three replicates using same cDNA but PCR and SBE done separately) for 
rs2075853 are plotted against those for rs2672785, there is an apparent correlation 
between the results. Greater signal differences were detected for rs2672785 than for 
rs2075853.
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Figure 4-10 - Graph of Allelic Ratios for rs2075853 against Allelic Ratios for rs2672785. Each 
point on graph represents the averaged allelic ratios for a different individual.
The explanation for this is not obvious. It was possible that this was related to 
the sequence context o f the two different SNPs in terms o f GC% content and thus 
local melting temperatures and primary or secondary structures formed differed, 
although it is necessary to hypothesise a differential effect on the two alleles at one 
or both loci.
In order to address the issue o f melting temperatures and secondary 
structures, two sample treatments were attempted. The first was a 5 min denaturation 
included before the cycling steps in the SBE reaction and the second was an 
extension o f the 96 °C denaturation steps from 10 sec to 20 sec, in the hope that these 
would help ensure that the DNA strands were fully unfolded and separated before the 
primer-annealing step. The additional denaturation times did not appear to affect the 
results in any significant way and the discrepancies in allelic ratios between the two 
SNP markers remained.
In view o f the fact that we were also testing a third SNP, it was decided to 
continue collecting the data and to combine results from more than one SNP. To do 
this, it was necessary to obtain full haplotype information on the samples, in order to 
determine phase and to link the exonic SNPs to the published promoter haplotypes, 
as described in full detail in the next chapter.
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4.8 DISCUSSION
The work in this chapter highlights the complexities o f detecting allele-specific 
differences in mRNA expression by the SBE method. The allelic bias in 
representation o f the different alleles (see section 4.6) necessitates the use o f gDNA 
as a control for adjusting cDNA allelic ratios. Although other studies on allelic 
variation in mRNA expression have adopted the same approach (Bray et al. 2003; 
Yan et al. 2002), none has attempted to address the possibility o f copy number 
variation influencing the results obtained. Given that copy number variation is 
increasingly considered widespread throughout the genome, this was an important 
consideration. Here I show that the allelic ratios obtained from the oligonucleotide 
mixes correspond well with the allelic ratios obtained from gDNA.
Although other studies have used different marker SNPs within the same 
gene and have noted good correlation between the markers, this is the first study that 
uses two marker SNPs (rs2672785 and rs2075853) found on the same PCR product. 
Hence, the absolute values o f the allelic ratios for cDNA were expected to be similar, 
although the direction o f  the allelic bias might be different depending on the phase. 
However, there were clear differences between the allelic ratios from the different 
marker SNPs. In rs2075853, the difference in allelic imbalance appeared to be 
suppressed in comparison with rs2672785. Nonetheless, there was an apparent 
correlation between the markers and the higher expressing alleles for both SNPs 
appeared to be in phase for all the five samples tested.
It is difficult to see what might be the real cause o f the discrepancies between 
the markers, although it is almost certainly technical. It seems unlikely that it is due 
to non-linearity o f the reaction because titration experiments failed to show that 
changes in primer and template concentrations significantly influence allelic ratios 
obtained. It is most probable that the problem is sequence-specific and reflects 
differences in conformation between PCR product derived from cDNA and gDNA. It 
is possible that these differences could have been corrected by using additives such
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as DMSO, but it seemed likely that such additives would interfere with the SBE 
reactions.
It is likely that all o f the allelic variation detection techniques that rely on 
allele-specific primers are susceptible to this type o f problem. The results from such 
experiments need to be carefully considered in light o f this, because the extent o f the 
allelic variation observed is highly dependent on the marker chosen.
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CHAPTER 5
STUDY OF ALLELIC VARIATION 
IN MUC5B EXPRESSION
5 STUDY OF ALLELIC VARIATION IN MUC5B EXPRESSION
5.1 INTRODUCTION
The chapter is concerned with the study o f allelic variation in MUC5B 
mRNA expression. Unlike MUC4, MUC5B shows no evidence o f  a variable TR 
length or o f  extensive alternative splicing. Hence, it should be in principle easier to 
detect and account for allele-specific differences in mRNA expression. In addition, in 
vitro experiments carried out by Kamio and colleagues had suggested the presence o f 
allelic differences in MUC5B mRNA expression. The background o f  their work is 
described here:
5.1.1 MUC5B and Diffuse Panbronchiolitis (DPB) -  Initial Research 
Suggesting the Presence of Allelic Variation in MUC5B Expression
Diffuse Panbronchiolitis (DPB) is an inflammatory airway disease 
characterised by a thickening o f the wall o f the respiratory bronchiole, coupled with 
infiltration o f lymphocytes, plasm a cells and foamy histiocytes around respiratory 
bronchioles (Kudoh and Keicho 2003). The disease primarily affects East Asians. 
Patients suffer from chronic coughs, produce large amounts o f sputum and are prone 
to chronic bacterial infections (Homma et al. 1983). At advanced stages, patients 
become superinfected with Pseudomonas aeruginosa and prognosis is often bleak 
(Kudoh and Keicho 2003).
Since mucus hypersecretion is observed in DPB patients and because mucins 
are the principal proteins found in mucus, Kamio and colleagues hypothesised that 
transcriptional regulation o f the mucins might be altered in DPB (Kamio et al. 2005). 
They explored this possibility by analysing polymorphisms located in the promoter 
regions o f MUC2, MUC4, MUC5AC, MUC5B and MUC7, all o f which are known to 
be expressed in the respiratory tract (Copin et al. 2000).
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Their test population was 92 unrelated Japanese patients diagnosed with DPB 
and their control population was 128 anonymous individuals selected from the 
general Japanese population. A case-control association study was then conducted 
using 22 different polymorphisms, spread across the five MUC  genes chosen. Three 
(rs885454, rsl7235353 and rs7115457) o f  the 22 polymorphisms, all found in 
MUC5B, were significantly associated with DPB (P values 0.0052, 0.0001 and 
0.0488 respectively). Armed with this information, Kamio and colleagues analysed 
MUC5B haplotype frequencies in cases vs. controls.
To do so, they used an SSCP-based molecular haplotyping method to 
determine the haplotypes (comprised o f 6 MUC5B promoter polymorphisms, 
including the three polym orphisms significantly associated with DPB) present in the 
Japanese test subjects (Kamio et al. 2004). Figure 5-1 shows the positions o f these 
polymorphisms on the MUC5B promoter.
rs885455 rsl7235353 rs7115457 rs2735738
rs885454 rs7118568
ATG
5'
Proximal Exon 1 
TATA box
Distal 
TATA box
NRF-2ADR1
GCR1
AML-la
NF-kP
-1142 -864-851 -605 -236-216 -77 +1 +58
Position relative to start of transcription from proximal TATA box
Figure 5-1 - MUC5B promoter polymorphisms identified by Kamio and colleagues. Relative 
positions of polymorphisms shown. Putative transcription factor binding sites detected using 
TRANSFAC shown (see section 5.8). Diagram not to scale.
Thirteen promoter haplotypes were detected, shown in Table 5-1, o f which 
three major haplotypes (HI,  H2 and H3) collectively represented approximately 80% 
of all the alleles. Kamio and colleagues found that the haplotype distribution was 
significantly different between cases and controls. In particular, the frequency o f H2
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was significantly decreased in the patient population. HI was increased in patients 
but the difference did not reach statistical significance (P value = 0.063).
Promoter
Haplotype
Identifier rs
88
54
55
rs
88
54
54 IT)rovn
r-
CAu r
s7
11
54
57
rs
71
18
56
8
rs
27
35
73
8 Haplotype Freq
Controls DPBPatients
HI G G I A G C 0.379 0.467
H2 G A D G C T 0.238 0.098
H3 A G I G C T 0.191 0.212
H4 G A I G C C 0.094 0.098
H5 G G I G C C 0.035 0.038
H6 G G I G C T 0.023 0.054
H7 G G D G C T 0.016 0.005
H8 A G I G C C 0.008 0.000
H9 G A I G C T 0.008 0.160
H10 G G I G G C 0.004 0.000
H I 1 G G I A G T 0.004 0.000
H12 A A I G C C 0.000 0.005
H13 A G I A G C 0.000 0.005
Table 5-1 - MUC5B promoter haplotypes detected by Kamio et al. For rsl7235353, I: CA 
insertion, D: CA deletion
M otivated by these findings, Kamio and colleagues investigated whether the 
different MUC5B haplotypes affected MUC5B transcription levels by utilising 
reporter assays. DNA sequences representing H I, H2 and H3 were transfected into 
MUC5B expressing NCI-H292 cells and relative luciferase activity in the steady state 
was measured. They found that H2 resulted in the lowest transcriptional activity, 
whilst H3 was intermediate and HI the highest.
Taken together, Kamio and colleagues’ findings suggest that polymorphisms 
in the MUC5B promoter region might affect the expression levels o f MUC5B (due to 
allele-specific differences in expression) and influence the pathogenesis o f DPB.
The work in this chapter investigates the presence and extent o f allelic 
variation in the constitutive expression o f MUC5B in fetal tissue and attempts to 
address the question o f  whether the MUC5B promoter haplotypes are differentially 
expressed in vivo, using the SBE method.
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5.2 INITIAL SELECTION OF SAMPLES
Individuals from the fetal population were initially selected for this study based 
on the range o f  tissues available. MUC5B has been detected in fetal trachea (13 
weeks onwards) (Reid, Gould, and Harris 1997) and fetal gall bladder (18 weeks 
onwards but not tested in less mature tissue) (Buisine et al. 1999b; Reid, Gould, and 
Harris 1997). MUC5B is also expressed in bronchi (13 weeks onwards) (Buisine et 
al. 1999b), bronchioles (23 weeks onwards) (Reid, Gould, and Harris 1997) and 
strongly expressed in adult salivary glands (Alos et al. 2005; Veerman et al. 2003), 
suggesting the possibility o f  detecting MUC5B in fetal lung and salivary glands. 
Thus, only individuals for whom trachea, gall bladder, salivary glands or lung tissue 
were available were chosen. RNA and gDNA were extracted from these tissues. 
Table 5-2 below gives a summary o f the individuals chosen and the tissue types 
available from them.
Trachea GallBladder
Salivary
Glands Lung
No. of 
Individuals 
(n=92)
Average
Gestational 15.2 ± 1.6 15.8 ± 0 .9 19.7 ±1.1 14.2 ± 1.8
Age (weeks)
* 13
«/ 12
✓ 2
✓ 53
✓ ✓ 1
4
✓ >/ 6
✓ ✓ V* 1
Total Number
of Samples 21 18 2 64
(n=105)
Table 5-2 -  Individuals from fetal population initially chosen for MUC5B study and their 
available tissue types
5.3 GENOTYPE ANALYSIS
The extracted gDNA was used to genotype these individuals for three 
MUC5B SNPs, rs2672785 found in exon 2, rs2075853 in exon 3 and rs2075859 in
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exon 9. These three SNPS were chosen because they had been successfully validated 
in both the HapMap and dbSNP databases and because they were located in exons, 
allowing them to function as marker SNPs for the SBE experiments. Representative 
genotyping results for the three SNPs are shown in Figure 5-2, Figure 5-3 and Figure 
5-4.
296 b p s  ►
 ►
149 bps
M arker GG GA AA
Figure 5-2 -  Representative MUC5B rs2672785 (exon 2) genotyping results. Typed by Tetra- 
ARMS PCR
151 bps
 ►
88 b p s  ►
 ►
66 bps
M arker CC CT CC CT TT CC CC CC
Figure 5-3 - Representative MUC5B rs2075853 (exon 3) genotyping results. Digested by Msp I.
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204 bps 
187 bps >
Marker CC TT TT CT CT CT CC TT
Figure 5-4 - Representative MUC5B rs2075859 (exon 9) genotyping results. Engineered restriction 
site. Digested by Bts I.
Table 5-3 shows the MUC5B genotype frequencies for the fetal population 
compared with the genotype frequencies for the HapMap CEPHs sample set and 
gives an indication o f the number o f informative individuals available for use in SBE 
experiments. Chi Square tests were performed for each SNP to test for deviation 
from expected Hardy-Weinberg frequencies.
SNP rs2672785 rs2075853 rs2075859
Genotypes AA AG GG CC CT TT CC CT TT
Fetal Genotype 0.511 0.402 0.087 0.750 0.217 0.033 0.326 0.457 0.217
Frequencies (n=92) (47) (37) (8) (69) (20) (3) (30) (42) (20)
X2Test P value for
HW in Fetal 0.983 0.607 0.766
Population
CEPH Genotype 0.567 0.383 0.050 0.850 0.150 0.000 0.417 0.450 0.133
Frequencies (n=60) (34) (23) (3) (51) (9) (0) (25) (27) (8)
Table 5-3 -  MUC5B exonic SNP genotype frequencies in fetal population compared with 
HapMap CEPH population
The genotype frequencies between the two groups are very similar for all 
three markers, as was also noted for the MUC4 SNPs (see section 3.3). The P values 
indicate that there is no significant deviation from Hardy-Weinberg equilibrium and 
suggests no serious genotyping errors or problems with population admixture.
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5.4 ANALYSIS OF LINKAGE DISEQUILIBRIUM BETWEEN MUC5B
SNPS
Table 5-4 shows the results o f the MUC5B linkage disequilibrium (LD) 
analysis for the fetal and HapMap CEPH populations, whilst Figure 5-5 shows the 
positions o f  the SNPs on a scale diagram of the MUC5B gene structure and the 
measures o f  LD between the SNPs.
Pair-wise
rs2672785 
vs. rs2075853
rs2672785 
vs. rs2075859
rs2075853 
vs. rs2075859
Comparisons Chi Sq 
P value
Lewontin
D'
Chi Sq 
P value
Lewontin
D'
Chi Sq 
P value
Lewontin
D'
Fetal
Population <0.00001 1 0.53145 0.089 0.00009 0.800
HapMap
CEPHs <0.00001 1 0.58915 0.156 0.01715 0.758
Table 5-4 - Measures of LD between MUC5B exonic SNPs in fetal and HapMap CEPH
populations
D' = 0.8
P value = 0.00009
D=1  _______________________________________________________________
P value = 0
<-------------------► D' = 0.089
P value = 0.53146
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9
rs2672785 rs2075853 rs2075859
Figure 5-5 -  Scale diagram showing positions of MUC5B exonic SNPs and associated measures 
of LD in fetal population
The LD analysis shows that there is significant LD between rs2672785 and 
rs2075853 and between rs2075853 and rs2075859 but a lack o f significant 
association between rs2672785 and rs2075859. The pattern o f LD is very similar in 
both fetal and HapMap populations.
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5.5 HAPLOTYPE ANALYSIS
5.5.1 Haplotype Reconstruction using MUC5B Exonic SNPs
The exonic SNP genotypes were used to reconstruct haplotypes using the 
Phase program. Figure 5-6 shows the various deduced haplotypes and their 
associated frequency within the fetal and HapMap CEPH populations. To make the 
analysis comparable since the CEPH genotyping data originates from family trios, all 
30 offspring samples were excluded from the haplotype reconstruction and 
haplotypes were inferred without using family information.
> 0 - 6 n
o
S 0.4-H
3  
CT
£ 0.3
I  0.2 4- 
1  0.1
ACC ACT GCC GCT GTC GTT
□  Fetal □  HapMap CEPHs
Exonic
Haplotype
Identifier
rs2672785 rs2075853 rs2075853
Haplotype Freq
Fetal HaPMaP 
CEPHs
XI A C C 0.413 0.467
X2 A C T 0.304 0.292
X3 G C C 0.125 0.167
X4 G C T 0.016 0.000
X5 G T C 0.016 0.008
X6 G T T 0.125 0.067
Figure 5-6 - MUC5B Exonic Haplotype Frequencies in fetal and HapMap CEPH populations
There appear to be six haplotypes occurring within the fetal population: two 
common haplotypes (ACC and ACT), two less common (GCC and GTT) and two 
rare haplotypes (GCT and GTC). These have been numbered XI to X6. The 
haplotype frequencies appear to be quite similar between the fetal and HapMap 
CEPH groups. The most striking difference between the two groups is probably the 
nearly twice as frequent X6 haplotype in the fetal vs. CEPH populations, which
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could be due to slight admixture within the fetal group. However, the haplotype 
distributions between the two populations are not significantly different (exact test of 
population differentiation using Arlequin program, P value = 0.71582).
5.5.2 Haplotype Reconstruction using MUC5B Exonic SNPs and Promoter 
Polymorphisms from Kamio Study
A major aim o f  this project was to determine whether the MUC5B promoter 
haplotypes are associated with expression in vivo by using the SBE method (see 
section 5.1.1). In order to achieve this, it was first necessary to establish the link 
between the exonic SNP haplotypes (which would serve as markers for SBE) and the 
promoter haplotypes.
Hence, the MUC5B promoter, approximately 1.1 kb upstream from the start 
o f transcription, was sequenced in the fetal samples (representative results shown in 
Figure 5-7). This provided genotype information for the six promoter polymorphisms 
previously investigated by Kamio and colleagues (see section 5.1.1).
148
rs885455 (A/G) Individual 100
rs885454 (A/G)
Individual 71 rs!7235353
(CA indel) Overlapping sequence
Decause 01 presence 01 Doth
Individual 19
rs7118568 (G/C)
/  A Ars7115457 (A/G)
rs2735738 (C/T)
Individual 28
Figure 5-7 -  Representative electropherograms of the MUCSB promoter sequence. Sequences 
from individuals heterozygous for the various promoter polymorphisms shown. Sequences analysed 
using Sequencing Analysis v5.1.1.
These data were used in conjunction with the exonic SNP genotypes as input 
for the Phase program, in order to generate ‘combined’ haplotypes containing all 
nine MUC5B polymorphisms.
Figure 5-8 shows the frequency o f  each combined haplotype within the fetal 
population. Table 5-5 shows the actual alleles in each combined haplotype, its 
associated frequency, as well as the combination o f promoter and exonic haplotypes 
(see Figure 5-6 and Table 5-1) that make up each combined haplotype.
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Figure 5-8 - Combined haplotypes and their frequencies in the feta! population
Combined Combined Haplotype Promoter Exonic Haplotype
FreqHaplotypeIdentifier Promoter Haplotype
Exonic
Haplotype
Haplotype
Identifier
Haplotype
Identifier
Cl A G I G C C A C T X2 0.008
C2 A G I G C C A C C H8 XI 0.039
C3 A G I G C C G C C X3 0.063
C4 A G I G C T A C T X2 0.320
C5 A G I G C T A C C H3 XI 0.266C6 A G I G C T G C T X4 0.008
C7 A G I G C T G T T X6 0.016
C8 A G I G G C G T T H14 X6 0.008C9 A G I G G C G T C X5 0.008
CIO G G I A C C G C C H15 X3 0.008C ll G G I A C C G T T X6 0.008
C12 G G I A G C G T T HI X6 0.109C13 G G I A G C G T C X5 0.016
C14 G G I G C C G C C H5 X3 0.023
C15 G G I G C T A C T H6 X2 0.016C16 G G I G C T A C C XI 0.008
C17 G A I A G C G T T H16 X6 0.008
C18 G A I G C C G C T H4 X4 0.008C19 G A I G C C G C C X3 0.047
C20 G A D G C T A C C H2 XI 0.016
Table 5-5 - Combined MUC5B haplotypes and their frequencies in the fetal population (n = 92).
Haplotypes occurring at frequency greater than 0.05 shown in bold.
Inspection o f these data reveals the presence o f four combined haplotypes at a 
frequency greater than 0.05 within the fetal population. These are C3, C4, C5 and
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C12 shown in bold in Table 5-5. Some o f the remaining haplotypes occur only once 
within the entire population. Promoter haplotypes H I 4, H I 5 and H I 6 were not 
detected in the Japanese population studied by Kamio and colleagues and could be 
European-specific. The H2 haplotype was not previously detected in a group o f 40 
Europeans (Kamio et al. 2005). Thus, the presence o f C20 chromosomes in the fetal 
group suggests that these individuals might be, at least in part, o f  Far-Eastern 
ancestry.
Perhaps the most noteworthy observation is that each o f the four most 
frequent combined haplotypes has a different exonic haplotype. Hence, the 
determination o f the exonic haplotypes o f an individual provides a good indication o f 
which promoter haplotypes are likely to be present in that individual and this is 
exploited in the analysis described in Chapter 6.
5.6 TESTING FOR ALLELIC VARIATION IN MUC5B MRNA 
EXPRESSION BY SBE METHOD
5.6.1 Final Selection of Samples for Study
A large number o f samples from the initial 92 individuals chosen for this 
study (see section 5.3) could not be tested for the following two reasons:
• Some individuals were non-informative (i.e. homozygous) at all three 
marker SNPs.
• MUC5B expression is generally much lower in fetal tissue compared to 
adult tissue. Thus, the cDNA from some samples failed to produce a 
sufficiently strong PCR product when used in RT PCR reactions. This 
was particularly an issue for cDNA derived from lungs, most probably 
because the piece o f lung tissue used to extract the mRNA contained 
insufficient bronchial tissue. cDNA derived from trachea, gall bladder and 
salivary glands tended to produce strong PCR products.
The final sample set consists o f 42 samples from 38 different individuals.
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5.6.2 SBE Results
Figure 5-9, Figure 5-10 and Figure 5-11 are representative o f the SBE results 
obtained.
G
Sam ple 19T a 
gDNA j \
A
G/A Ratio = 0.692
B B  3R 1_18T_0_Q_ED1 JWfsa /
G
i
Sam ple 19T 
cDNA II G/A Ratio = 1.626
JT  : t_IOT_E2_BOS_p4 f s j  / B H  3R : l.H T .B .B O B .M .ta  /
Sam ple 101G 
cDNA
A
G G/A Ratio = 0.688
■ ■  1R l_10l G_E2_F05_11 I s .  1
Sam ple 92L 
cDNA G
A
G/A Ratio = 0.367
Figure 5-9 - Representative SBE results from MUC5B rs2672785. One gDNA sample and three 
cDNA samples shown. cDNA allelic ratios are uncorrected.
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Figure 5-10 - Representative SBE results from MUC5B  rs2075853. One gDNA sample and three 
cDNA samples shown. cDNA allelic ratios are uncorrected.
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Figure 5-11 - Representative SBE results from MUC5B  rs2075859. One gDNA sample and three 
cDNA samples shown. cDNA allelic ratios are uncorrected.
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Three replicates were performed for each gDNA sample. For the cDNA 
samples, up to five replicates were performed. For every replicate, the PCR step, 
PCR product purification, SBE, post-extension treatment and detection steps were 
performed separately. For each sample, the gDNA used for the replicates was from 
the same extraction, whilst the cDNA used for the replicates was from the same RT 
reaction.
5.6.2.1 gDNA Allelic R atio  R esults
The gDNA allelic ratio results for the three MUC5B marker SNPs are shown 
in Table 5-6. Each mean allelic ratio was calculated using all three replicate readings. 
G/A, T/C and T/C allelic ratios were calculated for rs2672785, rs2075853 and 
rs2075859 since preliminary cDNA investigations indicated that the G (rs2672785) 
and T (rs2075853) alleles were usually expressed at a higher level than their 
counterpart alleles (see section 4.1) and haplotype analysis indicated that the ACC 
haplotype was most frequent (see section 5.5.1). Thus, calculating the allelic ratios 
this way would help keep the alleles in the correct phase in most cases for ease o f 
analysis.
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rs2672785 rs2075853 rs2075859
(G/A allelic ratio) (T/C allelic ratio) (T/C allelic ratio)
Mean StDev Mean StDev Mean StDev
3SG 0.712 0.108 0.543 0.051 - -
4SG - - - - 0.757 0.068
6T - - - - 0.638 0.003
9G 0.689 0.052 - - - -
10T - - - - 0.663 0.040
11G - - 0.662 0.056 - -
12G - - - - 0.655 0.056
14G - - - - 0.634 0.009
15T - - - - 0.654 0.041
16T 0.718 0.074 - - 0.615 0.042
17T 0.690 0.028 - - - -
19T 0.689 0.042 0.761 0.096 - -
26L 0.708 0.035 - - 0.742 0.010
28L 0.752 0.026 0.609 0.057 0.619 0.010
29L 0.690 0.050 - - 0.702 0.016
30T 0.667 0.078 - - - -
34L 0.672 0.080 0.668 0.033 - -
43 L 0.706 0.058 0.665 0.025 - -
44G 0.708 0.060 0.600 0.052 0.633 0.047
45G 0.715 0.016 - - - -
53L - - - - 0.736 0.067
57L - - - - 0.606 0.065
63L - - - - 0.689 0.017
66L 0.709 0.037 - - - -
67S 0.690 0.028 0.562 0.070 0.617 0.032
71L - - - - 0.674 0.037
73 L - - - - 0.643 0.025
86T - - - - 0.757 0.023
88T - - - - 0.661 0.009
92L 0.690 0.071 - - - -
94T 0.723 0.064 0.639 0.012 0.648 0.017
97L 0.703 0.069 0.631 0.017 0.606 0.027
98T - - - - 0.702 0.082
100L 0.668 0.045 - - 0.649 0.035
101G 0.676 0.033 0.635 0.029 - -
103T - - - - 0.785 0.016
112L - - - - 0.656 0.023
116L - - - - 0.654 0.032
Overall 0.699 0.021 0.634 0.059 0.669 0.050
Table 5-6 - MUC5B gDNA allelic ratio results. The overall mean value represents the averaged 
mean allelic ratio of all the samples for a particular SNP. The overall stdev represents the inter­
individual variation in mean allelic ratios for a particular SNP.
The overall allelic ratios were calculated by taking an average o f  all the 
replicate readings available for each marker SNP, whilst the overall standard 
deviations reflect the inter-individual variation in mean allelic ratios.
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§.6.2.2 Corrected cDNA Allelic Ratio Results
For cDNA, extreme outlier results were excluded from the mean allelic ratios, 
which were derived from at least three replicates. The corrected cDNA allelic ratios 
for the three MUC5B SNPs are shown in Table 5-7. For the data shown, the allelic 
ratios o f the samples were corrected using the overall gDNA allelic ratios for each 
SNP (see Equation 4-1 and Table 5-6), although they were also corrected using the 
mean gDNA allelic ratios from their corresponding gDNA samples (data not shown, 
see Equation 4-2 and Table 5-6). There was very little difference between the allelic 
ratios when corrected using either method.
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rs2672785 
(G/A allelic ratio) 
Mean StDev 95% Cl
rs2075853 
(T/C allelic ratio) 
Mean StDev 95% Cl
rs2075859 
(T/C allelic ratio) 
Mean StDev 95% Cl
3SG 2.451 0.183 0.455 1.260 0.149 0.371 - - -
4SG - - - - - - 0.887 0.191 0.475
6T - - - - - - 1.124 0.092 0.229
9G 1.574 0.031 0.076 - - - - - -
10T - - - - - - 1.040 0.018 0.044
11G - - - 1.215 0.038 0.094 - - -
12G - - - - - - 0.610 0.230 0.571
14G - - - - - - 1.140 0.200 0.497
15G - - - - - - 0.885 0.231 0.574
15T - - - - - - 1.062 0.086 0.214
16T 1.141 0.077 0.192 - - - 0.926 0.103 0.256
17T 1.193 0.125 0.310 - - - - - -
19T 2.082 0.269 0.667 1.061 0.206 0.511 - - -
26L 1.623 1.050 2.607 - - - 0.553 0.105 0.260
28L 1.846 0.234 0.582 1.027 0.056 0.139 0.917 0.326 0.810
29L 2.140 0.334 0.830 - - - 0.969 0.111 0.276
30T 1.439 0.219 0.543 - - - - - -
34L 2.244 0.267 0.663 1.216 0.045 0.111 - - -
43L 2.918 0.203 0.504 1.559 0.092 0.229 - - -
44G 1.839 0.208 0.517 0.991 0.058 0.144 1.580 0.115 0.285
45G 1.234 0.108 0.268 - - - - - -
53L - - - - - - 1.938 0.480 1.191
57L - - - - - - 1.270 0.246 0.610
63L - - - - - - 1.088 0.218 0.541
66L 2.472 0.693 1.721 - - - - - -
67L 2.296 0.536 0.852 1.284 0.095 0.235 0.918 0.328 0.522
71L - - - - - - 0.661 0.099 0.245
73L - - - - - - 1.006 0.374 0.929
86T - - - - - - 1.016 0.179 0.445
88G - - - - - - 1.008 0.066 0.163
88T - - - - - - 1.087 0.061 0.152
92 L 0.420 0.202 0.502 - - - - - -
94T 1.618 0.072 0.179 0.912 0.055 0.136 1.634 0.134 0.333
97L 1.115 0.071 0.176 0.725 0.008 0.021 1.032 0.163 0.405
97G 1.499 0.079 0.196 0.547 0.216 0.535 0.747 0.182 0.453
98T - - - - - - 1.182 0.147 0.365
100L 1.650 0.381 0.945 - - - 1.091 0.413 1.026
101G 1.004 0.046 0.113 0.590 0.021 0.051 - - -
103T - - - - - - 1.465 0.092 0.227
112L - - - - - - 1.679 0.286 0.709
116G - - - - - - 1.230 0.115 0.286
116L - - - - - - 0.518 0.292 0.726
Overall 1.705 0.594 - 1.032 0.302 - 1.075 0.330 -
Table 5-7 -  MUC5B corrected cDNA allelic ratio results. Allelic ratios corrected using overall 
gDNA allelic ratios (see Equation 4-1). The overall mean value represents the averaged mean allelic 
ratio of all the samples for a particular SNP. The overall stdev represents the inter-individual variation 
in mean allelic ratios for a particular SNP. 95% Confidence intervals of the mean = standard error of 
mean * 4.3 (t-distribution, a =0.05, 2 degrees of freedom). Allelic ratios in italics were inverted when 
used to calculate the averaged corrected cDNA allelic ratios (see section 5.7).
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Overall, approximately 50% o f the samples showed mean corrected cDNA 
allelic ratios o f  20% or more above or below the expected ratio o f  1. This effect was 
seen in all tissues.
Figure 5-12 shows the standard deviations for various aspects o f  the SBE 
experiments for all three MUC5B SNPs.
Figure 5-12 - Graph of standard deviations for SBE experiments. Inter-replicate oligonucleotide 
Stdev calculated for three replicates per SNP. Inter-replicate gDNA and cDNA Stdev values are 
averaged Stdev across all the samples tested. Inter-individual gDNA and cDNA Stdev represent the 
variation in mean allelic ratios across all the samples tested.
Several observations can be made from these results. First, there is a very 
small standard deviation in allelic ratios between the oligonucleotide mixture 
replicates, implying that the SBE reaction and detection o f  SBE products are highly 
reproducible (since the oligonucleotide mixtures do not require a PCR step prior to 
the SBE reaction). The reproducibility o f  the SBE reaction was confirmed in 
experiments in which the SBE reactions were repeated using the same PCR 
templates and the reproducibility was shown to be good (data not shown).
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Second, the low standard deviation in allelic ratios for gDNA suggests that 
the reproducibility o f  the readings is good, whereas it appears to be noticeably less so 
for cDNA. Given that the cDNA used is from the same RT, it follows that the 
experimental variability must arise from the subsequent steps in the entire process. 
Since we have already established that the SBE reaction and detection steps are 
highly reproducible, this suggests that the major source o f  experimental variability is 
at the PCR step.
Nevertheless, there appears to be significant inter-sample variability in allelic 
ratios for cDNA but not for gDNA, and this suggests that there are clear differences 
in MUC5B expression between individuals.
Figure 5-13 is a graph o f  rs2672785 allelic ratios plotted against rs2075853 
allelic ratios for all o f  the samples doubly heterozygous for both SNPs, as was done 
in Chapter 4 (see Figure 4-10).
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Figure 5-13 - Graph of rs2075853 (T/C) allelic ratios against rs2672785 (G/A) allelic ratios. Each 
point on graph represents the averaged allelic ratios for a different individual.
This new graph plotted using a larger data set confirms that there is in fact a 
very good correlation between the allelic ratios from both SNPs. In addition, this 
graph also implies that the G allele (rs2782785) and T allele (rs2075853) are in phase
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for all o f  the samples. Again, however, the allelic ratios for rs2672785 are inflated in 
comparison to rs2075853, implying that despite our best efforts with the technique, 
the allelic ratios obtained using different SNPs are not directly interchangeable. No 
correlation was found between the other SNP markers (data not shown), probably 
because o f  variation in phase, which was to be expected from the breakdown o f LD 
(see section 5.4).
5.7 RELATING SBE RESULTS TO HAPLOTYPES
It was now possible to address the question o f whether the MUC5B promoter 
haplotypes are differentially expressed in vivo. I f  the promoter haplotypes are 
differentially expressed in vivo, we hypothesised that the samples heterozygous for 
promoter haplotype would be more likely to exhibit a significant difference in 
MUC5B allelic expression than samples that are homozygous for promoter 
haplotype.
To do this, it was necessary to combine the results from several SNPs. Hence, 
we needed to have information on the phase o f the exonic SNPs in each individual:
In most cases, phases assigned by the Phase program were with 0.9 or greater 
confidence and these were taken to be correct. Where the confidence was lower, the 
most likely haplotypes present were inferred by comparing the allelic ratios from the 
rs2672785 and rs2075859 SNP markers and in four individuals, the alternative 
haplotypes suggested by the Phase program were taken. The most likely haplotypes 
for each sample tested are shown in Table 5-8. The promoter haplotypes were 
inferred from the combined haplotypes (see Table 5-5) and individuals were 
classified as heterozygous or homozygous for promoter haplotype.
The allelic ratios from all three SNPs were then be averaged and are shown in 
Table 5-8 as ‘Averaged Corrected cDNA Allelic Ratios’. These averaged allelic 
ratios represent the difference in MUC5B expression between the two MUC5B 
haplotypes.
160
As an initial analysis, the averaged corrected cDNA allelic ratios from 
individuals homozygous for promoter haplotype were compared to those from 
individuals heterozygous for promoter haplotype (see Figure 5-14).
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Figure 5-14 - Comparison of averaged corrected cDNA allelic ratios in individuals homozygous 
for promoter haplotype vs. individuals heterozygous for promoter haplotype
As can be seen, the averaged corrected cDNA allelic ratios for homozygous 
individuals tends to cluster around 1.0 (no allelic differences in expression) whilst 
the allelic ratios for heterozygous individuals tend to vary more widely. Indeed, a t- 
test indicates that the distribution o f allelic ratios is significantly different between 
the two groups (P Value = 0.012). This suggests that there is a significant association 
between heterozygosity vs. homozygosity for promoter haplotype and the extent o f 
the allelic differences detected.
In order to test the robustness o f this observation, the data was also analysed 
in another way. Here the SNP markers were not averaged and were considered 
separately as follows:
• The allelic ratio was beyond the 0.8 to 1.2 range. This range was 
shown to discriminate from a control gene where there was no 
difference in allelic expression (Yan et al. 2002).
1 6 1
•  The 95% confidence interval for the cDNA mean allelic ratio did not 
overlap with the 95% confidence interval derived from the gDNA 
overall mean allelic ratio. In practice, samples were not significant if  
their confidence intervals extend into 0.99 to 1.01 for rs2672785, 0.96 
to 1.04 for rs2075853 or 0.98 to 1.02 for rs2075859.
If  a sample fulfilled both criteria, that sample was deemed to show strong 
evidence o f  allelic differences in MUC5B expression, as indicated in Table 5-8.
In the case o f  double and triple heterozygote individuals, if  the above two 
conditions were met for two or more SNP markers, the sample was considered to 
exhibit significant allelic variation in mRNA expression. If  only one marker fulfilled 
the criteria, the sample was classified as unknown. Otherwise, the sample was 
classified as non-significant.
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Samples PromoterHaplotypes
Exonic
Haplotypes
Averaged 
Corrected 
cDNA Allelic 
Ratios
Strong Evidence of 
Allelic Difference in 
MUC5B expression?
3SG H1/H8 X6/X2 1.855 ?
4SG H3/H3 X2/X1 0.887 No
6T H3/H3 X2/X1 1.124 No
9G H4/H8 X3/X1 1.574 Yes
10T H6/H6 X2/X1 1.040 No
11G H1/H8 X5/X3 1.215 Yes
12G H3/H3 X2/X1 0.610 No
14G H3/H3 X2/X1 1.140 No
15G H3/H3 X2/X1 0.885 No
15T H3/H3 X2/X1 1.062 No
16T H4/H3 X3/X2 1.111 No
17T H8/H8 X3/X1 1.193 No
19T H1/H3 X6/X2 1.572 ?
26L H5/H3 X3/X2 1.715 ?
28L HJ/H3 X5/X2 1.321 No
29L H8/H3 X3/X2 1.586 9
30T H8/H3 X3/X1 1.439 No
34L H1/H3 X6/X2 1.730 Yes
43L H1/H3 X6/X2 2.239 Yes
44G H1/H3 X6/X1 1.470 Yes
45G H5/H3 X3/X1 1.234 No
53L H3/H3 X2/X1 1.938 No
57L H3/H3 X2/X1 1.270 No
63L H3/H3 X2/X1 1.088 No
66L H8/H3 X3/X1 2.472 No
67L H1/H8 X5/X2 1.556 Yes
71L H3/H2 X2/X1 0.661 Yes
73L H3/H3 X2/X1 1.006 No
86T H3/H3 X2/X1 1.016 No
88G H3/H3 X2/X1 1.008 No
88T H3/H3 X2/X1 1.087 No
92L H4/H3 X3/X1 0.420 Yes
94T H1/H3 X6/X1 1.388 Yes
97G H3/H3 X6/X1 0.957 No
97L H3/H3 X6/X1 0.931 No
98T H3/H3 X2/X1 1.182 No
100L H4/H3 X4/X1 1.371 ?
101G H15/H3 X6ZY2 0.797 ?
103T H3/H3 X2/X1 1.465 Yes
112L Hl/Hl X6/X5 1.679 No
116G H3/H3 X2/X1 1.230 No
116L H3/H3 X2/X1 0.518 No
Table 5-8 - Promoter, exonic haplotypes and averaged corrected cDNA allelic ratios for each 
individual tested. Allelic ratios represent difference in expression of first haplotype vs. second 
haplotype in exonic and promoter haplotype columns. Yes: Sample shows strong evidence of 
significant allelic differences in MUC5B expression (also in bold). No: Sample does not show strong 
evidence of significant allelic differences in MUC5B expression. ?: Unknown. Haplotypes shown in 
italics are those where the alternative haplotypes suggested by the Phase program were used.
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This information, together with promoter haplotype heterozygosity is 
tabulated in Table 5-9.
Heterozygous for Homozygous for 
Promoter Haplotype Promoter Haplotype
Allelic Difference 
in MUC5B Expression 
No Allelic Difference 
in MUC5B Expression
1
21
Table 5-9 - 2 by 2 table showing number of samples showing strong evidence of allelic variation 
in MUCSB expression and whether they are heterozygous or homozygous for promoter 
haplotype
A Fisher’s Exact Test (P value <0.0002) showed that there was a highly 
significant difference in distribution between promoter haplotype heterozygosity and 
significance o f allelic variation in mRNA expression, and that samples which were 
heterozygous for promoter haplotype were much more likely to demonstrate strong 
evidence o f  differences in allelic expression.
Hence, these results strongly supported the original hypothesis that the 
MUC5B promoter haplotypes are differentially expressed in vitro as well as in vivo.
5.7.1 Inferring Relative Transcriptional Activities of Promoter Haplotypes
The data was also examined in another way. Using all the data, the averaged 
corrected cDNA allelic ratios from the four most common diplotypes (H3H3, H1H3, 
H1H8 and H3H8) were compared.
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Figure 5-15 -  Comparison of averaged corrected cDNA allelic ratios between common 
diplotypes. Allelic ratios shown derived from taking an average from all the individuals of a 
particular diplotype. Error bars are one standard deviation from the mean.
Figure 5-15 clearly shows that HI is more highly expressed than H3 and H8, 
whilst H8 is more highly expressed than H3. However, H4 is either lower than, equal 
to, or higher than H3. Thus, it is difficult to fit all possible haplotypes into a scheme 
to rank their relative expression levels. This was the case even when only using the 
more stringently selected samples showing the strongest evidence o f allelic 
differences in MUC5B expression (see Table 5-8). This is probably at least in part 
due to H3 for which there is clearly also variability in allelic expression in the 
homozygotes.
5.8 DISCUSSION
The work in this chapter demonstrates that MUC5B exhibits allelic variation 
in mRNA expression in fetal tissue. Large inter-sample differences were detected, 
although the extent o f the difference in allelic expression was generally small; the 
greatest difference detected between the expression o f two alleles in a single 
individual was about two-fold. In none o f the samples was there evidence o f  
anything approaching mono-allelic expression, which might have been found if  post-
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transcriptional regulation such as alternative splicing (as was seen for MUC4) was 
affecting MUC5B expression or if  epigenetic effects such as parental imprinting were 
involved.
Allelic variation in MUC5B expression was detected in all the tissue types 
tested, i.e. gall bladder, lungs, salivary glands and trachea. It had been hoped that the 
collection o f more than one tissue from a single individual would allow us to 
investigate the effect o f tissue-specificity on MUC5B expression. However, only four 
such individuals were available and there was no strong evidence o f allelic 
differences in expression for any o f  the tissues tested. Further study involving a 
greater number o f  individuals with two or more tissues will be necessary to address 
this issue.
Slight inter-individual variations were observed in gDNA allelic ratios. 
Single factor ANOVA analyses indicated that these differences are statistically 
significant for rs2075853 and rs2075859 (P values <0.005 and <0.000005 
respectively), although not for rs2672785 (P value = 0.977).
The nature o f these inter-individual differences is unclear. These could be due 
to an unknown polymorphism(s) present within the SBE primer-annealing site or 
within the gDNA PCR primer-annealing sites. Either might have led to altered 
primer binding efficiencies in some individuals, which could have ultimately affected 
the allelic ratios. With the benefit o f hindsight, it would have been better to first 
sequence the primer-annealing sites to check for unknown polymorphisms, but this 
could not be done retrospectively for this project due to time-constraints.
In an attempt to allow for polymorphisms under the primers, cDNA allelic 
ratios were corrected in two ways: first, by using an overall gDNA allelic ratio for 
each SNP, derived from all the individuals tested; second by using individualised 
gDNA allelic ratios. The corrected cDNA allelic ratios were then compared between 
the two correction methods. The rationale behind this was that if  there were unknown 
polymorphisms under the primer-annealing sites, these are highly unlikely to occur 
in every single individual. There was very little difference in the results when
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corrected using either method, suggesting that this variation was not an important 
confounder.
The inter-replicate standard deviations for cDNA were noticeably higher than 
for gDNA. The small inter-replicate standard deviations for the oligonucleotide 
mixes suggested that the main source o f variability between replicates occurred at the 
PCR stage. The PCR step is common to both gDNA and cDNA samples and is 
performed in a similar fashion, albeit with different primers and thermocycling 
conditions. It follows that the difference in reproducibility between gDNA and 
cDNA is most likely due to the nature o f the samples themselves:
The expression o f MUC5B in fetal tissue is known to be lower compared to in 
adults (Buisine et al. 1999b; Reid, Gould, and Harris 1997). Thus, it is possible that 
the lack o f starting template could affect the final relative proportions o f each allelic 
transcript in the PCR product, leading to variations in allelic ratios between different 
PCR replicates. This could have resulted in the greater standard deviation in allelic 
ratios for cDNA compared to gDNA. Nevertheless, this is puzzling in view o f the 
fact that many investigators routinely use 40 or more cycles o f amplification for 
quantitative work, whilst here only 35 cycles were used.
It would be useful to repeat the SBE experiments using cDNA obtained from 
a different reverse transcription reaction. W hilst the reproducibility o f the cDNA 
allelic ratios might still be an issue, this would nonetheless allow us to take an 
average o f  the results from two separate RTs.
In this chapter, a significant correlation between heterozygosity for promoter 
haplotype and differential MUC5B allelic expression was demonstrated. By using the 
data obtained from SBE experiments, an attempt was made to infer the relative 
expression levels o f the promoter haplotypes. This was met with some difficulty due 
to the lack o f comparisons between some o f the haplotypes as well as the fact that the 
inference was based on a small number o f samples. As such, it was not possible to 
elucidate the relative expression levels o f every promoter haplotype present in the 
samples tested. Nevertheless, it was quite clear that haplotype H I is expressed more 
highly than H3 and H8. The association with promoter haplotype and expression
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levels is an argument against parental imprinting as the cause o f the observed allelic 
differences in MUC5B expression.
Reporter assays had previously demonstrated that promoter haplotype HI was 
the higher expressing than H3, which was in turn expressed at a higher level than H2 
(Kamio et al. 2005). Here, we confirm part o f this study that H I is higher expressing 
than H3 in vivo.
The SBE results (on the basis o f one sample) suggest that H2 is higher 
expressing than H3, unlike what was previously shown (Kamio et al. 2005). 
However, here we provide strong suggestive evidence o f variation in H3 expression 
levels, which could reflect the involvement o f more distant regulatory elements not 
examined in the reporter assays.
The HI haplotype differs at four nucleotide positions from the H3 haplotype 
and at three from the H8 haplotype (see Table 5-1). The sequences surrounding and 
including these four differences were analysed on the TRANSFAC database 
(http://motif.uenom e.jp/M OTlF.html) using the default cut-off score o f  85.
One o f  the nucleotide differences is at rs7115457, which was previously 
reported to reside in a putative NF-Kp transcription factor-binding site (Chen et al. 
2001) (see Figure 5-1). This binding site was not detected when the default cut-off 
score was used but was detected when the score was reduced. The A allele on the HI 
haplotype background results in the disruption o f this binding site. This is somewhat 
counterintuitive since one might have expected the higher expressing HI haplotype 
to be associated with the more active NF-Kp transcription factor-binding site, leading 
to higher expression at least under conditions o f inflammation.
Another nucleotide difference is at rs7 118568, which resides in a putative 
NRF-2 (nuclear factor, erythroid 2 related factor) binding site, detected using the 
default cut-off score. The G allele on the H I haplotype background again results in 
the disruption o f this binding site. Interestingly, NRF-2 has been shown to play an 
important role in protection against oxidative stress and influences inflammatory 
processes and is thought to be important in diseases such as emphysema and cancer
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(Cho, Reddy, and Kleeberger 2006; Ishii et al. 2005; Yu and Kensler 2005). If the 
binding site were to be genuine, it is plausible that MUC5B expression might be 
upregulated by NRF-2 in response to oxidative stress.
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CHAPTER 6
STUDY OF MUC5B EXPRESSION IN RELATION 
TO RESPIRATORY OUTCOMES IN A 
LONGITUDINAL BIRTH COHORT
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6 STUDY OF MUC5B EXPRESSION IN RELATION TO
RESPIRATORY OUTCOMES IN A LONGITUDINAL BIRTH 
COHORT
6.1 INTRODUCTION
6.1.1 The 1946 Birth Cohort
The MRC National Survey o f Health and Development is a sample o f all 
births in England, W ales and Scotland in a week (3-9 th  March) in 1946. The 1946 
birth cohort was originally composed o f  16,695 individuals before it was stratified by 
social class and reduced to 5362 members. The cohort study was started at the time 
o f the immediate post-war baby boom in Britain, before the subsequent mass 
immigration into Britain. Hence, the vast majority o f the participants are o f Northern 
European ancestry.
This population was studied at birth, a further 10 times up to age 15 years, 
and then 11 more times in adulthood, most recently at 53 years. Data including birth 
weight, height, adult respiratory outcomes (for example diagnosed with asthma, 
wheezing), FEV i (forced expiratory volume in 1 second) was collected.
At age 53, 3035 o f the 3673 (83%) with whom contact was attempted 
provided information. The rest o f the original sample had died, previously refused 
information or were living abroad. Importantly, the study sample at 53 years was 
shown to be representative o f  the national population o f a similar age when 
compared with Census data (W adsworth et al. 2003).
Acute challenges to the respiratory tract, such as infectious pathogens, toxins 
and allergens activate lung inflammatory/immune response mediators. Some o f these 
inflammatory mediators can function as secretagogues to activate secretion o f mucins 
from surface goblet cells and/or glandular secretory cells, whilst others upregulate 
MUC gene expression, resulting in sustained mucin hypersecretion (see section
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1.2.5.3). Since mucins have been shown to bind bacteria and play an important role 
in protection o f the epithelial cell layer, these raised levels o f mucin production are 
part o f the normal response to inflammation, and typically revert to baseline levels 
once the inflammatory mediators have been removed, presumably in response to 
anti-inflammatory mechanisms.
However, in several chronic inflammatory airway diseases such as asthma, 
chronic bronchitis and cystic fibrosis, patients typically manifest goblet cell 
hyperplasia and glandular hyperplasia/hypertrophy (Fahy 2002), which results in 
permanently elevated baseline levels o f mucin production. As a result, mucus 
hypersecretion and mucus airway obstruction are prominent features o f such 
respiratory diseases.
Besides an increase in expression levels, the composition and properties o f 
mucins can be altered in disease states. For example, an increase in the low-charge 
glycoform o f  M UC5B was demonstrated in airway secretions in asthmatics vs. 
controls (Sheehan et al. 1999a), whilst MUC5B glycoproteins o f an extreme size 
were discovered in the mucus plugs from a patient who died o f acute asthma 
(Sheehan et al. 1995a).
From the work in the previous chapter, it was shown that promoter haplotype 
HI was a high expressing haplotype and that the exonic haplotype X6 was a good 
marker for this haplotype. In chronic inflammatory airway diseases such as asthma 
and bronchitis, the expression o f MUC5B is raised compared to normal (Kirkham et 
al. 2002). Our hypothesis therefore was that carriers o f  the X6 MUC5B exonic 
haplotype would be over-represented in groups o f people with these diseases. In 
addition to this characterised variation, other variations within the MUC5B gene, in 
which there may be an association with the MUC5B SNPs tested, may alter bacterial 
binding or affect M UC5B properties in other ways.
This chapter examines the possibility o f significant associations between 
MUC5B genotypes/exonic haplotypes, respiratory outcomes and measures o f lung 
function in the 1946 birth cohort. The focus is on asthma and measures o f lung 
function, although various other associated variables are also examined.
172
6.2 GENOTYPE & HAPLOTYPE ANALYSIS
For this study, genotyping was conducted as part o f a multiplex analysis, 
which consisted o f  other markers o f  interest to the group. This assay was optimised 
by adjusting the relative amounts o f  each SBE primer in the reaction mix. A 
representative result from the SBE multiplex used to genotype the cohort for the 
MUC5B exonic SNPs and three other loci is shown in Figure 6-1.
rsl 132440 
G allelers2075853 
C allele
rs2672785 
A allelers2070874 
C allelers2075859 
T allele
rsl 800925 
C allele
1800925 
r allelers2075859 
C allele rs2672785 
G allele
132440
allele
170874
illele
rs
Figure 6-1 - Representative genotyping result from SBE multiplex. Individual heterozygous at all 
six loci shown (Sample N188). Orange peaks are LIZ-120 size standards. All samples run on ABI 
3730XL sequencer and genotyped automatically using Genemapper 4.0.
Table 6-1 shows the MUC5B genotype frequencies for the 1946 population 
again compared with the genotype frequencies for the HapMap CEPHs sample set. x2 
tests were performed for each SNP to test for deviation from expected Hardy- 
Weinberg frequencies.
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SNP rs2672785 rs2075853 rs2075859
Genotypes AA AG GG CC CT TT CC CT TT
1946 Cohort 
Genotype Frequencies 
(n=2807)
0.643
(1804)
0.322
(905)
0.035
(98)
0.858
(2409)
0.137
(384)
0.005
(14)
0.399
(1120)
0.449
(1260)
0.152
(427)
X2 Test P value for 
HW in 1946 cohort 0.491 0.953 0.066
CEPH Genotype 0.567 0.383 0.050 0.850 0.150 0.000 0.417 0.450 0.133
Frequencies (n=60) (34) (23) (3) (51) (9) (0) (25) (27) (8)
Table 6-1- MUC5B exonic SNP genotype frequencies in 1946 cohort vs. HapMap CEPHs
As can be seen, the genotype frequencies between the cohort and HapMap 
CEPHS are very similar, as would be expected. The % test P value for rs2075859 
approached significance (P value = 0.066) which suggested that there might possibly 
be a problem with the genotyping for this SNP. Hence, the genotyping results were 
carefully re-examined. No evidence o f  serious errors was detected.
The haplotypes were inferred from the genotypes by using the Phase 
program. The inferred haplotype frequencies in the birth cohort, compared with the 
fetal population and HapMap CEPHs are shown in Table 6-2.
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Exonic
Haplotype
Identifier
rs2672785 rs2075853 rs2075859
Haplotype Freq
1946 HapMap 
Fetal CEPHs
C0h0rt (n=2807)
XI A C C 0.495 0.413 0.467
X2 A C T 0.304 0.304 0.292
X3 G C C 0.125 0.125 0.167
X4 G C T 0.002 0.016 0.000
X5 G T C 0.001 0.016 0.008
X6 G T T 0.068 0.125 0.067
X7 A T C 0.001 0.000 0.000
X8 A T T 0.004 0.000 0.000
Table 6-2 - MUC5B exonic SNP haplotype frequencies in 1946 cohort, fetal and HapMap CEPH 
populations
Haplotype inference showed that the haplotype frequencies between the three 
population groups are highly similar. Two new exonic haplotypes were identified in 
the 1946 cohort: X7 and X8, although both are very rare in the population.
6.3 VARIOUS VARIABLES TESTED AND RATIONALE FOR TESTING 
THEM
This section describes the variables tested for correlation with the MUC5B 
exonic genotypes and X6 haplotype carrier status.
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6.3.1 Respiratory Outcomes and Measures of Lung Function
The respiratory outcomes and measures o f lung function examined are shown 
in Table 6-3. The majority o f the variables studied are derived from questionnaires 
(questions asked are shown in Table 6-3) in 1989 (age 43) and 1999 (age 53) because 
these provided the most complete data sets.
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Original
Variable Explanation/Question asked Original Outcome Codes
Recoded
Variable Recoded Outcome Codes
ALLG89 Have you ever had an allergy (1946-1989)?
0 - N o
1 -  Yes, once
2 -  Yes, recurring
ALLG89R 0 -  Never (original code 0)1 -  Ever (original codes 1 or 2)
ALLERGY In the last ten years (1989-1999), have you had any allergies?
1 - Ye s
2 - N o - -
ASTH89 Have you ever had asthma (1946-1989)?
0 - N o
1 -  Yes, once
2 -  Yes, recurring
ASTH89R 0 -  Never (original code 0)1 -  Ever (original codes 1 or 2)
ASTHMA In the last ten years (1989-1999), did you have asthma?
1 - Ye s
2 - N o -
BRONC89 Have you ever had bronchitis (1946-1989)?
0 - N o
1 -  Yes, once
2 -  Yes, recurring
BRONC89R 0 -  Never (original code 0)1 -  Ever (original codes 1 or 2)
BRONC
During the past 3 years (1997-1999), did you 
have any chest illness, such as bronchitis or 
pneumonia, which kept you off work or indoors 
for a week or more?
1 -  Yes 
2 - N o - -
HAY89 Have you ever had hay fever (1946-1989)
0 - N o
1 -  Yes, once
2 -  Yes, recurring
HAY89R 0 -  Never (original code 0)1 -  Ever (original codes 1 or 2)
HAYF In the last ten years (1989-1999), did you have hay fever?
1 - Ye s
2 - N o
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Original
Variable Explanation/Question asked Original outcome codes
Recoded
variable Recoded outcome codes
LRIP
Cohort member’s mother was asked if cohort 
member ever had a lower respiratory infection 
(i.e. bronchitis, broncho pneumonia or 
pneumonia) in early childhood (0 to 24 mths)?
0 -  No attacks of LRI
1 -  One attack; no treatment sought
2 -  One attack; saw private doctor 
or was hospital out-patient
3 -  One attack; was in-patient at 
hospital/nursing home
4 -  More than one attack; no 
treatment sought
5 -  More than one attack; saw 
private doctor or was hospital out­
patient
6 -  More than one attack; was in­
patient at hospital/nursing home
LRIPY 0 -  Never (original code 0) 1- Ever (original codes 1-6)
WZY89
Has your chest ever sounded wheezy or whistling 
(1946-1989)7
0 - N o
1 - Ye s WZY89C
0 -  No or not most days or nights
1 -  Yes, most days or nights
Did you get this most days (or nights)? 0 - N o1 - Ye s
WZY
Has your chest ever sounded wheezy or whistling 
(1946-1999)7
1 -  Yes 
2 - N o WZYC
0 -  No or not most days or nights
1 -  Yes, most days or nights
Did you get this most days (or nights)? 1 -  Yes 2 - N o
FEVM89 Max FEV1 reading when participant was 43 yrs old. - FEVM89C
Outliers removed: 0.01 -  1.00 
litres
FEVM99 Max FEV1 reading when participant was 53 yrs old. - FEVM99D
Outliers removed: 0.00 - 0.07, 
0.31 - 1.00, 9 .70-9 .99  litres
FEVM89C -  
FEVM99D
Difference in Max FEV 1 over 10 years 
(1989-1999). - DELTA -
Table 6-3 -  Respiratory outcomes and measures of lung function examined in 1946 cohort. Answers from questionnaires were converted into outcome codes in order to 
be analysed. Some o f the original variables were recoded for the analysis performed in this project and the recoded outcome codes are shown above.
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As can be seen, the questions asked were not identical on the different 
occasions. Although subsidiary questions were asked concerning whether or not the 
doctor or health worker had confirmed the diagnosis, previous experience showed 
that this served to reduce the data set slightly and only altered responses marginally 
(i.e. most answering ‘yes’ to these questions had a doctor diagnosis).
The rationale for choosing to examine these particular variables is described 
in the following sections:
6.3.1.1 Asthma History (ASTH89R and ASTHMA)
Asthm a is a respiratory disease in which there is constriction o f the airways 
and an over-secretion o f mucus in the respiratory tract. In the most severe cases o f 
asthma, the excess mucus forms gelatinous plugs, which occlude the airways (Rogers 
2004; Sidebotham and Roche 2003). Asthmatics also suffer from decreased lung 
function, which in a large proportion o f patients is due to mucus hypersecretion 
(Rogers 2004). Since mucins are the main glycoproteins found in mucus secretions, 
mucus hypersecretion is by extension associated with an increase in mucin 
production (Morcillo and Cortijo 2006), and relative changes in mucin gene 
expression will alter the composition o f  the secreted mucins.
Research has shown that the airway immune response plays an important part 
in the clinical manifestation o f  this disease (reviewed in (Ying et al. 2006b)). Atopy 
(a tendency to develop allergic reactions and is characterised by elevated levels o f 
allergy-specific IgE antibodies) is commonly associated with asthma, although some 
asthmatics are non-atopic (Humbert et al. 1999)
Allergens are processed and presented by antigen-presenting cells such as 
dendritic cells and macrophages. Depending on the cytokines acting on the precursor 
cells at the time o f antigen presentation, T hl or Th2 cells are produced. The two T 
helper cell types secrete different cytokine patterns, which influence other immune 
cells. This distinction between the two T helper cell types is critical because only the
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type 2 pattern o f the Th2 cells (IL4, IL5, IL6, ILL9, IL10 and IL13) is associated 
with asthma (Nakamura and Hoshino 2005; Robinson et al. 1992).
It is widely accepted that atopy and also susceptibility to asthma is heritable 
and a number o f  twin studies have shown an increased concordance between 
monozygotic vs. dizygotic twins (Duffy et al. 1990; Nieminen, Kaprio, and 
Koskenvuo 1991). In addition, other studies have demonstrated that asthma and its 
associated phenotypes are more prevalent amongst relatives o f  asthmatics than in 
relatives o f  non-asthmatics, lending further support for the notion that there is a 
genetic com ponent in this disease (Sibbald, Horn, and Gregg 1980; Sibbald and 
Tum er-W arwick 1979; Ying et al. 2006a).
Various genes have been shown to be associated with asthma. These include 
ADAM 33, (a disintegrin and metalloprotease (ADAM)33) (Holgate et al. 2006; 
Holloway et al. 2004), GPRA (G-protein-coupled receptor for asthma susceptibility), 
IL4 (interleukin 4) (reviewed in (Holloway, Beghe, and Holgate 1999; Holloway and 
Koppelman 2007)) and genes associated with atopy such as IL13.
Two genetic studies on MUC  genes have been carried out by our lab to 
investigate the possibility o f  an association with susceptibility to asthma. The first o f 
which established an association between MUC7 and asthma (Vinall et al. 2000), 
with a particular allele (MUC7*5) found at significantly lower frequency in 
asthmatics (Kirkbride et al. 2001) vs normal. The second identified an association 
between longer MUC2 TR alleles and a cohort o f atopic, non-asthmatic patients than 
in asthmatic patients. In addition, significant linkage between l i p  15 (where the 
MUC5B gene resides) and asthma in Caucasians has been discovered (A genome- 
wide search for asthma susceptibility loci in ethnically diverse populations. The 
Collaborative Study on the Genetics o f Asthma (CSGA) 1997). Taken together, this 
suggests that the expression levels and properties o f MUC5B could be important:
Together with MUC5AC, MUC5B is a major mucin species found in airway 
secretions from asthma patients and its expression has been shown to be increased in 
asthma patients compared to normal controls (Groneberg et al. 2002; Kirkham et al.
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2002). In addition, the properties o f MUC5B have been shown to be altered in 
asthma (Sheehan et al. 1995b; Sheehan et al. 1999b)
Thus, the MUC5B genotypes/haplotypes an individual possesses could play a 
prominent role in the etiology o f asthma and this respiratory outcome was therefore 
examined in this project.
6.3.1.2 Bronchitis History (BRONC89R and BRONO
Bronchitis is an inflammation o f the bronchial tubes, accompanied by 
coughing symptoms, mucus hypersecretion and is often secondary to an upper 
respiratory tract viral infection. Chronic bronchitis is a more persistent condition that 
is strongly associated with smoking, although not all smokers get chronic bronchitis 
(Urrutia et al. 2005). The BRONC89R and BRONC variables would include 
participants suffering from chronic bronchitis as well as some for whom bronchitis 
was due to a one off-secondary infection.
6.3.1.3 Wheeze (WZY89C and WZYC1
The wheeze variable is a measure o f breathing difficulties, which results from 
a range o f respiratory dysfunction including asthma, chronic obstructive pulmonary 
disease and chronic bronchitis. This variable is a simple concept for the participant to 
answer and was previously shown to correlate well with FEVi and be associated with 
MUC7 variation (Rousseau et al. 2006).
6.3.1.4 Hay Fever History (HAY89R and HAYF)
Hay fever or seasonal allergic rhinitis is characterised by sneeze attacks and 
itchy runny noses in sufferers, triggered by pollen during early spring to late summer 
in the UK. The main distinction with this variable and the aforementioned ones is 
that although there is mucus hypersecretion, airway obstruction is much less o f a 
feature o f hay fever.
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6.3.1.5 Allergy History (ALLG89R and ALLERGY'!
The allergy variable is a broad measure that would include various allergic 
conditions such as allergic rhinitis and skin allergies. Unfortunately, the way the data 
was collected for this variable (cohort members were asked ‘Have you ever had any 
allergies?’) means that the answers given were largely dependent on the subject’s 
understanding o f what constitutes an allergy. Thus, for example, whilst hay fever is 
an allergic disease, a cohort member might have answered ‘yes’ to whether he/she 
ever had hay fever but ‘no’ to whether he/she ever had an allergy. Indeed, 
examination o f  the data showed that whilst there was a significant correlation 
between positive responses for allergy and asthma/hay fever, there were 
discrepancies.
6.3.1.6 Lower Respiratory Tract Infections in Infancy (LRIPY)
This variable represents the presence or absence o f lower respiratory tract 
infections in members o f the cohort during early childhood (0-24 mths), determined 
from interviewing the mothers o f the cohort members at age 2. Since mucins are 
known to bind bacteria and are believed to play a protective role in defence against 
infection, it was possible that variation in MUC5B expression might be associated 
with susceptibility to early childhood infections Hence, there was interest in 
investigating the relationship between this variable and MUC5B.
6.3.1.7 Measures of Lung Function - Fixed Expiratory Volume in one second 
(FEVi) (FEVM89C. FEVM99D and DELTAS
Lung function was measured using a Micro Medical Micro Plus turbine 
spirometer (Stirling, Scotland) at ages 43 and 53 years by nurses during home visits. 
Two readings o f FEVi were taken and the maximum reading (in litres) was used to 
derive the FEVM89C and FEVM99D measures. DELTA represents the decline 
(because lung function decreases with age) in FEVi over 10 years, calculated using
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the FEVM89C and FEM99D values. Reduced FEVi results from poor lung 
development and also from congestion and constriction o f the airways (Vestbo, 
Prescott, and Lange 1996).
6.3.2 Potential Confounding Variables
A confounding variable is a variable that is correlated with an outcome o f 
interest. Such variables need to be taken into consideration when testing for an 
association between respiratory outcomes and MUC5B, since these may result in a 
spurious correlation between the two.
The variables shown in Table 6-4 were identified as potential confounders 
and were tested for correlation with MUC5B, so that any that showed a positive 
correlation could be included in an adjusted model.
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Original
Variable Explanation/Question asked Original outcome codes
Recoded
Variable Recoded outcome codes
CIG89C
Do you smoke cigarettes? Question was 
asked in 1966, 1971, 1977, 1982 and 
1989.
1 -  Currently smoking
2 -  Ex-smoker
3 -  Never smoked
CIG89CR Never (code 3) —> 0 Ever (codes 1 or 2) —> 1
CIG99C
Do you smoke cigarettes? Question 
asked in 1966, 1971, 1977, 1982, 1989 
and 1999.
1 -  Currently smoking
2 -  Ex-smoker
3 -  Never smoked
CIG99CR Never (code 3) -> 0 Ever (codes 1 or 2) -> 1
FSC50C Participant’s father’s social class at age 4, inferred from father’s occupation
1- Professional
2 -  Intermediate
3 -  Skilled (non-manual)
4 -  Skilled (manual)
5 -  Partly skilled
6 -  Unskilled
FSC50R Non-manual job (codes 1- 3) —> 0 Manual job (codes 4-6) -» 1
REG46AR Participant’s region of birth
1 -  Scotland
2 -  North
3 -  Central
4 -  London + S.Eastem
- -
SCL89C Participant’s own social class at age 43, inferred from subject’s occupation
1- Professional
2 -  Intermediate
3 -  Skilled (non-manual)
4 -  Skilled (manual)
5 -  Partly skilled
6 -  Unskilled
SCL89CR
Non-manual job (codes 1- 3) -> 0 
Manual job (codes 4-6) -> 1
SCL99C Participant’s own social class at age 53, inferred from subject’s occupation
1- Professional
2 -  Intermediate
3 -  Skilled (non-manual)
4 -  Skilled (manual)
5 -  Partly skilled
6 -  Unskilled
SCL99CR Non-manual job (codes 1- 3) —> 0 Manual job (codes 4-6) —> 1
SEXX Sex of participant 1 -  Male2 -  Female SEXXR
Male -  0 
Female -  1
Table 6-4 - Potentially Confounding Variables. Answers from questionnaires were converted into outcome codes in order to be analysed. Some of the original variables 
were recoded for the analysis performed in this project and the recoded outcome codes are shown above.
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6.4 RESULTS OF TESTS FOR ASSOCIATION WITH VARIABLES
The results o f the tests for association with MUC5B exonic SNPs/X6 
haplotype carrier status and respiratory outcomes, using ANOVA, cross-tabulations 
and x2 tests are shown in Table 6-5. The results o f the tests for association with 
MUC5B and potential confounding variables are shown in Table 6-6. All analysis 
was carried out using SPSS.
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Variables Type of
T ested Test Used
ALG89R Crosstab t
Variables
Tested
Type of 
Test Used
rs2672785 rs2075853 rs2075859 MUC5B Haplotype
Explanation No.
Tested P Value
No.
Tested P Value
No.
Tested P Value
No.
Tested P Value
CIG89CR Crosstab Cigarette smoking history (1966-1989) 2626 0.038 2627 0.604 2623 0.026 2626
0.591
CIG99CR Crosstab Cigarette smoking history (1966-1999) 2799 0.121 2800 0.847 2796 0.032 2799
0.789
FSC50R Crosstab Father’s social class at age 4 2572 0.740 2573 0.700 2569 0.661 2572 0.407
SCL89R Crosstab Social class at age 43 2472 0.269 2473 0.723 2469 0.858 2890 0.569
SCL99R Crosstab Social class at age 53 2517 0.723 2518 0.857 2514 0.310 2517 0.796
REG46AR Crosstab Region of birth 2800 0.925 2801 0.267 2797 0.626 2800 0.185
SEXX Crosstab Sex 2800 0.599 2801 0.812 2797 0.155 2800 0.500
Table 6-6 -  Results of tests for correlation with potential confounding variables. Significant (P value <0.05) correlations are shown in bold.
187
As can be seen from the results, there are significant associations between 
MUC5B and a number o f respiratory outcomes (ALLERGY, HAY89R, HAYF and 
WZY89C, see Table 6-5) as well as a significant correlation between cigarette 
smoking and MUC5B (see Table 6-6), although it is not clear why this should be. 
Cigarette smoking history is also marginally correlated with ALLERGY in this 
cohort (P value = 0.082, analysis done by A.Teixeira) and is therefore a confounding 
variable that must be adjusted for.
All analyses were adjusted for region o f birth (associated with HAY89R (P 
value = 0.009) and ALLERGY (P value = 0.010), analysis done by A.Teixeira) even 
though it did not appear to be associated with MUC5B, because hidden population 
stratification is a well-known genetic confounder.
In the case o f the measures o f lung function (FEVM89C, FEVM99D and 
DELTA), FEVi values are usually expressed in a clinical setting as a percentage as 
expected for age, height and sex. In this project, since raw FEVi readings were used, 
these had to be adjusted for height and sex. An adjustment for age was unnecessary 
since the population tested is a birth cohort.
6.5 ADJUSTMENT FOR CONFOUNDING VARIABLES
The MUC5B alleles that exhibited evidence o f a significant association with 
respiratory outcomes in the preliminary analyses (i.e. only bolded values; see Table 
6-5,) were reanalysed by logistic regression using STATA 10, to correct for cigarette 
smoking history and region o f  birth.
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Variables
Tested
Type of Test 
Used
rs2672785 rs2075853 rs2075859 MUC5B Haplotype
Explanation No.
Tested P Value
No.
Tested P Value
No.
Tested P Value
No.
Tested P Value
ALLERGY
Crosstab
Adjusted Log 
Regression
Allergy history 
(1989-1999)
Allergy history (1989-1999) 
adjusted for cigarette smoking 
history and region of birth
2798 0.543 2799
2799
0.043
0.033
2795
2795
0.039
0.039
2798
2798
0.021
0.017
Crosstab Hay fever histoiy (1946-1989) 2628 0.489 2629 0.030 2625 0.090 2628 0.049
HAY89R Adjusted Log 
Regression
Hay fever history (1946-1989) 
adjusted for cigarette smoking 
history and region of birth
- - 2623 0.060 - - 2622 0.054
Crosstab Hay fever history (1989-1999) 2798 0.311 2799 0.050 2795 0.635 2798 0.749
HAYF Adjusted Log 
Regression
Hay fever history (1989-1999) 
adjusted for cigarette smoking 
history and region of birth
- - 2799 0.104 - - - -
Crosstab Wheeze history (1946-1989) 2541 0.022 2542 0.317 2538 0.398 2541 0.054
WZY89C Adjusted Log 
Regression
Wheeze histoiy (1946-1989) 
adjusted for cigarette smoking 
history and region of birth
2535 0.029 - - - - 2535 0.062
ANOVA Max FEVi at age 43 2577 0.325 2578 0.837 2574 0.473 2577 0.583
FEVM89C Adjusted Log 
Regression
Max FEVi at age 43 adjusted for 
height and sex 2563 0.927 2564 0.878 2560 0.634
2563 0.989
ANOVA Max FEVi at age 53 2693 0.799 2694 0.721 2690 0.131 2577 0.815
FEVM99D Adjusted Log 
Regression
Max FEVj at age 53 adjusted for 
height and sex 2684 0.699 2685 0.892 2681 0.095
2684 0.477
ANOVA Change in Max FEVi over 10 years (1989-1999) 2492 0.803 2493 0.811 2489 0.082 2492
0.589
DELTA Adjusted Log 
Regression
Change in Max FEV i 
over 10 years (1989-1999) 
adjusted for height and sex
2483 0.738 2484 0.793 2480 0.057 2483 0.535
Table 6-7 - Comparison of results before and after adjusting for confounding variables. Significant (P value <0.05) correlations are shown in bold. Original results 
from cross tabulations compared with adjusted results from logistic regressions.
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After adjusting for confounding variables, the associations previously 
detected between MUC5B and hay fever (HAY89R and HAYF) are now no longer 
statistically significant. This suggests that it is most likely that cigarette smoking 
history was confounding the results and that there is no significant link between 
MUC5B and hay fever.
The measures o f lung function were still not significantly associated with 
MUC5B after adjustments.
In contrast, the associations between MUC5B and allergy history 
(ALLERGY) and between MUC5B and wheeze history (W ZY89C) have remained 
significant, suggesting that there may be a genuine correlation between these 
outcomes and MUC5B .
6.6 TEST FOR INTERACTION BETWEEN MUC5B AND IL13
Allergies are associated with a production o f elevated levels o f IgE antibody. 
In individuals suffering from allergies, IgE antibodies bind to receptors on mast cells 
and basophil surfaces, releasing mediators that initiate an immunological cascade and 
the accompanying inflammatory symptoms. IL13 is a cytokine produced by activated 
Th2 cells and plays an essential role in IgE synthesis. Thus, IL13 is important in the 
development o f allergies.
A SNP in the IL13 gene (IL13 R110Q) involves an amino-acid substitution 
and has been shown to be associated with an increase in IgE (Graves et al. 2000; 
Howard et al. 2001; Leung et al. 2001). This polymorphism is thought to be 
functionally important in ligand binding and IL13 110Q was shown to be 
significantly more active in IgE switching than IL13 11 OR in a cellular model 
(Vladich et al. 2005). Indeed, work in our group showed that this polymorphism was 
correlated significantly w ith asthma and the allergy variables in this cohort (see 
Table 6-8).
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Respiratory Outcome P ValueLog Regression Crosstabs
ASTH89R 0.002 <0.0001
ASTHMA N ot done 0.042
ALLG89R 0.042 0.030
ALLERGY N ot done 0.007
Table 6-8 - Results of tests for association with IL13 R100Q genotypes and asthma and allergy 
history variables. Analysis done by A.Teixiera. P values for logistic regression and cross tabulations 
shown. Significant association not observed for wheeze history.
Table 6-9 shows the logistic regression result for ALLERGY, using IL13 Q 
carriers vs. non-carriers.
Respiratory Outcome Odds Ratio and 95% Cl P Value
ALLERGY 
(Allergy history 1989-1999) 1.320(1.071-1.629) 0.009
Table 6-9 -  Result of logistic regression analysis between IL13 Q carriers and ALLERGY.
Analysis done by A.Teixeira.
Published research suggests that IL13 induces MUC5AC expression (Liu et 
al. 2004; Yasuo et al. 2006). Thus, it is conceivable that IL13 might affect MUC5B 
expression levels in a similar fashion. Therefore, a test for interaction between 
MUC5B and IL13 R110Q, affecting allergy history (ALLERGY), which was shown 
to be significantly correlated with MUC5B (see Table 6-7) was performed. The 
results o f the tests for interaction, using logistic regression are shown in Table 6-10.
MUC5B marker P Value
rs2075853 0.4469
rs2075859 0.0358
MUC5B Haplotype 0.7270
Table 6-10 -  P values obtained for tests for interaction between MUC5B and IL13E influencing 
allergy history outcomes. Statistically significant (P value <0.05) results are shown in bold. All 
results adjusted for cigarette smoking history, region of birth, sex and social class.
The results show that the rare allele o f  IL13 together with the common allele 
o f rs2075859 confers a greater risk o f  allergy. Curiously, the results indicate that 
there is a significant interaction between rs2075859 and IL13 R110Q but not
2 Two variables are said to be interacting when together they exert a multiplicative effect on an 
outcome of interest
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between rs2075853 and MUC5B haplotype, suggesting that the IL13 only interacts 
with certain MUC5B genotypes to influence allergy.
6.7 DISCUSSION
The work in this chapter has shown that there is a significant correlation 
between certain MUC5B genotypes/haplotypes, wheeze history (W ZY89C) and 
allergy history (ALLERGY). In some cases, there is an association with a respiratory 
outcome for rs2672785 or rs2075853 but never both together. This is unexpected 
since both SNPs are in strong LD with each other (see section 5.4).
People counts for the statistically significant cross-tabulations are shown in 
Appendix II. For wheeze, there are more G allele (rs2672785) carrying individuals 
with wheeze than without wheeze, which was expected since the G allele is on the 
high expressing X6 haplotype background. Curiously, the X6 haplotype is under­
represented in individuals with allergies rather than the other way around. It is not 
obvious why this is the case, although it is plausible that the high expressing X6 
haplotype is protective against allergic responses, acting by clearing allergens more 
efficiently from the nasal and respiratory tracts.
The significant correlations observed between MUC5B genotypes and 
cigarette smoking history are quite unexpected, as this implies that there is a 
difference in distribution o f MUC5B alleles between smokers (both current and ex) 
and non-smokers. It is difficult to propose a rationale explanation for this and it is 
most likely that the positive correlation is simply due to chance.
There are a number o f possible reasons for the significant correlations 
observed in this study:
If  the associations are genuine, it is possible that the significant associations 
detected reflect differences in MUC5B properties, rather than differences in mRNA 
expression levels, since both rs2672785 (G: glycine, A: glutamine) and rs2075853
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(T: tryptophan, C: arginine) result in non-synonymous, non-conserved amino acid 
changes, which could alter the physical properties o f MUC5B in airway secretions.
Alternatively, the SNPs tested might be in LD with other functional 
substitutions in MUC5B and the positive correlations observed could be a reflection 
o f this.
The significant associations seen could also have resulted from Type I errors 
(false positives). These could be due to problems such as population stratification 
and systematic genotyping errors. Population stratification is unlikely to be a 
problem since the 1946 cohort pre-dates the mass immigration into the UK beginning 
in the 1950s. The possibility o f systematic genotyping errors has been addressed at 
the beginning o f  this study by checking for significant deviations from expected 
Hardy-W einberg frequencies (see section 6.2)
However, given the number o f variables tested, there is a risk that the 
significant correlations observed have arisen due to multiple testing. A Bonferroni 
correction can be applied to help control for this (Bland and Altman 1995). Since 
some o f the variables, such as HAYF and ALLERGY, are likely to be closely related 
to each other (i.e. not independent), a standard Bonferroni correction is likely to be 
overly conservative (thereby increasing Type II errors). Hence, other statistical 
methods such as false discovery rate and permutation testing might be more 
appropriate for such variables (Benjamini et al. 2001; Doerge and Churchill 1996).
In order to better address the possibility o f  Type I errors in this study, it 
would be useful to test other cohorts for MUC5B, such as the 1958 longitudinal 
cohort (Power 1992) and a small asthma cohort we have in our lab, which has yet to 
be tested.
It would be also be interesting to test the 1946 cohort for other markers in the 
1 l p l 5.5 MUC  gene complex, as is currently being done for a SNP in MUC5AC by 
another lab member.
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7 FINAL DISCUSSION AND CONCLUSIONS
There is mounting evidence to suggest that cX-acting regulatory variants are 
widespread throughout the genome and that allelic variation in mRNA expression 
might be a common occurrence. Here, a principal aim o f this project was to address 
the issue o f  whether MUC4 and MUC5B exhibited allelic variation in mRNA 
expression. In order to achieve this aim, a single-base extension (SBE) based method 
was developed. It was hoped that using this technique would enable us to test for 
allelic variation in MUC4 expression and to determine if  TR length had any influence 
on levels o f  expression. Unfortunately, we had not anticipated the extent to which 
MUC4 was alternatively spliced and the various complications caused by this led us 
to abandon this aspect o f  the project.
However, background data showed that MUC4 TR length was associated 
with SNPs downstream o f the TR domain, and by inference from HapMap, also 
upstream. The RT PCR data showed evidence o f more extensive alternative splicing 
than previously reported. Interestingly, there seem to be tissue and inter-individual 
differences in this and preliminary experiments suggested that this might be e x ­
acting. This clearly needs further investigation.
The rest o f  this project focussed on MUC5B. Using the SBE method, clear 
allelic differences in MUC5B expression were demonstrated. These differences were 
relatively small, which was probably why the various technical issues affected the 
results so much.
Fetal tissue was used as a source o f mRNA for testing the constitutive 
expression o f MUC5B in vivo. The initial plan was to compare the cDNA allelic 
ratios from different tissues originating from the same individual in order to test for 
tissue-specificity in MUC5B allelic variation. Unfortunately, difficulties in obtaining 
sufficient MUC5B cDNA template from a sizeable proportion o f the samples meant 
that this comparison could only be done for a small handful o f individuals. The 
results were therefore inconclusive.
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In retrospect, the decision to collect multiple fetal tissue types was a double- 
edged sword. W hilst doing so allowed the opportunity to test for tissue-specificity in 
a wide range o f different tissue types, it reduced the total number o f individuals o f a 
single tissue type available for testing. As a result, in order to increase the total 
number o f individuals tested, allelic ratios from different tissue sources had to be 
used. Thus, it is quite likely that if  tissue-specific effects were present, this might 
have masked the true extent o f allelic variation in MUC5B mRNA expression.
Although it might have been better to concentrate on just one tissue type, 
there is still the possibility o f intra-tissue specificity to contend with, as 
demonstrated by Wilkins and colleagues for bone morphogenic protein 5 (BMP5) 
(W ilkins et al. 2007). This is likely to be more crucial for the more complex tissues, 
such as stomach and lungs, where a different subset o f cell types could conceivably 
be sampled each time. The best way to approach this problem is unclear.
Nevertheless, a highly significant association between promoter haplotype 
heterozygosity and the magnitude o f the allelic differences in MUC5B expression in 
vivo was demonstrated. This finding supported a previous in vitro study in which 
differential expression o f  MUC5B promoter haplotypes was shown. Importantly, this 
finding also provided evidence for the allelic differences observed being due to cis- 
acting regulatory variants rather than an epigenetic effect such as parental 
imprinting.
An attempt was made to rank the relative expression levels o f the different 
promoter haplotypes. W hilst this was possible for a few o f the haplotypes, this could 
not be accomplished for every haplotype due to the small numbers o f samples and 
the variability in allelic ratios even for individuals homozygous for promoter 
haplotype. Nevertheless, the HI promoter haplotype was clearly established as a high 
expressing MUC5B haplotype.
Hence, carrier status for H I and MUC5B exonic SNP genotypes were 
examined in a longitudinal birth cohort in relation to various respiratory outcomes. 
Significant correlations between wheeze and allergy history and MUC5B were
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observed. If correct, rather than being a consequence o f multiple testing, these might 
reflect differences in MUC5B properties rather than in mRNA expression levels, 
possibly due to other polymorphisms associated with the ones tested here. Further 
work on the cohort by testing for association with other polymorphisms in the 
11 p i 5.5 MUC  gene complex might help to shed further light on this.
It would have been interesting to test markers in the cohort that could 
distinguish between the H3 and H8 promoter haplotypes, since H8 was shown to be 
higher expressing than H3. Unfortunately, since the cohort work was done 
concurrently with the SBE work, the information regarding the relative expression 
levels o f  H3 vs. H8 was not available in time.
In conclusion, the work in this thesis has clearly demonstrated that there is 
constitutive allelic variation in MUC5B mRNA expression and that this variation is 
most likely due to ds-acting regulatory polymorphisms in the promoter. It would be 
o f great interest to test for this phenomenon in other MUC  genes.
It would now be interesting to test for facultative allelic differences in 
MUC5B expression. It is possible that the true significance and extent o f the allelic 
differences in expression are manifested only in the context o f inflammation and that 
much greater allelic differences in expression might be observed. Respiratory cells 
grown at the air liquid interface (ALI culture), which can differentiate into mucus 
producing and ciliated cells, would be an ideal cellular model to study this (Gray et 
al. 1996). The ALI culture cells could be tested using the SBE method, after 
challenging the cells with inflammatory mediators known to upregulate MUC5B 
expression, such as human neutrophil defensins and PMA (Aarbiou et al. 2004; 
Yuan-Chen et al. 2007). The advantage o f this kind o f approach is that cells from the 
same individual could be tested before and after challenging with inflammatory 
mediators, thereby controlling for many experimental variables.
It would also be interesting to see if  high expressing alleles/haplotypes 
respond more (or perhaps less) to certain challenges. For example, by using this 
approach, it should be possible to test whether NF-Kp and NRF-2 play a role in 
controlling MUC5B expression and whether this differs in HI and H3 haplotypes.
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One could for example treat ALI culture cells with bacterial LPS, which is known to 
upregulate N F-kP and then examine the relative allelic expression in heterozygotes 
for promoter haplotype. Since there is suggestive evidence o f more distant regulators 
such as enhancers and/or silencers, it would be important to test this in several 
different individuals, as well as to test individuals homozygous for promoter 
haplotype.
Ultimately, it will be possible to test whether the differences in allelic 
expression also correlate w ith total expression levels and with the relative amounts o f 
MUC5B protein produced by these alleles. This would be an ultimate demonstration 
o f allelic differences in mRNA expression.
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APPENDICES
Appendix I -  MUC4 Biliary Tract Cancer Study
I contributed to this project by:
• Supervising and assisting with the western blotting, including experimental 
design.
• M aking the first biliary RNA sample, showing that it was possible to extract 
RNA from bile.
Are MUC4 and/or MUC5AC Useful Tumour Markers for Biliary Tract Cancer 
(BTC)?
W olf-rudiger Matull, Andrew Loh, Andreola Fausto, Zwelal Adiguzel, Maesha 
Deheragoda, Uzma Qureshi, Dallas M. Swallow, Stephen P. Pereira
Introduction: Alterations in epithelial mucin expression are associated with 
carcinogenesis. MUC4 contains an EGF-like domain that can induce cell 
proliferation and differentiation via the ERBB2 receptor (1). In pancreatic disease, 
MUC4 is a diagnostic and prognostic marker for malignancy (2) (3), while 
MUC5AC has been proposed as a serum marker for BTC (4). Methods: We 
investigated MUC4 and M UC5AC expression in: (i) 79 archive Biliary tissues (69) 
BTC, 10 benign) by immunohistochemistry (IHC), and (ii) bile and serum specimens 
from 72 patients with biliary obstruction (39 BTC, 8 other malignancies, 9 primary 
sclerosing cholangitis (PSC), 16 benign) by western blot and quantitative real-time 
RT PCR (qPCR). Two monoclonal M UC4 antibodies (against transmembrane and 
secretory unit epitopes) and a mono- and polyclonal MUC5AC antibody were used. 
qPCR was based on the Taqman® method. M ucin gene primers were custom- 
synthesised. MUC4 and M UC5AC mRNA expression was normalised against the 
housekeeping gene GAPDH. Results: In archive tissues, MUC4 and MUC5AC 
proteins were detected exclusively in 37% and 10% o f  BTC samples, respectively, 
vs. in none o f the benign (p=0.02 and p+0.4) respectively). In bile, MUC4 protein 
was detected in 27% o f BTC and 29% o f PSC cases, but not in benign conditions
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(p=0.04 for BTC vs. non-BTC). qPCR revealed a 2.3-fold increased expression o f 
MUC4 mRNA in the bile o f patients with BTC compared with benign disease. No 
such difference was seen for MUC5AC. In serum, MUC4 was detected in 5% of 
patients overall, with no significant difference between BTC and non-BTC patients. 
M UC5ACwas found exclusively in BTC and PSC sera (44% and 13%, respectively; 
pO.OOl for BTC vs. non-BTC). Conclusion: Biliary MUC4 and serum MUC5AC 
are highly specific tum our associated mucins in BTC, which may be o f  potential 
value in the early detection o f BTC. References: (1) Nature Rev 2004; 4:45-60. (2) 
Br J Cancer 2004;91:1633-8. (3) J Clin Pathol 2005;58:845-52. (4) Cancer Lett 
2003;195:93-9.
BTC prediction markers
(Western
Blotting) Bile MUC4 Serum MUC5AC
Bile MUC4 or serum 
MUC5AC
Sensitivity 27% (9/34) 44% (17/39) 58% (22/38)
Specificity 93% (26/28) 96% (26/27) 87% (22/23)
PPV 82% (9/11) 94% (17/18) 88% (22/25)
NPV 51% (26/51) 54% (26/48) 56% (20/36)
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Appendix II -  People Counts for Statistically Significant Cross Tabulations in
1946 Birth Cohort
p Never Ever
Variable Marker Value Genotype No.
Tested
%of
Total
No.
Tested
% o f
Total
Total
MUC5B
Haplotype
Non-carrier 1984 86.75% 446 87.28% 2430
0.749 X6 Carrier 303 13.25% 65 12.72% 368
TOTAL 2287 100.00% 511 100.00% 2798
HAYF CC 1962 85.75% 439 85.91% 2401
rs2075853 0.050
CT
TT
318
8
13.90%
0.35%
66
6
12.92%
1.17%
384
14
TOTAL 2288 100.00% 511 100.00% 2799
CC 1902 86.57% 359 83.10% 2261
rs2075853 0.030
CT
TT
287
8
13.06%
0.36%
68
5
15.74%
1.16%
355
13
HAY89 TOTAL 2197 100.00% 432 100.00% 2629
MUC5B
Haplotype
Non-carrier 1922 87.52% 363 84.03% 2285
0.049 X6 Carrier 274 12.48% 69 15.97% 343
TOTAL 2196 100.00% 432 100.00% 2628
AA 1555 64.98% 84 56.76% 1639
WZY89 rs2672785 0.022
AG
GG
762
76
31.84%
3.18%
54
10
36.49%
6.76%
816
86
TOTAL 2393 100.00% 148 100.00% 2541
CC 1896 84.95% 505 89.07% 2401
rs2075853 0.043
CT
TT
324
12
14.52%
0.54%
60
2
10.58%
0.35%
384
14
TOTAL 2232 100.00% 567 100.00% 2799
CC 879 39.43% 236 41.70% 1115
ALLERGY
rs2075859 0.039
CT
TT
990
360
44.41%
16.15%
263
67
46.47%
11.84%
1253
427
TOTAL 2229 100.00% 566 100.00% 2795
Non-carrier 1921 86.10% 509 89.77% 2430
MUC5B
Haplotype 0.021
X6 Carrier 310 13.90% 58 10.23% 368
TOTAL 2231 100.00% 567 100.00% 2798
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P Never Ever
Variable M arker JrValue Genotype No. % o f No. % o f Total
Tested Total Tested Total
AA 511 65.94% 1185 64.02% 1696
rs2672785 0.038
AG
GG
229
35
29.55%
4.52%
612
54
33.06%
2.92%
841
89
CIG89CR
TOTAL 775 100.00% 1851 100.00% 2626
CC 332 42.84% 717 38.80% 1049
rs2075859 0.026
CT
TT
314
129
40.52%
16.65%
855
276
46.27%
14.94%
1169
405
TOTAL 775 100.00% 1848 100.00% 2623
CC 340 42.24% 776 38.98% 1116
CIG99CR rs2075859 0.032
CT
TT
330
135
40.99%
16.77%
923
292
46.36%
14.67%
1253
427
TOTAL | 805 100.00% 1991 100.00% 2796
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